id	sid	tid	token	lemma	pos
cord-268140-s5lailkp	1	1	key	key	JJ
cord-268140-s5lailkp	1	2	:	:	:
cord-268140-s5lailkp	1	3	cord-268140-s5lailkp	cord-268140-s5lailkp	NN
cord-268140-s5lailkp	1	4	authors	author	NNS
cord-268140-s5lailkp	1	5	:	:	:
cord-268140-s5lailkp	1	6	Atal	Atal	NNP
cord-268140-s5lailkp	1	7	,	,	,
cord-268140-s5lailkp	1	8	Shubham	Shubham	NNP
cord-268140-s5lailkp	1	9	;	;	:
cord-268140-s5lailkp	1	10	Fatima	Fatima	NNP
cord-268140-s5lailkp	1	11	,	,	,
cord-268140-s5lailkp	1	12	Zeenat	Zeenat	NNP
cord-268140-s5lailkp	1	13	title	title	NN
cord-268140-s5lailkp	1	14	:	:	:
cord-268140-s5lailkp	1	15	IL-6	IL-6	NNP
cord-268140-s5lailkp	1	16	Inhibitors	Inhibitors	NNP
cord-268140-s5lailkp	1	17	in	in	IN
cord-268140-s5lailkp	1	18	the	the	DT
cord-268140-s5lailkp	1	19	Treatment	Treatment	NNP
cord-268140-s5lailkp	1	20	of	of	IN
cord-268140-s5lailkp	1	21	Serious	Serious	NNP
cord-268140-s5lailkp	1	22	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	1	23	:	:	:
cord-268140-s5lailkp	1	24	A	a	DT
cord-268140-s5lailkp	1	25	Promising	promise	VBG
cord-268140-s5lailkp	1	26	Therapy	therapy	NN
cord-268140-s5lailkp	1	27	?	?	.
cord-268140-s5lailkp	2	1	date	date	NN
cord-268140-s5lailkp	2	2	:	:	:
cord-268140-s5lailkp	2	3	2020	2020	CD
cord-268140-s5lailkp	2	4	-	-	HYPH
cord-268140-s5lailkp	2	5	06	06	CD
cord-268140-s5lailkp	2	6	-	-	SYM
cord-268140-s5lailkp	2	7	13	13	CD
cord-268140-s5lailkp	2	8	journal	journal	NN
cord-268140-s5lailkp	2	9	:	:	:
cord-268140-s5lailkp	3	1	Pharmaceut	Pharmaceut	NNP
cord-268140-s5lailkp	3	2	Med	Med	NNP
cord-268140-s5lailkp	3	3	DOI	doi	NN
cord-268140-s5lailkp	3	4	:	:	:
cord-268140-s5lailkp	3	5	10.1007	10.1007	CD
cord-268140-s5lailkp	3	6	/	/	SYM
cord-268140-s5lailkp	3	7	s40290	s40290	CD
cord-268140-s5lailkp	3	8	-	-	HYPH
cord-268140-s5lailkp	3	9	020	020	CD
cord-268140-s5lailkp	3	10	-	-	HYPH
cord-268140-s5lailkp	3	11	00342-z	00342-z	CD
cord-268140-s5lailkp	3	12	sha	sha	NNP
cord-268140-s5lailkp	3	13	:	:	:
cord-268140-s5lailkp	4	1	aedf5624658c6f4490f3a1f22925649970fb6c26	aedf5624658c6f4490f3a1f22925649970fb6c26	NNP
cord-268140-s5lailkp	4	2	doc_id	doc_id	CD
cord-268140-s5lailkp	4	3	:	:	:
cord-268140-s5lailkp	4	4	268140	268140	CD
cord-268140-s5lailkp	4	5	cord_uid	cord_uid	NNS
cord-268140-s5lailkp	4	6	:	:	:
cord-268140-s5lailkp	4	7	s5lailkp	s5lailkp	NN
cord-268140-s5lailkp	5	1	At	at	IN
cord-268140-s5lailkp	5	2	present	present	JJ
cord-268140-s5lailkp	5	3	,	,	,
cord-268140-s5lailkp	5	4	there	there	EX
cord-268140-s5lailkp	5	5	are	be	VBP
cord-268140-s5lailkp	5	6	no	no	DT
cord-268140-s5lailkp	5	7	proven	prove	VBN
cord-268140-s5lailkp	5	8	agents	agent	NNS
cord-268140-s5lailkp	5	9	for	for	IN
cord-268140-s5lailkp	5	10	treatment	treatment	NN
cord-268140-s5lailkp	5	11	of	of	IN
cord-268140-s5lailkp	5	12	coronavirus	coronavirus	NN
cord-268140-s5lailkp	5	13	disease	disease	NN
cord-268140-s5lailkp	5	14	(	(	-LRB-
cord-268140-s5lailkp	5	15	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	5	16	)	)	-RRB-
cord-268140-s5lailkp	5	17	.	.	.
cord-268140-s5lailkp	6	1	The	the	DT
cord-268140-s5lailkp	6	2	available	available	JJ
cord-268140-s5lailkp	6	3	evidence	evidence	NN
cord-268140-s5lailkp	6	4	has	have	VBZ
cord-268140-s5lailkp	6	5	not	not	RB
cord-268140-s5lailkp	6	6	allowed	allow	VBN
cord-268140-s5lailkp	6	7	guidelines	guideline	NNS
cord-268140-s5lailkp	6	8	to	to	TO
cord-268140-s5lailkp	6	9	clearly	clearly	RB
cord-268140-s5lailkp	6	10	recommend	recommend	VB
cord-268140-s5lailkp	6	11	any	any	DT
cord-268140-s5lailkp	6	12	drugs	drug	NNS
cord-268140-s5lailkp	6	13	outside	outside	IN
cord-268140-s5lailkp	6	14	the	the	DT
cord-268140-s5lailkp	6	15	context	context	NN
cord-268140-s5lailkp	6	16	of	of	IN
cord-268140-s5lailkp	6	17	clinical	clinical	JJ
cord-268140-s5lailkp	6	18	trials	trial	NNS
cord-268140-s5lailkp	6	19	.	.	.
cord-268140-s5lailkp	7	1	The	the	DT
cord-268140-s5lailkp	7	2	novel	novel	JJ
cord-268140-s5lailkp	7	3	coronavirus	coronavirus	NN
cord-268140-s5lailkp	7	4	SARS	SARS	NNP
cord-268140-s5lailkp	7	5	-	-	:
cord-268140-s5lailkp	7	6	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	7	7	that	that	WDT
cord-268140-s5lailkp	7	8	causes	cause	VBZ
cord-268140-s5lailkp	7	9	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	7	10	invokes	invoke	VBZ
cord-268140-s5lailkp	7	11	a	a	DT
cord-268140-s5lailkp	7	12	hyperinflammatory	hyperinflammatory	JJ
cord-268140-s5lailkp	7	13	state	state	NN
cord-268140-s5lailkp	7	14	driven	drive	VBN
cord-268140-s5lailkp	7	15	by	by	IN
cord-268140-s5lailkp	7	16	multiple	multiple	JJ
cord-268140-s5lailkp	7	17	cells	cell	NNS
cord-268140-s5lailkp	7	18	and	and	CC
cord-268140-s5lailkp	7	19	mediators	mediator	NNS
cord-268140-s5lailkp	7	20	like	like	IN
cord-268140-s5lailkp	7	21	interleukin	interleukin	NN
cord-268140-s5lailkp	7	22	(	(	-LRB-
cord-268140-s5lailkp	7	23	IL)-1	IL)-1	''
cord-268140-s5lailkp	7	24	,	,	,
cord-268140-s5lailkp	7	25	IL-6	IL-6	NNP
cord-268140-s5lailkp	7	26	,	,	,
cord-268140-s5lailkp	7	27	IL-12	IL-12	NNP
cord-268140-s5lailkp	7	28	,	,	,
cord-268140-s5lailkp	7	29	and	and	CC
cord-268140-s5lailkp	7	30	IL-18	IL-18	NNP
cord-268140-s5lailkp	7	31	,	,	,
cord-268140-s5lailkp	7	32	tumor	tumor	NN
cord-268140-s5lailkp	7	33	necrosis	necrosis	NN
cord-268140-s5lailkp	7	34	factor	factor	NN
cord-268140-s5lailkp	7	35	alpha	alpha	NN
cord-268140-s5lailkp	7	36	(	(	-LRB-
cord-268140-s5lailkp	7	37	TNFα	TNFα	NNP
cord-268140-s5lailkp	7	38	)	)	-RRB-
cord-268140-s5lailkp	7	39	,	,	,
cord-268140-s5lailkp	7	40	etc	etc	FW
cord-268140-s5lailkp	7	41	.	.	.
cord-268140-s5lailkp	8	1	Considering	consider	VBG
cord-268140-s5lailkp	8	2	the	the	DT
cord-268140-s5lailkp	8	3	proven	prove	VBN
cord-268140-s5lailkp	8	4	role	role	NN
cord-268140-s5lailkp	8	5	of	of	IN
cord-268140-s5lailkp	8	6	cytokine	cytokine	JJ
cord-268140-s5lailkp	8	7	dysregulation	dysregulation	NN
cord-268140-s5lailkp	8	8	in	in	IN
cord-268140-s5lailkp	8	9	causing	cause	VBG
cord-268140-s5lailkp	8	10	this	this	DT
cord-268140-s5lailkp	8	11	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	8	12	in	in	IN
cord-268140-s5lailkp	8	13	the	the	DT
cord-268140-s5lailkp	8	14	lungs	lung	NNS
cord-268140-s5lailkp	8	15	with	with	IN
cord-268140-s5lailkp	8	16	IL-6	IL-6	NNP
cord-268140-s5lailkp	8	17	being	be	VBG
cord-268140-s5lailkp	8	18	a	a	DT
cord-268140-s5lailkp	8	19	key	key	JJ
cord-268140-s5lailkp	8	20	driver	driver	NN
cord-268140-s5lailkp	8	21	,	,	,
cord-268140-s5lailkp	8	22	particularly	particularly	RB
cord-268140-s5lailkp	8	23	in	in	IN
cord-268140-s5lailkp	8	24	seriously	seriously	RB
cord-268140-s5lailkp	8	25	ill	ill	JJ
cord-268140-s5lailkp	9	1	COVID-19	covid-19	JJ
cord-268140-s5lailkp	9	2	patients	patient	NNS
cord-268140-s5lailkp	9	3	,	,	,
cord-268140-s5lailkp	9	4	it	-PRON-	PRP
cord-268140-s5lailkp	9	5	is	be	VBZ
cord-268140-s5lailkp	9	6	crucial	crucial	JJ
cord-268140-s5lailkp	9	7	to	to	TO
cord-268140-s5lailkp	9	8	further	further	RB
cord-268140-s5lailkp	9	9	explore	explore	VB
cord-268140-s5lailkp	9	10	selective	selective	JJ
cord-268140-s5lailkp	9	11	cytokine	cytokine	NN
cord-268140-s5lailkp	9	12	blockade	blockade	NN
cord-268140-s5lailkp	9	13	with	with	IN
cord-268140-s5lailkp	9	14	drugs	drug	NNS
cord-268140-s5lailkp	9	15	like	like	IN
cord-268140-s5lailkp	9	16	the	the	DT
cord-268140-s5lailkp	9	17	IL-6	IL-6	NNP
cord-268140-s5lailkp	9	18	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	9	19	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	9	20	,	,	,
cord-268140-s5lailkp	9	21	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	9	22	,	,	,
cord-268140-s5lailkp	9	23	and	and	CC
cord-268140-s5lailkp	9	24	siltuximab	siltuximab	NNP
cord-268140-s5lailkp	9	25	.	.	.
cord-268140-s5lailkp	10	1	These	these	DT
cord-268140-s5lailkp	10	2	targeted	target	VBN
cord-268140-s5lailkp	10	3	monoclonal	monoclonal	JJ
cord-268140-s5lailkp	10	4	antibodies	antibody	NNS
cord-268140-s5lailkp	10	5	can	can	MD
cord-268140-s5lailkp	10	6	dampen	dampen	VB
cord-268140-s5lailkp	10	7	the	the	DT
cord-268140-s5lailkp	10	8	downstream	downstream	NN
cord-268140-s5lailkp	10	9	IL-6	IL-6	NNP
cord-268140-s5lailkp	10	10	signaling	signal	VBG
cord-268140-s5lailkp	10	11	pathways	pathway	NNS
cord-268140-s5lailkp	10	12	,	,	,
cord-268140-s5lailkp	10	13	which	which	WDT
cord-268140-s5lailkp	10	14	can	can	MD
cord-268140-s5lailkp	10	15	lead	lead	VB
cord-268140-s5lailkp	10	16	to	to	IN
cord-268140-s5lailkp	10	17	decreased	decrease	VBN
cord-268140-s5lailkp	10	18	cell	cell	NN
cord-268140-s5lailkp	10	19	proliferation	proliferation	NN
cord-268140-s5lailkp	10	20	,	,	,
cord-268140-s5lailkp	10	21	differentiation	differentiation	NN
cord-268140-s5lailkp	10	22	,	,	,
cord-268140-s5lailkp	10	23	oxidative	oxidative	JJ
cord-268140-s5lailkp	10	24	stress	stress	NN
cord-268140-s5lailkp	10	25	,	,	,
cord-268140-s5lailkp	10	26	exudation	exudation	NN
cord-268140-s5lailkp	10	27	,	,	,
cord-268140-s5lailkp	10	28	and	and	CC
cord-268140-s5lailkp	10	29	improve	improve	VB
cord-268140-s5lailkp	10	30	clinical	clinical	JJ
cord-268140-s5lailkp	10	31	outcomes	outcome	NNS
cord-268140-s5lailkp	10	32	in	in	IN
cord-268140-s5lailkp	10	33	patients	patient	NNS
cord-268140-s5lailkp	10	34	with	with	IN
cord-268140-s5lailkp	10	35	evident	evident	JJ
cord-268140-s5lailkp	10	36	features	feature	NNS
cord-268140-s5lailkp	10	37	of	of	IN
cord-268140-s5lailkp	10	38	cytokine	cytokine	NN
cord-268140-s5lailkp	10	39	-	-	HYPH
cord-268140-s5lailkp	10	40	driven	drive	VBN
cord-268140-s5lailkp	10	41	inflammation	inflammation	NN
cord-268140-s5lailkp	10	42	like	like	IN
cord-268140-s5lailkp	10	43	persistent	persistent	JJ
cord-268140-s5lailkp	10	44	fever	fever	NN
cord-268140-s5lailkp	10	45	,	,	,
cord-268140-s5lailkp	10	46	dyspnea	dyspnea	NN
cord-268140-s5lailkp	10	47	and	and	CC
cord-268140-s5lailkp	10	48	elevated	elevated	JJ
cord-268140-s5lailkp	10	49	markers	marker	NNS
cord-268140-s5lailkp	10	50	.	.	.
cord-268140-s5lailkp	11	1	Preliminary	preliminary	JJ
cord-268140-s5lailkp	11	2	evidence	evidence	NN
cord-268140-s5lailkp	11	3	has	have	VBZ
cord-268140-s5lailkp	11	4	come	come	VBN
cord-268140-s5lailkp	11	5	for	for	IN
cord-268140-s5lailkp	11	6	tocilizumab	tocilizumab	NNS
cord-268140-s5lailkp	11	7	from	from	IN
cord-268140-s5lailkp	11	8	some	some	DT
cord-268140-s5lailkp	11	9	small	small	JJ
cord-268140-s5lailkp	11	10	studies	study	NNS
cord-268140-s5lailkp	11	11	,	,	,
cord-268140-s5lailkp	11	12	and	and	CC
cord-268140-s5lailkp	11	13	interim	interim	JJ
cord-268140-s5lailkp	11	14	analysis	analysis	NN
cord-268140-s5lailkp	11	15	of	of	IN
cord-268140-s5lailkp	11	16	a	a	DT
cord-268140-s5lailkp	11	17	randomized	randomized	JJ
cord-268140-s5lailkp	11	18	controlled	control	VBN
cord-268140-s5lailkp	11	19	trial	trial	NN
cord-268140-s5lailkp	11	20	;	;	:
cord-268140-s5lailkp	11	21	the	the	DT
cord-268140-s5lailkp	11	22	latter	latter	JJ
cord-268140-s5lailkp	11	23	also	also	RB
cord-268140-s5lailkp	11	24	being	be	VBG
cord-268140-s5lailkp	11	25	available	available	JJ
cord-268140-s5lailkp	11	26	for	for	IN
cord-268140-s5lailkp	11	27	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	11	28	.	.	.
cord-268140-s5lailkp	12	1	International	international	JJ
cord-268140-s5lailkp	12	2	guidelines	guideline	NNS
cord-268140-s5lailkp	12	3	do	do	VBP
cord-268140-s5lailkp	12	4	include	include	VB
cord-268140-s5lailkp	12	5	IL-6	IL-6	NNP
cord-268140-s5lailkp	12	6	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	12	7	as	as	IN
cord-268140-s5lailkp	12	8	one	one	CD
cord-268140-s5lailkp	12	9	of	of	IN
cord-268140-s5lailkp	12	10	the	the	DT
cord-268140-s5lailkp	12	11	options	option	NNS
cord-268140-s5lailkp	12	12	available	available	JJ
cord-268140-s5lailkp	12	13	for	for	IN
cord-268140-s5lailkp	12	14	severe	severe	JJ
cord-268140-s5lailkp	12	15	or	or	CC
cord-268140-s5lailkp	12	16	critically	critically	RB
cord-268140-s5lailkp	12	17	ill	ill	JJ
cord-268140-s5lailkp	12	18	patients	patient	NNS
cord-268140-s5lailkp	12	19	.	.	.
cord-268140-s5lailkp	13	1	There	there	EX
cord-268140-s5lailkp	13	2	has	have	VBZ
cord-268140-s5lailkp	13	3	been	be	VBN
cord-268140-s5lailkp	13	4	increased	increase	VBN
cord-268140-s5lailkp	13	5	interest	interest	NN
cord-268140-s5lailkp	13	6	in	in	IN
cord-268140-s5lailkp	13	7	evaluating	evaluate	VBG
cord-268140-s5lailkp	13	8	these	these	DT
cord-268140-s5lailkp	13	9	drugs	drug	NNS
cord-268140-s5lailkp	13	10	with	with	IN
cord-268140-s5lailkp	13	11	a	a	DT
cord-268140-s5lailkp	13	12	series	series	NN
cord-268140-s5lailkp	13	13	of	of	IN
cord-268140-s5lailkp	13	14	clinical	clinical	JJ
cord-268140-s5lailkp	13	15	trials	trial	NNS
cord-268140-s5lailkp	13	16	being	be	VBG
cord-268140-s5lailkp	13	17	registered	register	VBN
cord-268140-s5lailkp	13	18	and	and	CC
cord-268140-s5lailkp	13	19	conducted	conduct	VBN
cord-268140-s5lailkp	13	20	in	in	IN
cord-268140-s5lailkp	13	21	different	different	JJ
cord-268140-s5lailkp	13	22	countries	country	NNS
cord-268140-s5lailkp	13	23	.	.	.
cord-268140-s5lailkp	14	1	The	the	DT
cord-268140-s5lailkp	14	2	level	level	NN
cord-268140-s5lailkp	14	3	of	of	IN
cord-268140-s5lailkp	14	4	investigation	investigation	NN
cord-268140-s5lailkp	14	5	though	though	IN
cord-268140-s5lailkp	14	6	perhaps	perhaps	RB
cord-268140-s5lailkp	14	7	needs	need	VBZ
cord-268140-s5lailkp	14	8	to	to	TO
cord-268140-s5lailkp	14	9	be	be	VB
cord-268140-s5lailkp	14	10	further	further	RB
cord-268140-s5lailkp	14	11	intensified	intensify	VBN
cord-268140-s5lailkp	14	12	as	as	IN
cord-268140-s5lailkp	14	13	there	there	EX
cord-268140-s5lailkp	14	14	is	be	VBZ
cord-268140-s5lailkp	14	15	a	a	DT
cord-268140-s5lailkp	14	16	need	need	NN
cord-268140-s5lailkp	14	17	to	to	TO
cord-268140-s5lailkp	14	18	focus	focus	VB
cord-268140-s5lailkp	14	19	on	on	IN
cord-268140-s5lailkp	14	20	therapeutic	therapeutic	JJ
cord-268140-s5lailkp	14	21	options	option	NNS
cord-268140-s5lailkp	14	22	that	that	WDT
cord-268140-s5lailkp	14	23	can	can	MD
cord-268140-s5lailkp	14	24	prove	prove	VB
cord-268140-s5lailkp	14	25	to	to	TO
cord-268140-s5lailkp	14	26	be	be	VB
cord-268140-s5lailkp	14	27	‘	'	``
cord-268140-s5lailkp	14	28	life	life	NN
cord-268140-s5lailkp	14	29	-	-	HYPH
cord-268140-s5lailkp	14	30	saving	save	VBG
cord-268140-s5lailkp	14	31	’	'	''
cord-268140-s5lailkp	14	32	as	as	IN
cord-268140-s5lailkp	14	33	the	the	DT
cord-268140-s5lailkp	14	34	number	number	NN
cord-268140-s5lailkp	14	35	of	of	IN
cord-268140-s5lailkp	14	36	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	14	37	fatalities	fatality	NNS
cord-268140-s5lailkp	14	38	worldwide	worldwide	RB
cord-268140-s5lailkp	14	39	keeps	keep	VBZ
cord-268140-s5lailkp	14	40	increasing	increase	VBG
cord-268140-s5lailkp	14	41	alarmingly	alarmingly	RB
cord-268140-s5lailkp	14	42	.	.	.
cord-268140-s5lailkp	15	1	IL-6	IL-6	NNP
cord-268140-s5lailkp	16	1	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	16	2	could	could	MD
cord-268140-s5lailkp	16	3	be	be	VB
cord-268140-s5lailkp	16	4	one	one	CD
cord-268140-s5lailkp	16	5	such	such	JJ
cord-268140-s5lailkp	16	6	treatment	treatment	NN
cord-268140-s5lailkp	16	7	option	option	NN
cord-268140-s5lailkp	16	8	,	,	,
cord-268140-s5lailkp	16	9	with	with	IN
cord-268140-s5lailkp	16	10	generation	generation	NN
cord-268140-s5lailkp	16	11	of	of	IN
cord-268140-s5lailkp	16	12	more	more	JJR
cord-268140-s5lailkp	16	13	evidence	evidence	NN
cord-268140-s5lailkp	16	14	and	and	CC
cord-268140-s5lailkp	16	15	completion	completion	NN
cord-268140-s5lailkp	16	16	of	of	IN
cord-268140-s5lailkp	16	17	a	a	DT
cord-268140-s5lailkp	16	18	larger	large	JJR
cord-268140-s5lailkp	16	19	number	number	NN
cord-268140-s5lailkp	16	20	of	of	IN
cord-268140-s5lailkp	16	21	systematic	systematic	JJ
cord-268140-s5lailkp	16	22	studies	study	NNS
cord-268140-s5lailkp	16	23	.	.	.
cord-268140-s5lailkp	17	1	At	at	IN
cord-268140-s5lailkp	17	2	the	the	DT
cord-268140-s5lailkp	17	3	time	time	NN
cord-268140-s5lailkp	17	4	of	of	IN
cord-268140-s5lailkp	17	5	writing	writing	NN
cord-268140-s5lailkp	17	6	,	,	,
cord-268140-s5lailkp	17	7	there	there	EX
cord-268140-s5lailkp	17	8	has	have	VBZ
cord-268140-s5lailkp	17	9	been	be	VBN
cord-268140-s5lailkp	17	10	a	a	DT
cord-268140-s5lailkp	17	11	total	total	NN
cord-268140-s5lailkp	17	12	of	of	IN
cord-268140-s5lailkp	17	13	>	>	$
cord-268140-s5lailkp	17	14	5.8	5.8	CD
cord-268140-s5lailkp	17	15	million	million	CD
cord-268140-s5lailkp	17	16	cases	case	NNS
cord-268140-s5lailkp	17	17	of	of	IN
cord-268140-s5lailkp	17	18	coronavirus	coronavirus	NN
cord-268140-s5lailkp	17	19	disease	disease	NN
cord-268140-s5lailkp	17	20	(	(	-LRB-
cord-268140-s5lailkp	17	21	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	17	22	)	)	-RRB-
cord-268140-s5lailkp	17	23	worldwide	worldwide	RB
cord-268140-s5lailkp	17	24	,	,	,
cord-268140-s5lailkp	17	25	and	and	CC
cord-268140-s5lailkp	17	26	more	more	JJR
cord-268140-s5lailkp	17	27	than	than	IN
cord-268140-s5lailkp	17	28	0.36	0.36	CD
cord-268140-s5lailkp	17	29	million	million	CD
cord-268140-s5lailkp	17	30	deaths	death	NNS
cord-268140-s5lailkp	17	31	;	;	:
cord-268140-s5lailkp	17	32	the	the	DT
cord-268140-s5lailkp	17	33	USA	USA	NNP
cord-268140-s5lailkp	17	34	being	be	VBG
cord-268140-s5lailkp	17	35	the	the	DT
cord-268140-s5lailkp	17	36	most	most	RBS
cord-268140-s5lailkp	17	37	heavily	heavily	RB
cord-268140-s5lailkp	17	38	affected	affect	VBN
cord-268140-s5lailkp	17	39	followed	follow	VBN
cord-268140-s5lailkp	17	40	by	by	IN
cord-268140-s5lailkp	17	41	Brazil	Brazil	NNP
cord-268140-s5lailkp	17	42	,	,	,
cord-268140-s5lailkp	17	43	Russia	Russia	NNP
cord-268140-s5lailkp	17	44	,	,	,
cord-268140-s5lailkp	17	45	UK	UK	NNP
cord-268140-s5lailkp	17	46	and	and	CC
cord-268140-s5lailkp	17	47	Spain	Spain	NNP
cord-268140-s5lailkp	17	48	[	[	-LRB-
cord-268140-s5lailkp	17	49	1	1	CD
cord-268140-s5lailkp	17	50	]	]	-RRB-
cord-268140-s5lailkp	17	51	.	.	.
cord-268140-s5lailkp	18	1	The	the	DT
cord-268140-s5lailkp	18	2	mortality	mortality	NN
cord-268140-s5lailkp	18	3	from	from	IN
cord-268140-s5lailkp	18	4	this	this	DT
cord-268140-s5lailkp	18	5	pandemic	pandemic	NN
cord-268140-s5lailkp	18	6	has	have	VBZ
cord-268140-s5lailkp	18	7	been	be	VBN
cord-268140-s5lailkp	18	8	shown	show	VBN
cord-268140-s5lailkp	18	9	to	to	TO
cord-268140-s5lailkp	18	10	vary	vary	VB
cord-268140-s5lailkp	18	11	between	between	IN
cord-268140-s5lailkp	18	12	1	1	CD
cord-268140-s5lailkp	18	13	%	%	NN
cord-268140-s5lailkp	18	14	to	to	IN
cord-268140-s5lailkp	18	15	more	more	JJR
cord-268140-s5lailkp	18	16	than	than	IN
cord-268140-s5lailkp	18	17	7	7	CD
cord-268140-s5lailkp	18	18	%	%	NN
cord-268140-s5lailkp	18	19	[	[	-LRB-
cord-268140-s5lailkp	18	20	2	2	CD
cord-268140-s5lailkp	18	21	]	]	-RRB-
cord-268140-s5lailkp	18	22	.	.	.
cord-268140-s5lailkp	19	1	The	the	DT
cord-268140-s5lailkp	19	2	biggest	big	JJS
cord-268140-s5lailkp	19	3	concerns	concern	NNS
cord-268140-s5lailkp	19	4	are	be	VBP
cord-268140-s5lailkp	19	5	the	the	DT
cord-268140-s5lailkp	19	6	transmissibility	transmissibility	NN
cord-268140-s5lailkp	19	7	of	of	IN
cord-268140-s5lailkp	19	8	this	this	DT
cord-268140-s5lailkp	19	9	virus	virus	NN
cord-268140-s5lailkp	19	10	leading	lead	VBG
cord-268140-s5lailkp	19	11	to	to	IN
cord-268140-s5lailkp	19	12	high	high	JJ
cord-268140-s5lailkp	19	13	rates	rate	NNS
cord-268140-s5lailkp	19	14	of	of	IN
cord-268140-s5lailkp	19	15	infection	infection	NN
cord-268140-s5lailkp	19	16	as	as	IN
cord-268140-s5lailkp	19	17	it	-PRON-	PRP
cord-268140-s5lailkp	19	18	spreads	spread	VBZ
cord-268140-s5lailkp	19	19	in	in	IN
cord-268140-s5lailkp	19	20	the	the	DT
cord-268140-s5lailkp	19	21	population	population	NN
cord-268140-s5lailkp	19	22	at	at	IN
cord-268140-s5lailkp	19	23	a	a	DT
cord-268140-s5lailkp	19	24	rate	rate	NN
cord-268140-s5lailkp	19	25	of	of	IN
cord-268140-s5lailkp	19	26	0.8	0.8	CD
cord-268140-s5lailkp	19	27	-	-	SYM
cord-268140-s5lailkp	19	28	3	3	CD
cord-268140-s5lailkp	19	29	%	%	NN
cord-268140-s5lailkp	19	30	,	,	,
cord-268140-s5lailkp	19	31	higher	high	JJR
cord-268140-s5lailkp	19	32	than	than	IN
cord-268140-s5lailkp	19	33	the	the	DT
cord-268140-s5lailkp	19	34	normal	normal	JJ
cord-268140-s5lailkp	19	35	flu	flu	NN
cord-268140-s5lailkp	19	36	.	.	.
cord-268140-s5lailkp	20	1	Management	management	NN
cord-268140-s5lailkp	20	2	of	of	IN
cord-268140-s5lailkp	20	3	serious	serious	JJ
cord-268140-s5lailkp	20	4	cases	case	NNS
cord-268140-s5lailkp	20	5	where	where	WRB
cord-268140-s5lailkp	20	6	respiratory	respiratory	JJ
cord-268140-s5lailkp	20	7	failure	failure	NN
cord-268140-s5lailkp	20	8	from	from	IN
cord-268140-s5lailkp	20	9	pneumonia	pneumonia	NN
cord-268140-s5lailkp	20	10	and	and	CC
cord-268140-s5lailkp	20	11	subsequent	subsequent	JJ
cord-268140-s5lailkp	20	12	acute	acute	JJ
cord-268140-s5lailkp	20	13	respiratory	respiratory	JJ
cord-268140-s5lailkp	20	14	distress	distress	NN
cord-268140-s5lailkp	20	15	syndrome	syndrome	NN
cord-268140-s5lailkp	20	16	(	(	-LRB-
cord-268140-s5lailkp	20	17	ARDS	ARDS	NNP
cord-268140-s5lailkp	20	18	)	)	-RRB-
cord-268140-s5lailkp	20	19	arising	arise	VBG
cord-268140-s5lailkp	20	20	from	from	IN
cord-268140-s5lailkp	20	21	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	20	22	in	in	IN
cord-268140-s5lailkp	20	23	the	the	DT
cord-268140-s5lailkp	20	24	lungs	lung	NNS
cord-268140-s5lailkp	20	25	,	,	,
cord-268140-s5lailkp	20	26	is	be	VBZ
cord-268140-s5lailkp	20	27	the	the	DT
cord-268140-s5lailkp	20	28	leading	leading	JJ
cord-268140-s5lailkp	20	29	cause	cause	NN
cord-268140-s5lailkp	20	30	of	of	IN
cord-268140-s5lailkp	20	31	mortality	mortality	NN
cord-268140-s5lailkp	20	32	[	[	-LRB-
cord-268140-s5lailkp	20	33	3	3	CD
cord-268140-s5lailkp	20	34	,	,	,
cord-268140-s5lailkp	20	35	4	4	CD
cord-268140-s5lailkp	20	36	]	]	-RRB-
cord-268140-s5lailkp	20	37	.	.	.
cord-268140-s5lailkp	21	1	It	-PRON-	PRP
cord-268140-s5lailkp	21	2	affects	affect	VBZ
cord-268140-s5lailkp	21	3	men	man	NNS
cord-268140-s5lailkp	21	4	more	more	JJR
cord-268140-s5lailkp	21	5	than	than	IN
cord-268140-s5lailkp	21	6	women	woman	NNS
cord-268140-s5lailkp	21	7	,	,	,
cord-268140-s5lailkp	21	8	since	since	IN
cord-268140-s5lailkp	21	9	the	the	DT
cord-268140-s5lailkp	21	10	X	X	NNS
cord-268140-s5lailkp	21	11	-	-	NNS
cord-268140-s5lailkp	21	12	chromosomes	chromosome	NNS
cord-268140-s5lailkp	21	13	express	express	VBP
cord-268140-s5lailkp	21	14	more	more	JJR
cord-268140-s5lailkp	21	15	genes	gene	NNS
cord-268140-s5lailkp	21	16	for	for	IN
cord-268140-s5lailkp	21	17	immunity	immunity	NN
cord-268140-s5lailkp	21	18	[	[	-LRB-
cord-268140-s5lailkp	21	19	5	5	CD
cord-268140-s5lailkp	21	20	]	]	-RRB-
cord-268140-s5lailkp	21	21	.	.	.
cord-268140-s5lailkp	22	1	Current	current	JJ
cord-268140-s5lailkp	22	2	management	management	NN
cord-268140-s5lailkp	22	3	of	of	IN
cord-268140-s5lailkp	22	4	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	22	5	is	be	VBZ
cord-268140-s5lailkp	22	6	supportive	supportive	JJ
cord-268140-s5lailkp	22	7	and	and	CC
cord-268140-s5lailkp	22	8	there	there	EX
cord-268140-s5lailkp	22	9	are	be	VBP
cord-268140-s5lailkp	22	10	no	no	DT
cord-268140-s5lailkp	22	11	complete	complete	JJ
cord-268140-s5lailkp	22	12	concrete	concrete	JJ
cord-268140-s5lailkp	22	13	clinical	clinical	JJ
cord-268140-s5lailkp	22	14	trial	trial	NN
cord-268140-s5lailkp	22	15	data	datum	NNS
cord-268140-s5lailkp	22	16	yet	yet	RB
cord-268140-s5lailkp	22	17	supporting	support	VBG
cord-268140-s5lailkp	22	18	any	any	DT
cord-268140-s5lailkp	22	19	preventive	preventive	JJ
cord-268140-s5lailkp	22	20	or	or	CC
cord-268140-s5lailkp	22	21	therapeutic	therapeutic	JJ
cord-268140-s5lailkp	22	22	drugs	drug	NNS
cord-268140-s5lailkp	22	23	or	or	CC
cord-268140-s5lailkp	22	24	biologics	biologic	NNS
cord-268140-s5lailkp	22	25	.	.	.
cord-268140-s5lailkp	23	1	Current	current	JJ
cord-268140-s5lailkp	23	2	management	management	NN
cord-268140-s5lailkp	23	3	guidelines	guideline	NNS
cord-268140-s5lailkp	23	4	in	in	IN
cord-268140-s5lailkp	23	5	various	various	JJ
cord-268140-s5lailkp	23	6	nations	nation	NNS
cord-268140-s5lailkp	23	7	are	be	VBP
cord-268140-s5lailkp	23	8	largely	largely	RB
cord-268140-s5lailkp	23	9	relying	rely	VBG
cord-268140-s5lailkp	23	10	on	on	IN
cord-268140-s5lailkp	23	11	anecdotal	anecdotal	JJ
cord-268140-s5lailkp	23	12	evidence	evidence	NN
cord-268140-s5lailkp	23	13	or	or	CC
cord-268140-s5lailkp	23	14	evidence	evidence	NN
cord-268140-s5lailkp	23	15	from	from	IN
cord-268140-s5lailkp	23	16	a	a	DT
cord-268140-s5lailkp	23	17	few	few	JJ
cord-268140-s5lailkp	23	18	small	small	JJ
cord-268140-s5lailkp	23	19	completed	complete	VBN
cord-268140-s5lailkp	23	20	studies	study	NNS
cord-268140-s5lailkp	23	21	or	or	CC
cord-268140-s5lailkp	23	22	very	very	RB
cord-268140-s5lailkp	23	23	few	few	JJ
cord-268140-s5lailkp	23	24	interim	interim	JJ
cord-268140-s5lailkp	23	25	analyses	analysis	NNS
cord-268140-s5lailkp	23	26	.	.	.
cord-268140-s5lailkp	24	1	Agents	agent	NNS
cord-268140-s5lailkp	24	2	previously	previously	RB
cord-268140-s5lailkp	24	3	tried	try	VBD
cord-268140-s5lailkp	24	4	in	in	IN
cord-268140-s5lailkp	24	5	Severe	severe	JJ
cord-268140-s5lailkp	24	6	Acute	acute	JJ
cord-268140-s5lailkp	24	7	Respiratory	Respiratory	NNP
cord-268140-s5lailkp	24	8	Syndrome	Syndrome	NNP
cord-268140-s5lailkp	24	9	(	(	-LRB-
cord-268140-s5lailkp	24	10	SARS	SARS	NNP
cord-268140-s5lailkp	24	11	)	)	-RRB-
cord-268140-s5lailkp	24	12	and	and	CC
cord-268140-s5lailkp	24	13	Middle	Middle	NNP
cord-268140-s5lailkp	24	14	East	East	NNP
cord-268140-s5lailkp	24	15	Respiratory	Respiratory	NNP
cord-268140-s5lailkp	24	16	Syndrome	Syndrome	NNP
cord-268140-s5lailkp	24	17	(	(	-LRB-
cord-268140-s5lailkp	24	18	MERS	MERS	NNP
cord-268140-s5lailkp	24	19	)	)	-RRB-
cord-268140-s5lailkp	24	20	,	,	,
cord-268140-s5lailkp	24	21	and	and	CC
cord-268140-s5lailkp	24	22	a	a	DT
cord-268140-s5lailkp	24	23	handful	handful	NN
cord-268140-s5lailkp	24	24	of	of	IN
cord-268140-s5lailkp	24	25	repurposed	repurpose	VBN
cord-268140-s5lailkp	24	26	drugs	drug	NNS
cord-268140-s5lailkp	24	27	are	be	VBP
cord-268140-s5lailkp	24	28	being	be	VBG
cord-268140-s5lailkp	24	29	considered	consider	VBN
cord-268140-s5lailkp	24	30	as	as	IN
cord-268140-s5lailkp	24	31	the	the	DT
cord-268140-s5lailkp	24	32	main	main	JJ
cord-268140-s5lailkp	24	33	potential	potential	JJ
cord-268140-s5lailkp	24	34	candidates	candidate	NNS
cord-268140-s5lailkp	24	35	to	to	TO
cord-268140-s5lailkp	24	36	treat	treat	VB
cord-268140-s5lailkp	24	37	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	24	38	along	along	IN
cord-268140-s5lailkp	24	39	with	with	IN
cord-268140-s5lailkp	24	40	approaches	approach	NNS
cord-268140-s5lailkp	24	41	like	like	IN
cord-268140-s5lailkp	24	42	convalescent	convalescent	JJ
cord-268140-s5lailkp	24	43	plasma	plasma	NN
cord-268140-s5lailkp	24	44	therapy	therapy	NN
cord-268140-s5lailkp	24	45	.	.	.
cord-268140-s5lailkp	25	1	Oxygen	oxygen	NN
cord-268140-s5lailkp	25	2	therapy	therapy	NN
cord-268140-s5lailkp	25	3	and	and	CC
cord-268140-s5lailkp	25	4	ventilator	ventilator	NN
cord-268140-s5lailkp	25	5	support	support	NN
cord-268140-s5lailkp	25	6	have	have	VBP
cord-268140-s5lailkp	25	7	also	also	RB
cord-268140-s5lailkp	25	8	been	be	VBN
cord-268140-s5lailkp	25	9	an	an	DT
cord-268140-s5lailkp	25	10	integral	integral	JJ
cord-268140-s5lailkp	25	11	part	part	NN
cord-268140-s5lailkp	25	12	of	of	IN
cord-268140-s5lailkp	25	13	treatment	treatment	NN
cord-268140-s5lailkp	25	14	protocols	protocol	NNS
cord-268140-s5lailkp	25	15	.	.	.
cord-268140-s5lailkp	26	1	Amongst	amongst	IN
cord-268140-s5lailkp	26	2	these	these	DT
cord-268140-s5lailkp	26	3	,	,	,
cord-268140-s5lailkp	26	4	the	the	DT
cord-268140-s5lailkp	26	5	antimalarial	antimalarial	JJ
cord-268140-s5lailkp	26	6	,	,	,
cord-268140-s5lailkp	26	7	anti	anti	JJ
cord-268140-s5lailkp	26	8	-	-	JJ
cord-268140-s5lailkp	26	9	arthritis	arthritis	JJ
cord-268140-s5lailkp	26	10	drug	drug	NN
cord-268140-s5lailkp	26	11	hydroxychloroquine	hydroxychloroquine	NNP
cord-268140-s5lailkp	26	12	had	have	VBD
cord-268140-s5lailkp	26	13	been	be	VBN
cord-268140-s5lailkp	26	14	touted	tout	VBN
cord-268140-s5lailkp	26	15	as	as	IN
cord-268140-s5lailkp	26	16	a	a	DT
cord-268140-s5lailkp	26	17	'	'	``
cord-268140-s5lailkp	26	18	game	game	NN
cord-268140-s5lailkp	26	19	-	-	HYPH
cord-268140-s5lailkp	26	20	changer	changer	NN
cord-268140-s5lailkp	26	21	drug	drug	NN
cord-268140-s5lailkp	26	22	'	'	''
cord-268140-s5lailkp	26	23	globally	globally	RB
cord-268140-s5lailkp	26	24	up	up	RB
cord-268140-s5lailkp	26	25	until	until	IN
cord-268140-s5lailkp	26	26	recently	recently	RB
cord-268140-s5lailkp	26	27	,	,	,
cord-268140-s5lailkp	26	28	although	although	IN
cord-268140-s5lailkp	26	29	the	the	DT
cord-268140-s5lailkp	26	30	initial	initial	JJ
cord-268140-s5lailkp	26	31	favorable	favorable	JJ
cord-268140-s5lailkp	26	32	evidence	evidence	NN
cord-268140-s5lailkp	26	33	had	have	VBD
cord-268140-s5lailkp	26	34	come	come	VBN
cord-268140-s5lailkp	26	35	only	only	RB
cord-268140-s5lailkp	26	36	from	from	IN
cord-268140-s5lailkp	26	37	small	small	JJ
cord-268140-s5lailkp	26	38	methodologically	methodologically	RB
cord-268140-s5lailkp	26	39	flawed	flawed	JJ
cord-268140-s5lailkp	26	40	French	french	JJ
cord-268140-s5lailkp	26	41	and	and	CC
cord-268140-s5lailkp	26	42	Chinese	chinese	JJ
cord-268140-s5lailkp	26	43	studies	study	NNS
cord-268140-s5lailkp	26	44	[	[	-LRB-
cord-268140-s5lailkp	26	45	6	6	CD
cord-268140-s5lailkp	26	46	]	]	-RRB-
cord-268140-s5lailkp	26	47	.	.	.
cord-268140-s5lailkp	27	1	Subsequently	subsequently	RB
cord-268140-s5lailkp	27	2	,	,	,
cord-268140-s5lailkp	27	3	more	more	JJR
cord-268140-s5lailkp	27	4	studies	study	NNS
cord-268140-s5lailkp	27	5	with	with	IN
cord-268140-s5lailkp	27	6	mixed	mixed	JJ
cord-268140-s5lailkp	27	7	results	result	NNS
cord-268140-s5lailkp	27	8	have	have	VBP
cord-268140-s5lailkp	27	9	been	be	VBN
cord-268140-s5lailkp	27	10	published	publish	VBN
cord-268140-s5lailkp	27	11	on	on	IN
cord-268140-s5lailkp	27	12	safety	safety	NN
cord-268140-s5lailkp	27	13	and	and	CC
cord-268140-s5lailkp	27	14	There	there	EX
cord-268140-s5lailkp	27	15	is	be	VBZ
cord-268140-s5lailkp	27	16	no	no	DT
cord-268140-s5lailkp	27	17	proven	prove	VBN
cord-268140-s5lailkp	27	18	treatment	treatment	NN
cord-268140-s5lailkp	27	19	for	for	IN
cord-268140-s5lailkp	27	20	coronavirus	coronavirus	NN
cord-268140-s5lailkp	27	21	disease	disease	NN
cord-268140-s5lailkp	27	22	as	as	IN
cord-268140-s5lailkp	27	23	of	of	IN
cord-268140-s5lailkp	27	24	yet	yet	RB
cord-268140-s5lailkp	27	25	,	,	,
cord-268140-s5lailkp	27	26	and	and	CC
cord-268140-s5lailkp	27	27	current	current	JJ
cord-268140-s5lailkp	27	28	treatment	treatment	NN
cord-268140-s5lailkp	27	29	guidelines	guideline	NNS
cord-268140-s5lailkp	27	30	do	do	VBP
cord-268140-s5lailkp	27	31	not	not	RB
cord-268140-s5lailkp	27	32	recommend	recommend	VB
cord-268140-s5lailkp	27	33	any	any	DT
cord-268140-s5lailkp	27	34	particular	particular	JJ
cord-268140-s5lailkp	27	35	drugs	drug	NNS
cord-268140-s5lailkp	27	36	outside	outside	IN
cord-268140-s5lailkp	27	37	the	the	DT
cord-268140-s5lailkp	27	38	context	context	NN
cord-268140-s5lailkp	27	39	of	of	IN
cord-268140-s5lailkp	27	40	clinical	clinical	JJ
cord-268140-s5lailkp	27	41	trials	trial	NNS
cord-268140-s5lailkp	27	42	.	.	.
cord-268140-s5lailkp	28	1	Sufficient	sufficient	JJ
cord-268140-s5lailkp	28	2	clinical	clinical	JJ
cord-268140-s5lailkp	28	3	evidence	evidence	NN
cord-268140-s5lailkp	28	4	is	be	VBZ
cord-268140-s5lailkp	28	5	lacking	lack	VBG
cord-268140-s5lailkp	28	6	for	for	IN
cord-268140-s5lailkp	28	7	all	all	DT
cord-268140-s5lailkp	28	8	drugs	drug	NNS
cord-268140-s5lailkp	28	9	that	that	WDT
cord-268140-s5lailkp	28	10	are	be	VBP
cord-268140-s5lailkp	28	11	being	be	VBG
cord-268140-s5lailkp	28	12	tried	try	VBN
cord-268140-s5lailkp	28	13	and	and	CC
cord-268140-s5lailkp	28	14	studied	study	VBN
cord-268140-s5lailkp	28	15	.	.	.
cord-268140-s5lailkp	29	1	Considering	consider	VBG
cord-268140-s5lailkp	29	2	the	the	DT
cord-268140-s5lailkp	29	3	proven	prove	VBN
cord-268140-s5lailkp	29	4	role	role	NN
cord-268140-s5lailkp	29	5	of	of	IN
cord-268140-s5lailkp	29	6	cytokine	cytokine	JJ
cord-268140-s5lailkp	29	7	dysregulation	dysregulation	NN
cord-268140-s5lailkp	29	8	in	in	IN
cord-268140-s5lailkp	29	9	serious	serious	JJ
cord-268140-s5lailkp	29	10	COVID-19	covid-19	NN
cord-268140-s5lailkp	29	11	and	and	CC
cord-268140-s5lailkp	29	12	interleukin	interleukin	NN
cord-268140-s5lailkp	29	13	(	(	-LRB-
cord-268140-s5lailkp	29	14	IL)-6	il)-6	NN
cord-268140-s5lailkp	29	15	being	be	VBG
cord-268140-s5lailkp	29	16	the	the	DT
cord-268140-s5lailkp	29	17	key	key	JJ
cord-268140-s5lailkp	29	18	driver	driver	NN
cord-268140-s5lailkp	29	19	of	of	IN
cord-268140-s5lailkp	29	20	this	this	DT
cord-268140-s5lailkp	29	21	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	29	22	,	,	,
cord-268140-s5lailkp	29	23	which	which	WDT
cord-268140-s5lailkp	29	24	can	can	MD
cord-268140-s5lailkp	29	25	cause	cause	VB
cord-268140-s5lailkp	29	26	multi	multi	JJ
cord-268140-s5lailkp	29	27	-	-	JJ
cord-268140-s5lailkp	29	28	organ	organ	JJ
cord-268140-s5lailkp	29	29	failure	failure	NN
cord-268140-s5lailkp	29	30	,	,	,
cord-268140-s5lailkp	29	31	a	a	DT
cord-268140-s5lailkp	29	32	series	series	NN
cord-268140-s5lailkp	29	33	of	of	IN
cord-268140-s5lailkp	29	34	clinical	clinical	JJ
cord-268140-s5lailkp	29	35	trials	trial	NNS
cord-268140-s5lailkp	29	36	with	with	IN
cord-268140-s5lailkp	29	37	IL-6	IL-6	NNP
cord-268140-s5lailkp	29	38	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	29	39	like	like	IN
cord-268140-s5lailkp	29	40	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	29	41	,	,	,
cord-268140-s5lailkp	29	42	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	29	43	and	and	CC
cord-268140-s5lailkp	29	44	siltuximab	siltuximab	NNPS
cord-268140-s5lailkp	29	45	are	be	VBP
cord-268140-s5lailkp	29	46	underway	underway	JJ
cord-268140-s5lailkp	29	47	.	.	.
cord-268140-s5lailkp	30	1	Some	some	DT
cord-268140-s5lailkp	30	2	preliminary	preliminary	JJ
cord-268140-s5lailkp	30	3	evidence	evidence	NN
cord-268140-s5lailkp	30	4	is	be	VBZ
cord-268140-s5lailkp	30	5	available	available	JJ
cord-268140-s5lailkp	30	6	for	for	IN
cord-268140-s5lailkp	30	7	their	-PRON-	PRP$
cord-268140-s5lailkp	30	8	clinical	clinical	JJ
cord-268140-s5lailkp	30	9	efficacy	efficacy	NN
cord-268140-s5lailkp	30	10	.	.	.
cord-268140-s5lailkp	31	1	With	with	IN
cord-268140-s5lailkp	31	2	the	the	DT
cord-268140-s5lailkp	31	3	increasing	increase	VBG
cord-268140-s5lailkp	31	4	case	case	NN
cord-268140-s5lailkp	31	5	fatalities	fatality	NNS
cord-268140-s5lailkp	31	6	,	,	,
cord-268140-s5lailkp	31	7	focus	focus	NN
cord-268140-s5lailkp	31	8	is	be	VBZ
cord-268140-s5lailkp	31	9	needed	need	VBN
cord-268140-s5lailkp	31	10	on	on	IN
cord-268140-s5lailkp	31	11	therapeutic	therapeutic	JJ
cord-268140-s5lailkp	31	12	options	option	NNS
cord-268140-s5lailkp	31	13	that	that	WDT
cord-268140-s5lailkp	31	14	can	can	MD
cord-268140-s5lailkp	31	15	prove	prove	VB
cord-268140-s5lailkp	31	16	to	to	TO
cord-268140-s5lailkp	31	17	be	be	VB
cord-268140-s5lailkp	31	18	life	life	NN
cord-268140-s5lailkp	31	19	saving	save	VBG
cord-268140-s5lailkp	31	20	.	.	.
cord-268140-s5lailkp	32	1	More	more	RBR
cord-268140-s5lailkp	32	2	extensive	extensive	JJ
cord-268140-s5lailkp	32	3	evidence	evidence	NN
cord-268140-s5lailkp	32	4	for	for	IN
cord-268140-s5lailkp	32	5	clinical	clinical	JJ
cord-268140-s5lailkp	32	6	utility	utility	NN
cord-268140-s5lailkp	32	7	of	of	IN
cord-268140-s5lailkp	32	8	IL-6	IL-6	NNP
cord-268140-s5lailkp	32	9	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	32	10	in	in	IN
cord-268140-s5lailkp	32	11	serious	serious	JJ
cord-268140-s5lailkp	32	12	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	32	13	should	should	MD
cord-268140-s5lailkp	32	14	be	be	VB
cord-268140-s5lailkp	32	15	generated	generate	VBN
cord-268140-s5lailkp	32	16	by	by	IN
cord-268140-s5lailkp	32	17	conducting	conduct	VBG
cord-268140-s5lailkp	32	18	exploratory	exploratory	JJ
cord-268140-s5lailkp	32	19	and	and	CC
cord-268140-s5lailkp	32	20	larger	large	JJR
cord-268140-s5lailkp	32	21	systematic	systematic	JJ
cord-268140-s5lailkp	32	22	studies	study	NNS
cord-268140-s5lailkp	32	23	.	.	.
cord-268140-s5lailkp	33	1	pertinent	pertinent	JJ
cord-268140-s5lailkp	33	2	to	to	TO
cord-268140-s5lailkp	33	3	note	note	VB
cord-268140-s5lailkp	33	4	that	that	IN
cord-268140-s5lailkp	33	5	recently	recently	RB
cord-268140-s5lailkp	33	6	released	release	VBD
cord-268140-s5lailkp	33	7	guidelines	guideline	NNS
cord-268140-s5lailkp	33	8	from	from	IN
cord-268140-s5lailkp	33	9	the	the	DT
cord-268140-s5lailkp	33	10	National	National	NNP
cord-268140-s5lailkp	33	11	Institutes	Institutes	NNPS
cord-268140-s5lailkp	33	12	of	of	IN
cord-268140-s5lailkp	33	13	Health	Health	NNP
cord-268140-s5lailkp	33	14	(	(	-LRB-
cord-268140-s5lailkp	33	15	NIH	NIH	NNP
cord-268140-s5lailkp	33	16	)	)	-RRB-
cord-268140-s5lailkp	33	17	,	,	,
cord-268140-s5lailkp	33	18	the	the	DT
cord-268140-s5lailkp	33	19	Infectious	Infectious	NNP
cord-268140-s5lailkp	33	20	Diseases	Diseases	NNPS
cord-268140-s5lailkp	33	21	Society	Society	NNP
cord-268140-s5lailkp	33	22	of	of	IN
cord-268140-s5lailkp	33	23	America	America	NNP
cord-268140-s5lailkp	33	24	guidelines	guideline	NNS
cord-268140-s5lailkp	33	25	and	and	CC
cord-268140-s5lailkp	33	26	latest	late	JJS
cord-268140-s5lailkp	33	27	WHO	who	WP
cord-268140-s5lailkp	33	28	interim	interim	JJ
cord-268140-s5lailkp	33	29	guidance	guidance	NN
cord-268140-s5lailkp	33	30	on	on	IN
cord-268140-s5lailkp	33	31	clinical	clinical	JJ
cord-268140-s5lailkp	33	32	management	management	NN
cord-268140-s5lailkp	33	33	of	of	IN
cord-268140-s5lailkp	33	34	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	33	35	state	state	NN
cord-268140-s5lailkp	34	1	that	that	IN
cord-268140-s5lailkp	34	2	there	there	EX
cord-268140-s5lailkp	34	3	are	be	VBP
cord-268140-s5lailkp	34	4	no	no	DT
cord-268140-s5lailkp	34	5	recommendations	recommendation	NNS
cord-268140-s5lailkp	34	6	for	for	IN
cord-268140-s5lailkp	34	7	or	or	CC
cord-268140-s5lailkp	34	8	against	against	IN
cord-268140-s5lailkp	34	9	any	any	DT
cord-268140-s5lailkp	34	10	drugs	drug	NNS
cord-268140-s5lailkp	34	11	per	per	IN
cord-268140-s5lailkp	34	12	se	se	FW
cord-268140-s5lailkp	34	13	for	for	IN
cord-268140-s5lailkp	34	14	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	34	15	,	,	,
cord-268140-s5lailkp	34	16	out	out	IN
cord-268140-s5lailkp	34	17	of	of	IN
cord-268140-s5lailkp	34	18	the	the	DT
cord-268140-s5lailkp	34	19	context	context	NN
cord-268140-s5lailkp	34	20	of	of	IN
cord-268140-s5lailkp	34	21	clinical	clinical	JJ
cord-268140-s5lailkp	34	22	trials	trial	NNS
cord-268140-s5lailkp	34	23	right	right	RB
cord-268140-s5lailkp	34	24	now	now	RB
cord-268140-s5lailkp	34	25	[	[	-LRB-
cord-268140-s5lailkp	34	26	11	11	CD
cord-268140-s5lailkp	34	27	]	]	-RRB-
cord-268140-s5lailkp	34	28	[	[	-LRB-
cord-268140-s5lailkp	34	29	12	12	CD
cord-268140-s5lailkp	34	30	]	]	-RRB-
cord-268140-s5lailkp	34	31	[	[	-LRB-
cord-268140-s5lailkp	34	32	13	13	CD
cord-268140-s5lailkp	34	33	]	]	-RRB-
cord-268140-s5lailkp	34	34	.	.	.
cord-268140-s5lailkp	35	1	IL-6	IL-6	NNP
cord-268140-s5lailkp	35	2	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	35	3	are	be	VBP
cord-268140-s5lailkp	35	4	one	one	CD
cord-268140-s5lailkp	35	5	class	class	NN
cord-268140-s5lailkp	35	6	of	of	IN
cord-268140-s5lailkp	35	7	drug	drug	NN
cord-268140-s5lailkp	35	8	that	that	WDT
cord-268140-s5lailkp	35	9	initially	initially	RB
cord-268140-s5lailkp	35	10	seemed	seem	VBD
cord-268140-s5lailkp	35	11	to	to	TO
cord-268140-s5lailkp	35	12	be	be	VB
cord-268140-s5lailkp	35	13	under	under	IN
cord-268140-s5lailkp	35	14	the	the	DT
cord-268140-s5lailkp	35	15	radar	radar	NN
cord-268140-s5lailkp	35	16	in	in	IN
cord-268140-s5lailkp	35	17	these	these	DT
cord-268140-s5lailkp	35	18	initial	initial	JJ
cord-268140-s5lailkp	35	19	frontline	frontline	JJ
cord-268140-s5lailkp	35	20	discussions	discussion	NNS
cord-268140-s5lailkp	35	21	and	and	CC
cord-268140-s5lailkp	35	22	the	the	DT
cord-268140-s5lailkp	35	23	major	major	JJ
cord-268140-s5lailkp	35	24	trials	trial	NNS
cord-268140-s5lailkp	35	25	;	;	:
cord-268140-s5lailkp	35	26	drugs	drug	NNS
cord-268140-s5lailkp	35	27	like	like	IN
cord-268140-s5lailkp	35	28	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	35	29	,	,	,
cord-268140-s5lailkp	35	30	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	35	31	,	,	,
cord-268140-s5lailkp	35	32	siltuximab	siltuximab	NNP
cord-268140-s5lailkp	35	33	and	and	CC
cord-268140-s5lailkp	35	34	clazakizumab	clazakizumab	NNP
cord-268140-s5lailkp	35	35	.	.	.
cord-268140-s5lailkp	36	1	They	-PRON-	PRP
cord-268140-s5lailkp	36	2	are	be	VBP
cord-268140-s5lailkp	36	3	now	now	RB
cord-268140-s5lailkp	36	4	considered	consider	VBN
cord-268140-s5lailkp	36	5	to	to	TO
cord-268140-s5lailkp	36	6	be	be	VB
cord-268140-s5lailkp	36	7	one	one	CD
cord-268140-s5lailkp	36	8	of	of	IN
cord-268140-s5lailkp	36	9	the	the	DT
cord-268140-s5lailkp	36	10	adjunctive	adjunctive	JJ
cord-268140-s5lailkp	36	11	immunomodulator	immunomodulator	NNP
cord-268140-s5lailkp	36	12	therapies	therapy	NNS
cord-268140-s5lailkp	36	13	that	that	WDT
cord-268140-s5lailkp	36	14	can	can	MD
cord-268140-s5lailkp	36	15	be	be	VB
cord-268140-s5lailkp	36	16	useful	useful	JJ
cord-268140-s5lailkp	36	17	in	in	IN
cord-268140-s5lailkp	36	18	severe	severe	JJ
cord-268140-s5lailkp	36	19	or	or	CC
cord-268140-s5lailkp	36	20	critical	critical	JJ
cord-268140-s5lailkp	36	21	COVID-19	covid-19	NN
cord-268140-s5lailkp	36	22	.	.	.
cord-268140-s5lailkp	37	1	In	in	IN
cord-268140-s5lailkp	37	2	recent	recent	JJ
cord-268140-s5lailkp	37	3	times	time	NNS
cord-268140-s5lailkp	37	4	,	,	,
cord-268140-s5lailkp	37	5	there	there	EX
cord-268140-s5lailkp	37	6	has	have	VBZ
cord-268140-s5lailkp	37	7	been	be	VBN
cord-268140-s5lailkp	37	8	marked	mark	VBN
cord-268140-s5lailkp	37	9	interest	interest	NN
cord-268140-s5lailkp	37	10	and	and	CC
cord-268140-s5lailkp	37	11	rapid	rapid	JJ
cord-268140-s5lailkp	37	12	pace	pace	NN
cord-268140-s5lailkp	37	13	of	of	IN
cord-268140-s5lailkp	37	14	international	international	JJ
cord-268140-s5lailkp	37	15	investigation	investigation	NN
cord-268140-s5lailkp	37	16	to	to	TO
cord-268140-s5lailkp	37	17	study	study	VB
cord-268140-s5lailkp	37	18	the	the	DT
cord-268140-s5lailkp	37	19	role	role	NN
cord-268140-s5lailkp	37	20	of	of	IN
cord-268140-s5lailkp	37	21	IL-6	IL-6	NNP
cord-268140-s5lailkp	37	22	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	37	23	as	as	IN
cord-268140-s5lailkp	37	24	a	a	DT
cord-268140-s5lailkp	37	25	therapy	therapy	NN
cord-268140-s5lailkp	37	26	for	for	IN
cord-268140-s5lailkp	37	27	serious	serious	JJ
cord-268140-s5lailkp	37	28	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	37	29	as	as	IN
cord-268140-s5lailkp	37	30	evidenced	evidence	VBN
cord-268140-s5lailkp	37	31	by	by	IN
cord-268140-s5lailkp	37	32	the	the	DT
cord-268140-s5lailkp	37	33	increasing	increase	VBG
cord-268140-s5lailkp	37	34	number	number	NN
cord-268140-s5lailkp	37	35	of	of	IN
cord-268140-s5lailkp	37	36	trials	trial	NNS
cord-268140-s5lailkp	37	37	registered	register	VBN
cord-268140-s5lailkp	37	38	for	for	IN
cord-268140-s5lailkp	37	39	these	these	DT
cord-268140-s5lailkp	37	40	drugs	drug	NNS
cord-268140-s5lailkp	37	41	.	.	.
cord-268140-s5lailkp	38	1	But	but	CC
cord-268140-s5lailkp	38	2	perhaps	perhaps	RB
cord-268140-s5lailkp	38	3	there	there	EX
cord-268140-s5lailkp	38	4	is	be	VBZ
cord-268140-s5lailkp	38	5	a	a	DT
cord-268140-s5lailkp	38	6	case	case	NN
cord-268140-s5lailkp	38	7	to	to	TO
cord-268140-s5lailkp	38	8	examine	examine	VB
cord-268140-s5lailkp	38	9	them	-PRON-	PRP
cord-268140-s5lailkp	38	10	more	more	RBR
cord-268140-s5lailkp	38	11	closely	closely	RB
cord-268140-s5lailkp	38	12	and	and	CC
cord-268140-s5lailkp	38	13	focus	focus	VB
cord-268140-s5lailkp	38	14	more	more	JJR
cord-268140-s5lailkp	38	15	attention	attention	NN
cord-268140-s5lailkp	38	16	on	on	IN
cord-268140-s5lailkp	38	17	their	-PRON-	PRP$
cord-268140-s5lailkp	38	18	use	use	NN
cord-268140-s5lailkp	38	19	and	and	CC
cord-268140-s5lailkp	38	20	evaluation	evaluation	NN
cord-268140-s5lailkp	38	21	in	in	IN
cord-268140-s5lailkp	38	22	serious	serious	JJ
cord-268140-s5lailkp	38	23	COVID-19	covid-19	NN
cord-268140-s5lailkp	38	24	.	.	.
cord-268140-s5lailkp	39	1	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	39	2	is	be	VBZ
cord-268140-s5lailkp	39	3	an	an	DT
cord-268140-s5lailkp	39	4	acute	acute	JJ
cord-268140-s5lailkp	39	5	respiratory	respiratory	JJ
cord-268140-s5lailkp	39	6	disease	disease	NN
cord-268140-s5lailkp	39	7	caused	cause	VBN
cord-268140-s5lailkp	39	8	by	by	IN
cord-268140-s5lailkp	39	9	a	a	DT
cord-268140-s5lailkp	39	10	highly	highly	RB
cord-268140-s5lailkp	39	11	pathogenic	pathogenic	JJ
cord-268140-s5lailkp	39	12	novel	novel	JJ
cord-268140-s5lailkp	39	13	coronavirus	coronavirus	NN
cord-268140-s5lailkp	39	14	SARS	SARS	NNP
cord-268140-s5lailkp	39	15	-	-	HYPH
cord-268140-s5lailkp	39	16	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	39	17	.	.	.
cord-268140-s5lailkp	40	1	The	the	DT
cord-268140-s5lailkp	40	2	widely	widely	RB
cord-268140-s5lailkp	40	3	reported	report	VBN
cord-268140-s5lailkp	40	4	symptoms	symptom	NNS
cord-268140-s5lailkp	40	5	of	of	IN
cord-268140-s5lailkp	40	6	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	40	7	are	be	VBP
cord-268140-s5lailkp	40	8	extremely	extremely	RB
cord-268140-s5lailkp	40	9	variable	variable	JJ
cord-268140-s5lailkp	40	10	,	,	,
cord-268140-s5lailkp	40	11	ranging	range	VBG
cord-268140-s5lailkp	40	12	from	from	IN
cord-268140-s5lailkp	40	13	minimal	minimal	JJ
cord-268140-s5lailkp	40	14	symptoms	symptom	NNS
cord-268140-s5lailkp	40	15	to	to	IN
cord-268140-s5lailkp	40	16	significant	significant	JJ
cord-268140-s5lailkp	40	17	hypoxia	hypoxia	NN
cord-268140-s5lailkp	40	18	with	with	IN
cord-268140-s5lailkp	40	19	ARDS	ARDS	NNP
cord-268140-s5lailkp	40	20	and	and	CC
cord-268140-s5lailkp	40	21	multiorgan	multiorgan	NNP
cord-268140-s5lailkp	40	22	involvement	involvement	NN
cord-268140-s5lailkp	40	23	,	,	,
cord-268140-s5lailkp	40	24	which	which	WDT
cord-268140-s5lailkp	40	25	could	could	MD
cord-268140-s5lailkp	40	26	be	be	VB
cord-268140-s5lailkp	40	27	fatal	fatal	JJ
cord-268140-s5lailkp	40	28	.	.	.
cord-268140-s5lailkp	41	1	Accordingly	accordingly	RB
cord-268140-s5lailkp	41	2	,	,	,
cord-268140-s5lailkp	41	3	the	the	DT
cord-268140-s5lailkp	41	4	cases	case	NNS
cord-268140-s5lailkp	41	5	are	be	VBP
cord-268140-s5lailkp	41	6	classified	classify	VBN
cord-268140-s5lailkp	41	7	into	into	IN
cord-268140-s5lailkp	41	8	asymptomatic	asymptomatic	JJ
cord-268140-s5lailkp	41	9	,	,	,
cord-268140-s5lailkp	41	10	mild	mild	JJ
cord-268140-s5lailkp	41	11	,	,	,
cord-268140-s5lailkp	41	12	moderate	moderate	JJ
cord-268140-s5lailkp	41	13	,	,	,
cord-268140-s5lailkp	41	14	severe	severe	JJ
cord-268140-s5lailkp	41	15	and	and	CC
cord-268140-s5lailkp	41	16	critical	critical	JJ
cord-268140-s5lailkp	41	17	.	.	.
cord-268140-s5lailkp	42	1	The	the	DT
cord-268140-s5lailkp	42	2	latter	latter	JJ
cord-268140-s5lailkp	42	3	two	two	CD
cord-268140-s5lailkp	42	4	categories	category	NNS
cord-268140-s5lailkp	42	5	can	can	MD
cord-268140-s5lailkp	42	6	be	be	VB
cord-268140-s5lailkp	42	7	considered	consider	VBN
cord-268140-s5lailkp	42	8	as	as	IN
cord-268140-s5lailkp	42	9	those	those	DT
cord-268140-s5lailkp	42	10	having	have	VBG
cord-268140-s5lailkp	42	11	serious	serious	JJ
cord-268140-s5lailkp	42	12	COVID-19	covid-19	NN
cord-268140-s5lailkp	42	13	,	,	,
cord-268140-s5lailkp	42	14	and	and	CC
cord-268140-s5lailkp	42	15	include	include	VBP
cord-268140-s5lailkp	42	16	patients	patient	NNS
cord-268140-s5lailkp	42	17	presenting	present	VBG
cord-268140-s5lailkp	42	18	with	with	IN
cord-268140-s5lailkp	42	19	pneumonia	pneumonia	NN
cord-268140-s5lailkp	42	20	,	,	,
cord-268140-s5lailkp	42	21	hypoxemia	hypoxemia	NN
cord-268140-s5lailkp	42	22	,	,	,
cord-268140-s5lailkp	42	23	ARDS	ARDS	NNP
cord-268140-s5lailkp	42	24	along	along	IN
cord-268140-s5lailkp	42	25	with	with	IN
cord-268140-s5lailkp	42	26	extrapulmonary	extrapulmonary	JJ
cord-268140-s5lailkp	42	27	features	feature	NNS
cord-268140-s5lailkp	42	28	like	like	IN
cord-268140-s5lailkp	42	29	shock	shock	NN
cord-268140-s5lailkp	42	30	,	,	,
cord-268140-s5lailkp	42	31	encephalopathy	encephalopathy	NN
cord-268140-s5lailkp	42	32	,	,	,
cord-268140-s5lailkp	42	33	myocardial	myocardial	JJ
cord-268140-s5lailkp	42	34	injury	injury	NN
cord-268140-s5lailkp	42	35	,	,	,
cord-268140-s5lailkp	42	36	heart	heart	NN
cord-268140-s5lailkp	42	37	failure	failure	NN
cord-268140-s5lailkp	42	38	,	,	,
cord-268140-s5lailkp	42	39	coagulation	coagulation	NN
cord-268140-s5lailkp	42	40	dysfunction	dysfunction	NN
cord-268140-s5lailkp	42	41	and	and	CC
cord-268140-s5lailkp	42	42	acute	acute	JJ
cord-268140-s5lailkp	42	43	kidney	kidney	NN
cord-268140-s5lailkp	42	44	injury	injury	NN
cord-268140-s5lailkp	42	45	[	[	-LRB-
cord-268140-s5lailkp	42	46	13	13	CD
cord-268140-s5lailkp	42	47	]	]	-RRB-
cord-268140-s5lailkp	42	48	.	.	.
cord-268140-s5lailkp	43	1	This	this	DT
cord-268140-s5lailkp	43	2	virus	virus	NN
cord-268140-s5lailkp	43	3	primarily	primarily	RB
cord-268140-s5lailkp	43	4	attacks	attack	VBZ
cord-268140-s5lailkp	43	5	airway	airway	NN
cord-268140-s5lailkp	43	6	and	and	CC
cord-268140-s5lailkp	43	7	alveolar	alveolar	JJ
cord-268140-s5lailkp	43	8	epithelial	epithelial	JJ
cord-268140-s5lailkp	43	9	cells	cell	NNS
cord-268140-s5lailkp	43	10	,	,	,
cord-268140-s5lailkp	43	11	vascular	vascular	JJ
cord-268140-s5lailkp	43	12	endothelial	endothelial	JJ
cord-268140-s5lailkp	43	13	cells	cell	NNS
cord-268140-s5lailkp	43	14	and	and	CC
cord-268140-s5lailkp	43	15	macrophages	macrophage	NNS
cord-268140-s5lailkp	43	16	in	in	IN
cord-268140-s5lailkp	43	17	the	the	DT
cord-268140-s5lailkp	43	18	lung	lung	NN
cord-268140-s5lailkp	43	19	,	,	,
cord-268140-s5lailkp	43	20	which	which	WDT
cord-268140-s5lailkp	43	21	express	express	VBP
cord-268140-s5lailkp	43	22	the	the	DT
cord-268140-s5lailkp	43	23	angiotensin	angiotensin	NN
cord-268140-s5lailkp	43	24	-	-	HYPH
cord-268140-s5lailkp	43	25	converting	convert	VBG
cord-268140-s5lailkp	43	26	enzyme	enzyme	NN
cord-268140-s5lailkp	43	27	2	2	CD
cord-268140-s5lailkp	43	28	(	(	-LRB-
cord-268140-s5lailkp	43	29	ACE2	ACE2	NNP
cord-268140-s5lailkp	43	30	)	)	-RRB-
cord-268140-s5lailkp	43	31	,	,	,
cord-268140-s5lailkp	43	32	which	which	WDT
cord-268140-s5lailkp	43	33	is	be	VBZ
cord-268140-s5lailkp	43	34	the	the	DT
cord-268140-s5lailkp	43	35	host	host	NN
cord-268140-s5lailkp	43	36	target	target	NN
cord-268140-s5lailkp	43	37	receptor	receptor	NN
cord-268140-s5lailkp	43	38	for	for	IN
cord-268140-s5lailkp	43	39	SARS	SARS	NNP
cord-268140-s5lailkp	43	40	-	-	HYPH
cord-268140-s5lailkp	43	41	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	43	42	[	[	-LRB-
cord-268140-s5lailkp	43	43	14	14	CD
cord-268140-s5lailkp	43	44	]	]	-RRB-
cord-268140-s5lailkp	43	45	[	[	-LRB-
cord-268140-s5lailkp	43	46	15	15	CD
cord-268140-s5lailkp	43	47	]	]	-RRB-
cord-268140-s5lailkp	43	48	[	[	-LRB-
cord-268140-s5lailkp	43	49	16	16	CD
cord-268140-s5lailkp	43	50	]	]	-RRB-
cord-268140-s5lailkp	43	51	.	.	.
cord-268140-s5lailkp	44	1	The	the	DT
cord-268140-s5lailkp	44	2	ACE2	ACE2	NNP
cord-268140-s5lailkp	44	3	expression	expression	NN
cord-268140-s5lailkp	44	4	in	in	IN
cord-268140-s5lailkp	44	5	the	the	DT
cord-268140-s5lailkp	44	6	lung	lung	NN
cord-268140-s5lailkp	44	7	cells	cell	NNS
cord-268140-s5lailkp	44	8	is	be	VBZ
cord-268140-s5lailkp	44	9	downregulated	downregulate	VBN
cord-268140-s5lailkp	44	10	,	,	,
cord-268140-s5lailkp	44	11	which	which	WDT
cord-268140-s5lailkp	44	12	causes	cause	VBZ
cord-268140-s5lailkp	44	13	acute	acute	JJ
cord-268140-s5lailkp	44	14	lung	lung	NN
cord-268140-s5lailkp	44	15	injury	injury	NN
cord-268140-s5lailkp	44	16	and	and	CC
cord-268140-s5lailkp	44	17	dysfunction	dysfunction	NN
cord-268140-s5lailkp	44	18	of	of	IN
cord-268140-s5lailkp	44	19	the	the	DT
cord-268140-s5lailkp	44	20	reninangiotensin	reninangiotensin	NNP
cord-268140-s5lailkp	44	21	system	system	NN
cord-268140-s5lailkp	44	22	(	(	-LRB-
cord-268140-s5lailkp	44	23	RAS	RAS	NNP
cord-268140-s5lailkp	44	24	)	)	-RRB-
cord-268140-s5lailkp	45	1	[	[	-LRB-
cord-268140-s5lailkp	45	2	17	17	CD
cord-268140-s5lailkp	45	3	]	]	-RRB-
cord-268140-s5lailkp	45	4	[	[	-LRB-
cord-268140-s5lailkp	45	5	18	18	CD
cord-268140-s5lailkp	45	6	]	]	-RRB-
cord-268140-s5lailkp	45	7	[	[	-LRB-
cord-268140-s5lailkp	45	8	19	19	CD
cord-268140-s5lailkp	45	9	]	]	-RRB-
cord-268140-s5lailkp	45	10	[	[	-LRB-
cord-268140-s5lailkp	45	11	20	20	CD
cord-268140-s5lailkp	45	12	]	]	-RRB-
cord-268140-s5lailkp	45	13	.	.	.
cord-268140-s5lailkp	46	1	Further	further	RB
cord-268140-s5lailkp	46	2	,	,	,
cord-268140-s5lailkp	46	3	there	there	EX
cord-268140-s5lailkp	46	4	is	be	VBZ
cord-268140-s5lailkp	46	5	pyroptosis	pyroptosis	NN
cord-268140-s5lailkp	46	6	(	(	-LRB-
cord-268140-s5lailkp	46	7	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	46	8	programed	programed	JJ
cord-268140-s5lailkp	46	9	cell	cell	NN
cord-268140-s5lailkp	46	10	death	death	NN
cord-268140-s5lailkp	46	11	seen	see	VBN
cord-268140-s5lailkp	46	12	with	with	IN
cord-268140-s5lailkp	46	13	cytopathic	cytopathic	JJ
cord-268140-s5lailkp	46	14	viruses	virus	NNS
cord-268140-s5lailkp	46	15	)	)	-RRB-
cord-268140-s5lailkp	46	16	which	which	WDT
cord-268140-s5lailkp	46	17	,	,	,
cord-268140-s5lailkp	46	18	in	in	IN
cord-268140-s5lailkp	46	19	association	association	NN
cord-268140-s5lailkp	46	20	with	with	IN
cord-268140-s5lailkp	46	21	vascular	vascular	JJ
cord-268140-s5lailkp	46	22	leakage	leakage	NN
cord-268140-s5lailkp	46	23	,	,	,
cord-268140-s5lailkp	46	24	triggers	trigger	VBZ
cord-268140-s5lailkp	46	25	subsequent	subsequent	JJ
cord-268140-s5lailkp	46	26	local	local	JJ
cord-268140-s5lailkp	46	27	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	46	28	response	response	NN
cord-268140-s5lailkp	46	29	[	[	-LRB-
cord-268140-s5lailkp	46	30	21	21	CD
cord-268140-s5lailkp	46	31	]	]	-RRB-
cord-268140-s5lailkp	46	32	[	[	-LRB-
cord-268140-s5lailkp	46	33	22	22	CD
cord-268140-s5lailkp	46	34	]	]	-RRB-
cord-268140-s5lailkp	46	35	[	[	-LRB-
cord-268140-s5lailkp	46	36	23	23	CD
cord-268140-s5lailkp	46	37	]	]	-RRB-
cord-268140-s5lailkp	46	38	.	.	.
cord-268140-s5lailkp	47	1	This	this	DT
cord-268140-s5lailkp	47	2	involves	involve	VBZ
cord-268140-s5lailkp	47	3	increased	increase	VBN
cord-268140-s5lailkp	47	4	secretion	secretion	NN
cord-268140-s5lailkp	47	5	of	of	IN
cord-268140-s5lailkp	47	6	the	the	DT
cord-268140-s5lailkp	47	7	pro	pro	JJ
cord-268140-s5lailkp	47	8	-	-	JJ
cord-268140-s5lailkp	47	9	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	47	10	cytokines	cytokine	NNS
cord-268140-s5lailkp	47	11	and	and	CC
cord-268140-s5lailkp	47	12	chemokines	chemokine	NNS
cord-268140-s5lailkp	47	13	IL-1β	IL-1β	NNP
cord-268140-s5lailkp	47	14	,	,	,
cord-268140-s5lailkp	47	15	IL-6	IL-6	NNP
cord-268140-s5lailkp	47	16	,	,	,
cord-268140-s5lailkp	47	17	interferon	interferon	NN
cord-268140-s5lailkp	47	18	gamma	gamma	NN
cord-268140-s5lailkp	47	19	(	(	-LRB-
cord-268140-s5lailkp	47	20	IFNγ	IFNγ	NNP
cord-268140-s5lailkp	47	21	)	)	-RRB-
cord-268140-s5lailkp	47	22	,	,	,
cord-268140-s5lailkp	47	23	monocyte	monocyte	NNP
cord-268140-s5lailkp	47	24	chemoattractant	chemoattractant	NNP
cord-268140-s5lailkp	47	25	protein	protein	NNP
cord-268140-s5lailkp	47	26	1	1	CD
cord-268140-s5lailkp	47	27	(	(	-LRB-
cord-268140-s5lailkp	47	28	MCP1	MCP1	NNP
cord-268140-s5lailkp	47	29	)	)	-RRB-
cord-268140-s5lailkp	47	30	,	,	,
cord-268140-s5lailkp	47	31	IFNγinduced	ifnγinduce	VBN
cord-268140-s5lailkp	47	32	protein	protein	NN
cord-268140-s5lailkp	47	33	10	10	CD
cord-268140-s5lailkp	47	34	(	(	-LRB-
cord-268140-s5lailkp	47	35	IP-10	IP-10	NNP
cord-268140-s5lailkp	47	36	)	)	-RRB-
cord-268140-s5lailkp	47	37	,	,	,
cord-268140-s5lailkp	47	38	etc	etc	FW
cord-268140-s5lailkp	47	39	.	.	.
cord-268140-s5lailkp	48	1	into	into	IN
cord-268140-s5lailkp	48	2	the	the	DT
cord-268140-s5lailkp	48	3	blood	blood	NN
cord-268140-s5lailkp	48	4	[	[	-LRB-
cord-268140-s5lailkp	48	5	24	24	CD
cord-268140-s5lailkp	48	6	]	]	-RRB-
cord-268140-s5lailkp	48	7	.	.	.
cord-268140-s5lailkp	49	1	In	in	IN
cord-268140-s5lailkp	49	2	most	most	JJS
cord-268140-s5lailkp	49	3	cases	case	NNS
cord-268140-s5lailkp	49	4	,	,	,
cord-268140-s5lailkp	49	5	this	this	DT
cord-268140-s5lailkp	49	6	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	49	7	reaction	reaction	NN
cord-268140-s5lailkp	49	8	ameliorates	ameliorate	VBZ
cord-268140-s5lailkp	49	9	the	the	DT
cord-268140-s5lailkp	49	10	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	49	11	infection	infection	NN
cord-268140-s5lailkp	49	12	and	and	CC
cord-268140-s5lailkp	49	13	the	the	DT
cord-268140-s5lailkp	49	14	patient	patient	NN
cord-268140-s5lailkp	49	15	recovers	recover	VBZ
cord-268140-s5lailkp	49	16	.	.	.
cord-268140-s5lailkp	50	1	Unfortunately	unfortunately	RB
cord-268140-s5lailkp	50	2	,	,	,
cord-268140-s5lailkp	50	3	a	a	DT
cord-268140-s5lailkp	50	4	dysfunctional	dysfunctional	JJ
cord-268140-s5lailkp	50	5	immune	immune	JJ
cord-268140-s5lailkp	50	6	response	response	NN
cord-268140-s5lailkp	50	7	occurs	occur	VBZ
cord-268140-s5lailkp	50	8	in	in	IN
cord-268140-s5lailkp	50	9	some	some	DT
cord-268140-s5lailkp	50	10	cases	case	NNS
cord-268140-s5lailkp	50	11	,	,	,
cord-268140-s5lailkp	50	12	referred	refer	VBD
cord-268140-s5lailkp	50	13	to	to	IN
cord-268140-s5lailkp	50	14	efficacy	efficacy	NN
cord-268140-s5lailkp	50	15	of	of	IN
cord-268140-s5lailkp	50	16	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	50	17	.	.	.
cord-268140-s5lailkp	51	1	The	the	DT
cord-268140-s5lailkp	51	2	largest	large	JJS
cord-268140-s5lailkp	51	3	amongst	amongst	IN
cord-268140-s5lailkp	51	4	these	these	DT
cord-268140-s5lailkp	51	5	is	be	VBZ
cord-268140-s5lailkp	51	6	the	the	DT
cord-268140-s5lailkp	51	7	recently	recently	RB
cord-268140-s5lailkp	51	8	published	publish	VBN
cord-268140-s5lailkp	51	9	multinational	multinational	JJ
cord-268140-s5lailkp	51	10	registry	registry	NN
cord-268140-s5lailkp	51	11	analysis	analysis	NN
cord-268140-s5lailkp	51	12	of	of	IN
cord-268140-s5lailkp	51	13	the	the	DT
cord-268140-s5lailkp	51	14	use	use	NN
cord-268140-s5lailkp	51	15	of	of	IN
cord-268140-s5lailkp	51	16	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	51	17	or	or	CC
cord-268140-s5lailkp	51	18	chloroquine	chloroquine	NN
cord-268140-s5lailkp	51	19	with	with	IN
cord-268140-s5lailkp	51	20	or	or	CC
cord-268140-s5lailkp	51	21	without	without	IN
cord-268140-s5lailkp	51	22	a	a	DT
cord-268140-s5lailkp	51	23	macrolide	macrolide	NN
cord-268140-s5lailkp	51	24	for	for	IN
cord-268140-s5lailkp	51	25	treatment	treatment	NN
cord-268140-s5lailkp	51	26	of	of	IN
cord-268140-s5lailkp	51	27	COVID-19	covid-19	CD
cord-268140-s5lailkp	51	28	in	in	IN
cord-268140-s5lailkp	51	29	more	more	JJR
cord-268140-s5lailkp	51	30	than	than	IN
cord-268140-s5lailkp	51	31	95,000	95,000	CD
cord-268140-s5lailkp	51	32	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	51	33	patients	patient	NNS
cord-268140-s5lailkp	51	34	,	,	,
cord-268140-s5lailkp	51	35	which	which	WDT
cord-268140-s5lailkp	51	36	reported	report	VBD
cord-268140-s5lailkp	51	37	no	no	DT
cord-268140-s5lailkp	51	38	benefit	benefit	NN
cord-268140-s5lailkp	51	39	in	in	IN
cord-268140-s5lailkp	51	40	hospital	hospital	NN
cord-268140-s5lailkp	51	41	outcomes	outcome	NNS
cord-268140-s5lailkp	51	42	;	;	:
cord-268140-s5lailkp	51	43	instead	instead	RB
cord-268140-s5lailkp	51	44	there	there	EX
cord-268140-s5lailkp	51	45	was	be	VBD
cord-268140-s5lailkp	51	46	an	an	DT
cord-268140-s5lailkp	51	47	association	association	NN
cord-268140-s5lailkp	51	48	with	with	IN
cord-268140-s5lailkp	51	49	higher	high	JJR
cord-268140-s5lailkp	51	50	mortality	mortality	NN
cord-268140-s5lailkp	51	51	and	and	CC
cord-268140-s5lailkp	51	52	an	an	DT
cord-268140-s5lailkp	51	53	increased	increase	VBN
cord-268140-s5lailkp	51	54	frequency	frequency	NN
cord-268140-s5lailkp	51	55	of	of	IN
cord-268140-s5lailkp	51	56	ventricular	ventricular	JJ
cord-268140-s5lailkp	51	57	arrhythmias	arrhythmia	NNS
cord-268140-s5lailkp	51	58	[	[	-LRB-
cord-268140-s5lailkp	51	59	7	7	CD
cord-268140-s5lailkp	51	60	]	]	-RRB-
cord-268140-s5lailkp	51	61	.	.	.
cord-268140-s5lailkp	52	1	Yet	yet	CC
cord-268140-s5lailkp	52	2	countries	country	NNS
cord-268140-s5lailkp	52	3	like	like	IN
cord-268140-s5lailkp	52	4	USA	USA	NNP
cord-268140-s5lailkp	52	5	,	,	,
cord-268140-s5lailkp	52	6	France	France	NNP
cord-268140-s5lailkp	52	7	,	,	,
cord-268140-s5lailkp	52	8	Brazil	Brazil	NNP
cord-268140-s5lailkp	52	9	,	,	,
cord-268140-s5lailkp	52	10	and	and	CC
cord-268140-s5lailkp	52	11	Israel	Israel	NNP
cord-268140-s5lailkp	52	12	have	have	VBP
cord-268140-s5lailkp	52	13	already	already	RB
cord-268140-s5lailkp	52	14	been	be	VBN
cord-268140-s5lailkp	52	15	importing	import	VBG
cord-268140-s5lailkp	52	16	this	this	DT
cord-268140-s5lailkp	52	17	drug	drug	NN
cord-268140-s5lailkp	52	18	from	from	IN
cord-268140-s5lailkp	52	19	countries	country	NNS
cord-268140-s5lailkp	52	20	like	like	IN
cord-268140-s5lailkp	52	21	India	India	NNP
cord-268140-s5lailkp	52	22	,	,	,
cord-268140-s5lailkp	52	23	which	which	WDT
cord-268140-s5lailkp	52	24	is	be	VBZ
cord-268140-s5lailkp	52	25	the	the	DT
cord-268140-s5lailkp	52	26	largest	large	JJS
cord-268140-s5lailkp	52	27	generic	generic	JJ
cord-268140-s5lailkp	52	28	producer	producer	NN
cord-268140-s5lailkp	52	29	of	of	IN
cord-268140-s5lailkp	52	30	this	this	DT
cord-268140-s5lailkp	52	31	molecule	molecule	NN
cord-268140-s5lailkp	52	32	.	.	.
cord-268140-s5lailkp	53	1	Among	among	IN
cord-268140-s5lailkp	53	2	the	the	DT
cord-268140-s5lailkp	53	3	other	other	JJ
cord-268140-s5lailkp	53	4	most	most	RBS
cord-268140-s5lailkp	53	5	promising	promising	JJ
cord-268140-s5lailkp	53	6	treatment	treatment	NN
cord-268140-s5lailkp	53	7	options	option	NNS
cord-268140-s5lailkp	53	8	are	be	VBP
cord-268140-s5lailkp	53	9	the	the	DT
cord-268140-s5lailkp	53	10	human	human	JJ
cord-268140-s5lailkp	53	11	immunodeficiency	immunodeficiency	NN
cord-268140-s5lailkp	53	12	virus	virus	NN
cord-268140-s5lailkp	53	13	(	(	-LRB-
cord-268140-s5lailkp	53	14	HIV	HIV	NNP
cord-268140-s5lailkp	53	15	)	)	-RRB-
cord-268140-s5lailkp	53	16	drug	drug	NN
cord-268140-s5lailkp	53	17	combination	combination	NN
cord-268140-s5lailkp	53	18	lopinavir	lopinavir	NNS
cord-268140-s5lailkp	53	19	/	/	SYM
cord-268140-s5lailkp	53	20	ritonavir	ritonavir	NNP
cord-268140-s5lailkp	53	21	,	,	,
cord-268140-s5lailkp	53	22	used	use	VBN
cord-268140-s5lailkp	53	23	in	in	IN
cord-268140-s5lailkp	53	24	different	different	JJ
cord-268140-s5lailkp	53	25	countries	country	NNS
cord-268140-s5lailkp	53	26	in	in	IN
cord-268140-s5lailkp	53	27	treating	treat	VBG
cord-268140-s5lailkp	53	28	COVID-19	covid-19	NN
cord-268140-s5lailkp	53	29	on	on	IN
cord-268140-s5lailkp	53	30	a	a	DT
cord-268140-s5lailkp	53	31	case	case	NN
cord-268140-s5lailkp	53	32	-	-	HYPH
cord-268140-s5lailkp	53	33	by	by	IN
cord-268140-s5lailkp	53	34	-	-	HYPH
cord-268140-s5lailkp	53	35	case	case	NN
cord-268140-s5lailkp	53	36	basis	basis	NN
cord-268140-s5lailkp	53	37	,	,	,
cord-268140-s5lailkp	53	38	and	and	CC
cord-268140-s5lailkp	53	39	the	the	DT
cord-268140-s5lailkp	53	40	investigational	investigational	JJ
cord-268140-s5lailkp	53	41	new	new	JJ
cord-268140-s5lailkp	53	42	broad	broad	JJ
cord-268140-s5lailkp	53	43	spectrum	spectrum	JJ
cord-268140-s5lailkp	53	44	antiviral	antiviral	JJ
cord-268140-s5lailkp	53	45	drug	drug	NN
cord-268140-s5lailkp	53	46	remdesivir	remdesivir	NNP
cord-268140-s5lailkp	53	47	,	,	,
cord-268140-s5lailkp	53	48	for	for	IN
cord-268140-s5lailkp	53	49	which	which	WDT
cord-268140-s5lailkp	53	50	US	US	NNP
cord-268140-s5lailkp	53	51	Food	Food	NNP
cord-268140-s5lailkp	53	52	and	and	CC
cord-268140-s5lailkp	53	53	Drug	Drug	NNP
cord-268140-s5lailkp	53	54	Administration	Administration	NNP
cord-268140-s5lailkp	53	55	(	(	-LRB-
cord-268140-s5lailkp	53	56	FDA	FDA	NNP
cord-268140-s5lailkp	53	57	)	)	-RRB-
cord-268140-s5lailkp	53	58	has	have	VBZ
cord-268140-s5lailkp	53	59	granted	grant	VBN
cord-268140-s5lailkp	53	60	an	an	DT
cord-268140-s5lailkp	53	61	Emergency	Emergency	NNP
cord-268140-s5lailkp	53	62	Use	Use	NNP
cord-268140-s5lailkp	53	63	Authorization	Authorization	NNP
cord-268140-s5lailkp	53	64	(	(	-LRB-
cord-268140-s5lailkp	53	65	EUA	EUA	NNP
cord-268140-s5lailkp	53	66	)	)	-RRB-
cord-268140-s5lailkp	53	67	for	for	IN
cord-268140-s5lailkp	53	68	the	the	DT
cord-268140-s5lailkp	53	69	treatment	treatment	NN
cord-268140-s5lailkp	53	70	of	of	IN
cord-268140-s5lailkp	53	71	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	53	72	COVID-19	covid-19	CD
cord-268140-s5lailkp	53	73	patients	patient	NNS
cord-268140-s5lailkp	53	74	[	[	-LRB-
cord-268140-s5lailkp	53	75	8	8	CD
cord-268140-s5lailkp	53	76	]	]	-RRB-
cord-268140-s5lailkp	53	77	.	.	.
cord-268140-s5lailkp	54	1	Initial	initial	JJ
cord-268140-s5lailkp	54	2	positive	positive	JJ
cord-268140-s5lailkp	54	3	results	result	NNS
cord-268140-s5lailkp	54	4	have	have	VBP
cord-268140-s5lailkp	54	5	been	be	VBN
cord-268140-s5lailkp	54	6	declared	declare	VBN
cord-268140-s5lailkp	54	7	for	for	IN
cord-268140-s5lailkp	54	8	this	this	DT
cord-268140-s5lailkp	54	9	drug	drug	NN
cord-268140-s5lailkp	54	10	,	,	,
cord-268140-s5lailkp	54	11	especially	especially	RB
cord-268140-s5lailkp	54	12	improved	improve	VBN
cord-268140-s5lailkp	54	13	time	time	NN
cord-268140-s5lailkp	54	14	to	to	IN
cord-268140-s5lailkp	54	15	recovery	recovery	NN
cord-268140-s5lailkp	54	16	in	in	IN
cord-268140-s5lailkp	54	17	moderate	moderate	JJ
cord-268140-s5lailkp	54	18	-	-	HYPH
cord-268140-s5lailkp	54	19	to	to	IN
cord-268140-s5lailkp	54	20	-	-	HYPH
cord-268140-s5lailkp	54	21	severe	severe	JJ
cord-268140-s5lailkp	54	22	illness	illness	NN
cord-268140-s5lailkp	54	23	,	,	,
cord-268140-s5lailkp	54	24	which	which	WDT
cord-268140-s5lailkp	54	25	is	be	VBZ
cord-268140-s5lailkp	54	26	sure	sure	JJ
cord-268140-s5lailkp	54	27	to	to	TO
cord-268140-s5lailkp	54	28	raise	raise	VB
cord-268140-s5lailkp	54	29	a	a	DT
cord-268140-s5lailkp	54	30	lot	lot	NN
cord-268140-s5lailkp	54	31	of	of	IN
cord-268140-s5lailkp	54	32	hope	hope	NN
cord-268140-s5lailkp	54	33	[	[	-LRB-
cord-268140-s5lailkp	54	34	9	9	CD
cord-268140-s5lailkp	54	35	]	]	-RRB-
cord-268140-s5lailkp	54	36	.	.	.
cord-268140-s5lailkp	55	1	WHO	who	WP
cord-268140-s5lailkp	55	2	's	be	VBZ
cord-268140-s5lailkp	55	3	large	large	JJ
cord-268140-s5lailkp	55	4	scale	scale	NN
cord-268140-s5lailkp	55	5	,	,	,
cord-268140-s5lailkp	55	6	multinational	multinational	JJ
cord-268140-s5lailkp	55	7	'	'	``
cord-268140-s5lailkp	55	8	Solidarity	Solidarity	NNP
cord-268140-s5lailkp	55	9	'	'	POS
cord-268140-s5lailkp	55	10	clinical	clinical	JJ
cord-268140-s5lailkp	55	11	trial	trial	NN
cord-268140-s5lailkp	55	12	,	,	,
cord-268140-s5lailkp	55	13	and	and	CC
cord-268140-s5lailkp	55	14	the	the	DT
cord-268140-s5lailkp	55	15	DisCoVeRy	DisCoVeRy	NNP
cord-268140-s5lailkp	55	16	trial	trial	NN
cord-268140-s5lailkp	55	17	launched	launch	VBD
cord-268140-s5lailkp	55	18	in	in	IN
cord-268140-s5lailkp	55	19	Europe	Europe	NNP
cord-268140-s5lailkp	55	20	included	include	VBD
cord-268140-s5lailkp	55	21	these	these	DT
cord-268140-s5lailkp	55	22	drugs	drug	NNS
cord-268140-s5lailkp	55	23	along	along	IN
cord-268140-s5lailkp	55	24	with	with	IN
cord-268140-s5lailkp	55	25	beta	beta	NN
cord-268140-s5lailkp	55	26	interferon	interferon	NN
cord-268140-s5lailkp	55	27	in	in	IN
cord-268140-s5lailkp	55	28	different	different	JJ
cord-268140-s5lailkp	55	29	arms	arm	NNS
cord-268140-s5lailkp	55	30	,	,	,
cord-268140-s5lailkp	55	31	although	although	IN
cord-268140-s5lailkp	55	32	the	the	DT
cord-268140-s5lailkp	55	33	WHO	who	WP
cord-268140-s5lailkp	55	34	temporarily	temporarily	RB
cord-268140-s5lailkp	55	35	suspended	suspend	VBD
cord-268140-s5lailkp	55	36	the	the	DT
cord-268140-s5lailkp	55	37	randomization	randomization	NN
cord-268140-s5lailkp	55	38	to	to	IN
cord-268140-s5lailkp	55	39	the	the	DT
cord-268140-s5lailkp	55	40	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	55	41	arm	arm	NN
cord-268140-s5lailkp	55	42	of	of	IN
cord-268140-s5lailkp	55	43	its	-PRON-	PRP$
cord-268140-s5lailkp	55	44	trial	trial	NN
cord-268140-s5lailkp	55	45	in	in	IN
cord-268140-s5lailkp	55	46	view	view	NN
cord-268140-s5lailkp	55	47	of	of	IN
cord-268140-s5lailkp	55	48	safety	safety	NN
cord-268140-s5lailkp	55	49	concerns	concern	NNS
cord-268140-s5lailkp	55	50	[	[	-LRB-
cord-268140-s5lailkp	55	51	10	10	CD
cord-268140-s5lailkp	55	52	]	]	-RRB-
cord-268140-s5lailkp	55	53	.	.	.
cord-268140-s5lailkp	56	1	These	these	DT
cord-268140-s5lailkp	56	2	pivotal	pivotal	JJ
cord-268140-s5lailkp	56	3	trials	trial	NNS
cord-268140-s5lailkp	56	4	focus	focus	VBP
cord-268140-s5lailkp	56	5	on	on	IN
cord-268140-s5lailkp	56	6	evaluating	evaluate	VBG
cord-268140-s5lailkp	56	7	the	the	DT
cord-268140-s5lailkp	56	8	current	current	JJ
cord-268140-s5lailkp	56	9	most	most	RBS
cord-268140-s5lailkp	56	10	promising	promising	JJ
cord-268140-s5lailkp	56	11	unproven	unproven	JJ
cord-268140-s5lailkp	56	12	treatment	treatment	NN
cord-268140-s5lailkp	56	13	options	option	NNS
cord-268140-s5lailkp	56	14	for	for	IN
cord-268140-s5lailkp	56	15	COVID	COVID	NNP
cord-268140-s5lailkp	56	16	19	19	CD
cord-268140-s5lailkp	56	17	,	,	,
cord-268140-s5lailkp	56	18	mainly	mainly	RB
cord-268140-s5lailkp	56	19	focusing	focus	VBG
cord-268140-s5lailkp	56	20	on	on	IN
cord-268140-s5lailkp	56	21	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	56	22	patients	patient	NNS
cord-268140-s5lailkp	56	23	(	(	-LRB-
cord-268140-s5lailkp	56	24	moderate	moderate	JJ
cord-268140-s5lailkp	56	25	-	-	HYPH
cord-268140-s5lailkp	56	26	severe	severe	JJ
cord-268140-s5lailkp	56	27	and	and	CC
cord-268140-s5lailkp	56	28	critically	critically	RB
cord-268140-s5lailkp	56	29	ill	ill	JJ
cord-268140-s5lailkp	56	30	cases	case	NNS
cord-268140-s5lailkp	56	31	)	)	-RRB-
cord-268140-s5lailkp	56	32	.	.	.
cord-268140-s5lailkp	57	1	It	-PRON-	PRP
cord-268140-s5lailkp	57	2	is	be	VBZ
cord-268140-s5lailkp	57	3	as	as	IN
cord-268140-s5lailkp	57	4	"	"	``
cord-268140-s5lailkp	57	5	Cytokine	Cytokine	NNP
cord-268140-s5lailkp	57	6	Release	Release	NNP
cord-268140-s5lailkp	57	7	Syndrome	Syndrome	NNP
cord-268140-s5lailkp	57	8	"	"	''
cord-268140-s5lailkp	57	9	(	(	-LRB-
cord-268140-s5lailkp	57	10	CRS	CRS	NNP
cord-268140-s5lailkp	57	11	)	)	-RRB-
cord-268140-s5lailkp	57	12	,	,	,
cord-268140-s5lailkp	57	13	which	which	WDT
cord-268140-s5lailkp	57	14	triggers	trigger	VBZ
cord-268140-s5lailkp	57	15	an	an	DT
cord-268140-s5lailkp	57	16	exaggerated	exaggerated	JJ
cord-268140-s5lailkp	57	17	release	release	NN
cord-268140-s5lailkp	57	18	of	of	IN
cord-268140-s5lailkp	57	19	cytokines	cytokine	NNS
cord-268140-s5lailkp	57	20	leading	lead	VBG
cord-268140-s5lailkp	57	21	to	to	IN
cord-268140-s5lailkp	57	22	widespread	widespread	JJ
cord-268140-s5lailkp	57	23	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	57	24	inflammation	inflammation	NN
cord-268140-s5lailkp	57	25	and	and	CC
cord-268140-s5lailkp	57	26	lung	lung	NN
cord-268140-s5lailkp	57	27	damage	damage	NN
cord-268140-s5lailkp	57	28	via	via	IN
cord-268140-s5lailkp	57	29	secretion	secretion	NN
cord-268140-s5lailkp	57	30	of	of	IN
cord-268140-s5lailkp	57	31	proteases	protease	NNS
cord-268140-s5lailkp	57	32	and	and	CC
cord-268140-s5lailkp	57	33	free	free	JJ
cord-268140-s5lailkp	57	34	radical	radical	JJ
cord-268140-s5lailkp	57	35	production	production	NN
cord-268140-s5lailkp	57	36	.	.	.
cord-268140-s5lailkp	58	1	There	there	EX
cord-268140-s5lailkp	58	2	is	be	VBZ
cord-268140-s5lailkp	58	3	desquamation	desquamation	NN
cord-268140-s5lailkp	58	4	of	of	IN
cord-268140-s5lailkp	58	5	alveolar	alveolar	JJ
cord-268140-s5lailkp	58	6	cells	cell	NNS
cord-268140-s5lailkp	58	7	,	,	,
cord-268140-s5lailkp	58	8	hyaline	hyaline	JJ
cord-268140-s5lailkp	58	9	membrane	membrane	NN
cord-268140-s5lailkp	58	10	formation	formation	NN
cord-268140-s5lailkp	58	11	and	and	CC
cord-268140-s5lailkp	58	12	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	58	13	edema	edema	NN
cord-268140-s5lailkp	58	14	limiting	limit	VBG
cord-268140-s5lailkp	58	15	the	the	DT
cord-268140-s5lailkp	58	16	gas	gas	NN
cord-268140-s5lailkp	58	17	exchange	exchange	NN
cord-268140-s5lailkp	58	18	in	in	IN
cord-268140-s5lailkp	58	19	the	the	DT
cord-268140-s5lailkp	58	20	lung	lung	NN
cord-268140-s5lailkp	58	21	,	,	,
cord-268140-s5lailkp	58	22	leading	lead	VBG
cord-268140-s5lailkp	58	23	to	to	IN
cord-268140-s5lailkp	58	24	difficult	difficult	JJ
cord-268140-s5lailkp	58	25	breathing	breathing	NN
cord-268140-s5lailkp	58	26	and	and	CC
cord-268140-s5lailkp	58	27	hypoxemia	hypoxemia	NN
cord-268140-s5lailkp	58	28	,	,	,
cord-268140-s5lailkp	58	29	making	make	VBG
cord-268140-s5lailkp	58	30	the	the	DT
cord-268140-s5lailkp	58	31	lung	lung	NN
cord-268140-s5lailkp	58	32	more	more	RBR
cord-268140-s5lailkp	58	33	susceptible	susceptible	JJ
cord-268140-s5lailkp	58	34	to	to	IN
cord-268140-s5lailkp	58	35	secondary	secondary	JJ
cord-268140-s5lailkp	58	36	infection	infection	NN
cord-268140-s5lailkp	58	37	[	[	-LRB-
cord-268140-s5lailkp	58	38	25	25	CD
cord-268140-s5lailkp	58	39	,	,	,
cord-268140-s5lailkp	58	40	26	26	CD
cord-268140-s5lailkp	58	41	]	]	-RRB-
cord-268140-s5lailkp	58	42	.	.	.
cord-268140-s5lailkp	59	1	IL-6	IL-6	NNP
cord-268140-s5lailkp	59	2	is	be	VBZ
cord-268140-s5lailkp	59	3	a	a	DT
cord-268140-s5lailkp	59	4	multifactorial	multifactorial	JJ
cord-268140-s5lailkp	59	5	cytokine	cytokine	NN
cord-268140-s5lailkp	59	6	and	and	CC
cord-268140-s5lailkp	59	7	plays	play	VBZ
cord-268140-s5lailkp	59	8	a	a	DT
cord-268140-s5lailkp	59	9	central	central	JJ
cord-268140-s5lailkp	59	10	role	role	NN
cord-268140-s5lailkp	59	11	in	in	IN
cord-268140-s5lailkp	59	12	acute	acute	JJ
cord-268140-s5lailkp	59	13	inflammation	inflammation	NN
cord-268140-s5lailkp	59	14	.	.	.
cord-268140-s5lailkp	60	1	It	-PRON-	PRP
cord-268140-s5lailkp	60	2	is	be	VBZ
cord-268140-s5lailkp	60	3	produced	produce	VBN
cord-268140-s5lailkp	60	4	by	by	IN
cord-268140-s5lailkp	60	5	monocytes	monocyte	NNS
cord-268140-s5lailkp	60	6	and	and	CC
cord-268140-s5lailkp	60	7	macrophages	macrophage	NNS
cord-268140-s5lailkp	60	8	stimulated	stimulate	VBN
cord-268140-s5lailkp	60	9	by	by	IN
cord-268140-s5lailkp	60	10	Toll	toll	NN
cord-268140-s5lailkp	60	11	-	-	HYPH
cord-268140-s5lailkp	60	12	like	like	JJ
cord-268140-s5lailkp	60	13	receptors	receptor	NNS
cord-268140-s5lailkp	60	14	,	,	,
cord-268140-s5lailkp	60	15	which	which	WDT
cord-268140-s5lailkp	60	16	in	in	IN
cord-268140-s5lailkp	60	17	turn	turn	NN
cord-268140-s5lailkp	60	18	stimulate	stimulate	VBP
cord-268140-s5lailkp	60	19	various	various	JJ
cord-268140-s5lailkp	60	20	cell	cell	NN
cord-268140-s5lailkp	60	21	populations	population	NNS
cord-268140-s5lailkp	60	22	.	.	.
cord-268140-s5lailkp	61	1	IL-1β	IL-1β	NNP
cord-268140-s5lailkp	61	2	and	and	CC
cord-268140-s5lailkp	61	3	TNFα	TNFα	NNP
cord-268140-s5lailkp	61	4	are	be	VBP
cord-268140-s5lailkp	61	5	the	the	DT
cord-268140-s5lailkp	61	6	main	main	JJ
cord-268140-s5lailkp	61	7	activators	activator	NNS
cord-268140-s5lailkp	61	8	of	of	IN
cord-268140-s5lailkp	61	9	IL-6	IL-6	NNP
cord-268140-s5lailkp	61	10	expression	expression	NN
cord-268140-s5lailkp	61	11	[	[	-LRB-
cord-268140-s5lailkp	61	12	27	27	CD
cord-268140-s5lailkp	61	13	]	]	-RRB-
cord-268140-s5lailkp	61	14	.	.	.
cord-268140-s5lailkp	62	1	IL-6	IL-6	NNP
cord-268140-s5lailkp	62	2	works	work	VBZ
cord-268140-s5lailkp	62	3	through	through	IN
cord-268140-s5lailkp	62	4	different	different	JJ
cord-268140-s5lailkp	62	5	signal	signal	NN
cord-268140-s5lailkp	62	6	transduction	transduction	NN
cord-268140-s5lailkp	62	7	pathways	pathway	NNS
cord-268140-s5lailkp	62	8	[	[	-LRB-
cord-268140-s5lailkp	62	9	28	28	CD
cord-268140-s5lailkp	62	10	]	]	-RRB-
cord-268140-s5lailkp	62	11	.	.	.
cord-268140-s5lailkp	63	1	In	in	IN
cord-268140-s5lailkp	63	2	the	the	DT
cord-268140-s5lailkp	63	3	classical	classical	JJ
cord-268140-s5lailkp	63	4	pathway	pathway	NN
cord-268140-s5lailkp	63	5	,	,	,
cord-268140-s5lailkp	63	6	it	-PRON-	PRP
cord-268140-s5lailkp	63	7	binds	bind	VBZ
cord-268140-s5lailkp	63	8	to	to	IN
cord-268140-s5lailkp	63	9	both	both	DT
cord-268140-s5lailkp	63	10	transmembrane	transmembrane	JJ
cord-268140-s5lailkp	63	11	and	and	CC
cord-268140-s5lailkp	63	12	soluble	soluble	JJ
cord-268140-s5lailkp	63	13	form	form	NN
cord-268140-s5lailkp	63	14	of	of	IN
cord-268140-s5lailkp	63	15	its	-PRON-	PRP$
cord-268140-s5lailkp	63	16	receptor	receptor	NN
cord-268140-s5lailkp	63	17	IL-6R	IL-6R	NNP
cord-268140-s5lailkp	63	18	;	;	:
cord-268140-s5lailkp	63	19	the	the	DT
cord-268140-s5lailkp	63	20	complex	complex	NN
cord-268140-s5lailkp	63	21	binds	bind	VBZ
cord-268140-s5lailkp	63	22	to	to	IN
cord-268140-s5lailkp	63	23	the	the	DT
cord-268140-s5lailkp	63	24	membrane	membrane	NN
cord-268140-s5lailkp	63	25	protein	protein	NN
cord-268140-s5lailkp	63	26	gp130	gp130	NNS
cord-268140-s5lailkp	63	27	and	and	CC
cord-268140-s5lailkp	63	28	downstream	downstream	JJ
cord-268140-s5lailkp	63	29	signaling	signaling	NN
cord-268140-s5lailkp	63	30	and	and	CC
cord-268140-s5lailkp	63	31	gene	gene	NN
cord-268140-s5lailkp	63	32	expression	expression	NN
cord-268140-s5lailkp	63	33	are	be	VBP
cord-268140-s5lailkp	63	34	triggered	trigger	VBN
cord-268140-s5lailkp	63	35	.	.	.
cord-268140-s5lailkp	64	1	In	in	IN
cord-268140-s5lailkp	64	2	the	the	DT
cord-268140-s5lailkp	64	3	trans	trans	NNP
cord-268140-s5lailkp	64	4	pathway	pathway	NNP
cord-268140-s5lailkp	64	5	,	,	,
cord-268140-s5lailkp	64	6	the	the	DT
cord-268140-s5lailkp	64	7	complex	complex	NN
cord-268140-s5lailkp	64	8	of	of	IN
cord-268140-s5lailkp	64	9	sIL-6	sIL-6	NNP
cord-268140-s5lailkp	64	10	with	with	IN
cord-268140-s5lailkp	64	11	the	the	DT
cord-268140-s5lailkp	64	12	receptor	receptor	NN
cord-268140-s5lailkp	64	13	binds	bind	VBZ
cord-268140-s5lailkp	64	14	to	to	IN
cord-268140-s5lailkp	64	15	gp130	gp130	NNS
cord-268140-s5lailkp	64	16	,	,	,
cord-268140-s5lailkp	64	17	and	and	CC
cord-268140-s5lailkp	64	18	intracellular	intracellular	JJ
cord-268140-s5lailkp	64	19	signal	signal	NN
cord-268140-s5lailkp	64	20	transduction	transduction	NN
cord-268140-s5lailkp	64	21	is	be	VBZ
cord-268140-s5lailkp	64	22	initiated	initiate	VBN
cord-268140-s5lailkp	64	23	.	.	.
cord-268140-s5lailkp	65	1	In	in	IN
cord-268140-s5lailkp	65	2	the	the	DT
cord-268140-s5lailkp	65	3	next	next	JJ
cord-268140-s5lailkp	65	4	step	step	NN
cord-268140-s5lailkp	65	5	,	,	,
cord-268140-s5lailkp	65	6	the	the	DT
cord-268140-s5lailkp	65	7	JAK	JAK	NNP
cord-268140-s5lailkp	65	8	-	-	HYPH
cord-268140-s5lailkp	65	9	STAT	STAT	NNP
cord-268140-s5lailkp	65	10	,	,	,
cord-268140-s5lailkp	65	11	RAS	RAS	NNP
cord-268140-s5lailkp	65	12	-	-	HYPH
cord-268140-s5lailkp	65	13	RAF	RAF	NNP
cord-268140-s5lailkp	65	14	and	and	CC
cord-268140-s5lailkp	65	15	other	other	JJ
cord-268140-s5lailkp	65	16	pathways	pathway	NNS
cord-268140-s5lailkp	65	17	are	be	VBP
cord-268140-s5lailkp	65	18	activated	activate	VBN
cord-268140-s5lailkp	65	19	,	,	,
cord-268140-s5lailkp	65	20	promoting	promote	VBG
cord-268140-s5lailkp	65	21	cellular	cellular	JJ
cord-268140-s5lailkp	65	22	proliferation	proliferation	NN
cord-268140-s5lailkp	65	23	,	,	,
cord-268140-s5lailkp	65	24	differentiation	differentiation	NN
cord-268140-s5lailkp	65	25	,	,	,
cord-268140-s5lailkp	65	26	oxidative	oxidative	JJ
cord-268140-s5lailkp	65	27	stress	stress	NN
cord-268140-s5lailkp	65	28	,	,	,
cord-268140-s5lailkp	65	29	and	and	CC
cord-268140-s5lailkp	65	30	immune	immune	JJ
cord-268140-s5lailkp	65	31	regulation	regulation	NN
cord-268140-s5lailkp	65	32	.	.	.
cord-268140-s5lailkp	66	1	The	the	DT
cord-268140-s5lailkp	66	2	classical	classical	JJ
cord-268140-s5lailkp	66	3	IL-6	IL-6	NNP
cord-268140-s5lailkp	66	4	signal	signal	NN
cord-268140-s5lailkp	66	5	is	be	VBZ
cord-268140-s5lailkp	66	6	limited	limit	VBN
cord-268140-s5lailkp	66	7	to	to	IN
cord-268140-s5lailkp	66	8	the	the	DT
cord-268140-s5lailkp	66	9	cells	cell	NNS
cord-268140-s5lailkp	66	10	(	(	-LRB-
cord-268140-s5lailkp	66	11	macrophages	macrophage	NNS
cord-268140-s5lailkp	66	12	,	,	,
cord-268140-s5lailkp	66	13	neutrophils	neutrophil	NNS
cord-268140-s5lailkp	66	14	,	,	,
cord-268140-s5lailkp	66	15	T	t	NN
cord-268140-s5lailkp	66	16	cells	cell	NNS
cord-268140-s5lailkp	66	17	,	,	,
cord-268140-s5lailkp	66	18	etc	etc	FW
cord-268140-s5lailkp	66	19	.	.	.
cord-268140-s5lailkp	66	20	)	)	-RRB-
cord-268140-s5lailkp	67	1	that	that	DT
cord-268140-s5lailkp	67	2	express	express	VBP
cord-268140-s5lailkp	68	1	IL-6R.	il-6r.	CD
cord-268140-s5lailkp	69	1	But	but	CC
cord-268140-s5lailkp	69	2	when	when	WRB
cord-268140-s5lailkp	69	3	IL-6	IL-6	NNP
cord-268140-s5lailkp	69	4	levels	level	NNS
cord-268140-s5lailkp	69	5	increase	increase	VBP
cord-268140-s5lailkp	69	6	,	,	,
cord-268140-s5lailkp	69	7	which	which	WDT
cord-268140-s5lailkp	69	8	is	be	VBZ
cord-268140-s5lailkp	69	9	what	what	WP
cord-268140-s5lailkp	69	10	happens	happen	VBZ
cord-268140-s5lailkp	69	11	in	in	IN
cord-268140-s5lailkp	69	12	subsets	subset	NNS
cord-268140-s5lailkp	69	13	of	of	IN
cord-268140-s5lailkp	69	14	patients	patient	NNS
cord-268140-s5lailkp	69	15	with	with	IN
cord-268140-s5lailkp	69	16	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	69	17	,	,	,
cord-268140-s5lailkp	69	18	the	the	DT
cord-268140-s5lailkp	69	19	signal	signal	NN
cord-268140-s5lailkp	69	20	is	be	VBZ
cord-268140-s5lailkp	69	21	widely	widely	RB
cord-268140-s5lailkp	69	22	expressed	express	VBN
cord-268140-s5lailkp	69	23	due	due	IN
cord-268140-s5lailkp	69	24	to	to	IN
cord-268140-s5lailkp	69	25	the	the	DT
cord-268140-s5lailkp	69	26	ubiquitous	ubiquitous	JJ
cord-268140-s5lailkp	69	27	nature	nature	NN
cord-268140-s5lailkp	69	28	of	of	IN
cord-268140-s5lailkp	69	29	gp130	gp130	NNS
cord-268140-s5lailkp	69	30	.	.	.
cord-268140-s5lailkp	70	1	Drugs	drug	NNS
cord-268140-s5lailkp	70	2	like	like	IN
cord-268140-s5lailkp	70	3	tocilizumab	tocilizumab	NN
cord-268140-s5lailkp	70	4	bind	bind	VBP
cord-268140-s5lailkp	70	5	with	with	IN
cord-268140-s5lailkp	70	6	cell	cell	NN
cord-268140-s5lailkp	70	7	-	-	HYPH
cord-268140-s5lailkp	70	8	related	relate	VBN
cord-268140-s5lailkp	70	9	and	and	CC
cord-268140-s5lailkp	70	10	the	the	DT
cord-268140-s5lailkp	70	11	soluble	soluble	JJ
cord-268140-s5lailkp	70	12	IL-6R	IL-6R	NNP
cord-268140-s5lailkp	70	13	,	,	,
cord-268140-s5lailkp	70	14	thus	thus	RB
cord-268140-s5lailkp	70	15	inhibiting	inhibit	VBG
cord-268140-s5lailkp	70	16	both	both	CC
cord-268140-s5lailkp	70	17	classical	classical	JJ
cord-268140-s5lailkp	70	18	and	and	CC
cord-268140-s5lailkp	70	19	trans	trans	NNP
cord-268140-s5lailkp	70	20	signals	signal	NNS
cord-268140-s5lailkp	70	21	.	.	.
cord-268140-s5lailkp	70	22	"	"	''
cord-268140-s5lailkp	71	1	Cytokine	Cytokine	NNP
cord-268140-s5lailkp	71	2	Release	Release	NNP
cord-268140-s5lailkp	71	3	Syndrome	Syndrome	NNP
cord-268140-s5lailkp	71	4	"	"	''
cord-268140-s5lailkp	71	5	or	or	CC
cord-268140-s5lailkp	71	6	CRS	CRS	NNP
cord-268140-s5lailkp	71	7	is	be	VBZ
cord-268140-s5lailkp	71	8	a	a	DT
cord-268140-s5lailkp	71	9	phenomenon	phenomenon	NN
cord-268140-s5lailkp	71	10	thought	think	VBN
cord-268140-s5lailkp	71	11	to	to	TO
cord-268140-s5lailkp	71	12	be	be	VB
cord-268140-s5lailkp	71	13	implicated	implicate	VBN
cord-268140-s5lailkp	71	14	in	in	IN
cord-268140-s5lailkp	71	15	serious	serious	JJ
cord-268140-s5lailkp	71	16	COVID-19	covid-19	NN
cord-268140-s5lailkp	71	17	as	as	IN
cord-268140-s5lailkp	71	18	evidenced	evidence	VBN
cord-268140-s5lailkp	71	19	by	by	IN
cord-268140-s5lailkp	71	20	multiple	multiple	JJ
cord-268140-s5lailkp	71	21	studies	study	NNS
cord-268140-s5lailkp	71	22	,	,	,
cord-268140-s5lailkp	71	23	there	there	EX
cord-268140-s5lailkp	71	24	is	be	VBZ
cord-268140-s5lailkp	71	25	an	an	DT
cord-268140-s5lailkp	71	26	uncontrolled	uncontrolled	JJ
cord-268140-s5lailkp	71	27	release	release	NN
cord-268140-s5lailkp	71	28	of	of	IN
cord-268140-s5lailkp	71	29	cytokines	cytokine	NNS
cord-268140-s5lailkp	71	30	like	like	IN
cord-268140-s5lailkp	71	31	IL-1	IL-1	NNP
cord-268140-s5lailkp	71	32	,	,	,
cord-268140-s5lailkp	71	33	IL-6	IL-6	NNP
cord-268140-s5lailkp	71	34	,	,	,
cord-268140-s5lailkp	71	35	IL-12	IL-12	NNP
cord-268140-s5lailkp	71	36	,	,	,
cord-268140-s5lailkp	71	37	and	and	CC
cord-268140-s5lailkp	71	38	IL-18	IL-18	NNP
cord-268140-s5lailkp	71	39	,	,	,
cord-268140-s5lailkp	71	40	TNFα	TNFα	NNS
cord-268140-s5lailkp	71	41	,	,	,
cord-268140-s5lailkp	71	42	IFNγ	IFNγ	NNS
cord-268140-s5lailkp	71	43	,	,	,
cord-268140-s5lailkp	71	44	and	and	CC
cord-268140-s5lailkp	71	45	other	other	JJ
cord-268140-s5lailkp	71	46	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	71	47	mediators	mediator	NNS
cord-268140-s5lailkp	71	48	,	,	,
cord-268140-s5lailkp	71	49	which	which	WDT
cord-268140-s5lailkp	71	50	in	in	IN
cord-268140-s5lailkp	71	51	turn	turn	NN
cord-268140-s5lailkp	71	52	may	may	MD
cord-268140-s5lailkp	71	53	increase	increase	VB
cord-268140-s5lailkp	71	54	alveolar	alveolar	NN
cord-268140-s5lailkp	71	55	-	-	HYPH
cord-268140-s5lailkp	71	56	capillary	capillary	JJ
cord-268140-s5lailkp	71	57	gas	gas	NN
cord-268140-s5lailkp	71	58	exchange	exchange	NN
cord-268140-s5lailkp	71	59	,	,	,
cord-268140-s5lailkp	71	60	thereby	thereby	RB
cord-268140-s5lailkp	71	61	reducing	reduce	VBG
cord-268140-s5lailkp	71	62	oxygenation	oxygenation	NN
cord-268140-s5lailkp	71	63	in	in	IN
cord-268140-s5lailkp	71	64	the	the	DT
cord-268140-s5lailkp	71	65	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	71	66	tissue	tissue	NN
cord-268140-s5lailkp	71	67	.	.	.
cord-268140-s5lailkp	72	1	This	this	DT
cord-268140-s5lailkp	72	2	phenomenon	phenomenon	NN
cord-268140-s5lailkp	72	3	is	be	VBZ
cord-268140-s5lailkp	72	4	thought	think	VBN
cord-268140-s5lailkp	72	5	to	to	TO
cord-268140-s5lailkp	72	6	be	be	VB
cord-268140-s5lailkp	72	7	part	part	NN
cord-268140-s5lailkp	72	8	of	of	IN
cord-268140-s5lailkp	72	9	the	the	DT
cord-268140-s5lailkp	72	10	underlying	underlie	VBG
cord-268140-s5lailkp	72	11	pathology	pathology	NN
cord-268140-s5lailkp	72	12	for	for	IN
cord-268140-s5lailkp	72	13	many	many	JJ
cord-268140-s5lailkp	72	14	conditions	condition	NNS
cord-268140-s5lailkp	72	15	such	such	JJ
cord-268140-s5lailkp	72	16	as	as	IN
cord-268140-s5lailkp	72	17	ARDS	ARDS	NNP
cord-268140-s5lailkp	72	18	,	,	,
cord-268140-s5lailkp	72	19	sepsis	sepsis	NN
cord-268140-s5lailkp	72	20	,	,	,
cord-268140-s5lailkp	72	21	Graft	graft	NN
cord-268140-s5lailkp	72	22	-	-	HYPH
cord-268140-s5lailkp	72	23	versus	versus	IN
cord-268140-s5lailkp	72	24	-	-	HYPH
cord-268140-s5lailkp	72	25	Host	host	NN
cord-268140-s5lailkp	72	26	Disease	Disease	NNP
cord-268140-s5lailkp	72	27	(	(	-LRB-
cord-268140-s5lailkp	72	28	GvHD	GvHD	NNP
cord-268140-s5lailkp	72	29	)	)	-RRB-
cord-268140-s5lailkp	72	30	,	,	,
cord-268140-s5lailkp	72	31	primary	primary	JJ
cord-268140-s5lailkp	72	32	and	and	CC
cord-268140-s5lailkp	72	33	secondary	secondary	JJ
cord-268140-s5lailkp	72	34	hemophagocytic	hemophagocytic	JJ
cord-268140-s5lailkp	72	35	lymphohistiocytosis	lymphohistiocytosis	NN
cord-268140-s5lailkp	72	36	(	(	-LRB-
cord-268140-s5lailkp	72	37	HLH	HLH	NNP
cord-268140-s5lailkp	72	38	)	)	-RRB-
cord-268140-s5lailkp	72	39	and	and	CC
cord-268140-s5lailkp	72	40	complication	complication	NN
cord-268140-s5lailkp	72	41	of	of	IN
cord-268140-s5lailkp	72	42	CAR	car	NN
cord-268140-s5lailkp	72	43	-	-	HYPH
cord-268140-s5lailkp	72	44	T	t	NN
cord-268140-s5lailkp	72	45	cell	cell	NN
cord-268140-s5lailkp	72	46	therapies	therapy	NNS
cord-268140-s5lailkp	72	47	(	(	-LRB-
cord-268140-s5lailkp	72	48	for	for	IN
cord-268140-s5lailkp	72	49	which	which	WDT
cord-268140-s5lailkp	72	50	IL-6	IL-6	NNP
cord-268140-s5lailkp	72	51	inhibitor	inhibitor	NN
cord-268140-s5lailkp	72	52	therapy	therapy	NN
cord-268140-s5lailkp	72	53	is	be	VBZ
cord-268140-s5lailkp	72	54	approved	approve	VBN
cord-268140-s5lailkp	72	55	)	)	-RRB-
cord-268140-s5lailkp	73	1	[	[	-LRB-
cord-268140-s5lailkp	73	2	28	28	CD
cord-268140-s5lailkp	73	3	]	]	-RRB-
cord-268140-s5lailkp	73	4	.	.	.
cord-268140-s5lailkp	74	1	Higher	high	JJR
cord-268140-s5lailkp	74	2	blood	blood	NN
cord-268140-s5lailkp	74	3	plasma	plasma	NN
cord-268140-s5lailkp	74	4	levels	level	NNS
cord-268140-s5lailkp	74	5	of	of	IN
cord-268140-s5lailkp	74	6	IL-2	IL-2	NNP
cord-268140-s5lailkp	74	7	,	,	,
cord-268140-s5lailkp	74	8	IL-7	IL-7	NNP
cord-268140-s5lailkp	74	9	,	,	,
cord-268140-s5lailkp	74	10	IL-10	IL-10	NNP
cord-268140-s5lailkp	74	11	,	,	,
cord-268140-s5lailkp	74	12	granulocyte	granulocyte	NN
cord-268140-s5lailkp	74	13	colony	colony	NN
cord-268140-s5lailkp	74	14	-	-	HYPH
cord-268140-s5lailkp	74	15	stimulating	stimulate	VBG
cord-268140-s5lailkp	74	16	factor	factor	NN
cord-268140-s5lailkp	74	17	(	(	-LRB-
cord-268140-s5lailkp	74	18	G	G	NNP
cord-268140-s5lailkp	74	19	-	-	HYPH
cord-268140-s5lailkp	74	20	CSF	CSF	NNP
cord-268140-s5lailkp	74	21	)	)	-RRB-
cord-268140-s5lailkp	74	22	,	,	,
cord-268140-s5lailkp	74	23	IP-10	IP-10	NNP
cord-268140-s5lailkp	74	24	,	,	,
cord-268140-s5lailkp	74	25	MCP1	MCP1	NNP
cord-268140-s5lailkp	74	26	,	,	,
cord-268140-s5lailkp	74	27	macrophage	macrophage	NN
cord-268140-s5lailkp	74	28	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	74	29	protein	protein	NN
cord-268140-s5lailkp	74	30	1α	1α	CD
cord-268140-s5lailkp	74	31	(	(	-LRB-
cord-268140-s5lailkp	74	32	MIP1α	MIP1α	NNP
cord-268140-s5lailkp	74	33	)	)	-RRB-
cord-268140-s5lailkp	74	34	and	and	CC
cord-268140-s5lailkp	74	35	TNF	TNF	NNP
cord-268140-s5lailkp	74	36	have	have	VBP
cord-268140-s5lailkp	74	37	been	be	VBN
cord-268140-s5lailkp	74	38	observed	observe	VBN
cord-268140-s5lailkp	74	39	in	in	IN
cord-268140-s5lailkp	74	40	severe	severe	JJ
cord-268140-s5lailkp	74	41	COVID19	covid19	NN
cord-268140-s5lailkp	74	42	patients	patient	NNS
cord-268140-s5lailkp	74	43	requiring	require	VBG
cord-268140-s5lailkp	74	44	intensive	intensive	JJ
cord-268140-s5lailkp	74	45	care	care	NN
cord-268140-s5lailkp	74	46	[	[	-LRB-
cord-268140-s5lailkp	74	47	24	24	CD
cord-268140-s5lailkp	74	48	]	]	-RRB-
cord-268140-s5lailkp	74	49	.	.	.
cord-268140-s5lailkp	75	1	However	however	RB
cord-268140-s5lailkp	75	2	,	,	,
cord-268140-s5lailkp	75	3	IL-6	IL-6	NNP
cord-268140-s5lailkp	75	4	is	be	VBZ
cord-268140-s5lailkp	75	5	the	the	DT
cord-268140-s5lailkp	75	6	key	key	JJ
cord-268140-s5lailkp	75	7	driver	driver	NN
cord-268140-s5lailkp	75	8	of	of	IN
cord-268140-s5lailkp	75	9	this	this	DT
cord-268140-s5lailkp	75	10	hyperinflammatory	hyperinflammatory	JJ
cord-268140-s5lailkp	75	11	process	process	NN
cord-268140-s5lailkp	75	12	in	in	IN
cord-268140-s5lailkp	75	13	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	75	14	.	.	.
cord-268140-s5lailkp	76	1	Unremitting	unremitting	JJ
cord-268140-s5lailkp	76	2	fever	fever	NN
cord-268140-s5lailkp	76	3	,	,	,
cord-268140-s5lailkp	76	4	hyperferritinemia	hyperferritinemia	NN
cord-268140-s5lailkp	76	5	and	and	CC
cord-268140-s5lailkp	76	6	significantly	significantly	RB
cord-268140-s5lailkp	76	7	elevated	elevate	VBD
cord-268140-s5lailkp	76	8	IL-6	IL-6	NNP
cord-268140-s5lailkp	76	9	,	,	,
cord-268140-s5lailkp	76	10	similar	similar	JJ
cord-268140-s5lailkp	76	11	to	to	IN
cord-268140-s5lailkp	76	12	that	that	DT
cord-268140-s5lailkp	76	13	seen	see	VBN
cord-268140-s5lailkp	76	14	in	in	IN
cord-268140-s5lailkp	76	15	secondary	secondary	JJ
cord-268140-s5lailkp	76	16	hemophagocytic	hemophagocytic	JJ
cord-268140-s5lailkp	76	17	lymphohistiocytosis	lymphohistiocytosis	NNP
cord-268140-s5lailkp	76	18	(	(	-LRB-
cord-268140-s5lailkp	76	19	sHLH	sHLH	NNP
cord-268140-s5lailkp	76	20	)	)	-RRB-
cord-268140-s5lailkp	76	21	,	,	,
cord-268140-s5lailkp	76	22	have	have	VBP
cord-268140-s5lailkp	76	23	been	be	VBN
cord-268140-s5lailkp	76	24	consistently	consistently	RB
cord-268140-s5lailkp	76	25	reported	report	VBN
cord-268140-s5lailkp	76	26	in	in	IN
cord-268140-s5lailkp	76	27	studies	study	NNS
cord-268140-s5lailkp	76	28	[	[	-LRB-
cord-268140-s5lailkp	76	29	3	3	CD
cord-268140-s5lailkp	76	30	,	,	,
cord-268140-s5lailkp	76	31	29	29	CD
cord-268140-s5lailkp	76	32	]	]	-RRB-
cord-268140-s5lailkp	76	33	.	.	.
cord-268140-s5lailkp	77	1	Evidence	evidence	NN
cord-268140-s5lailkp	77	2	from	from	IN
cord-268140-s5lailkp	77	3	a	a	DT
cord-268140-s5lailkp	77	4	meta	meta	JJ
cord-268140-s5lailkp	77	5	-	-	HYPH
cord-268140-s5lailkp	77	6	analysis	analysis	NN
cord-268140-s5lailkp	77	7	of	of	IN
cord-268140-s5lailkp	77	8	6	6	CD
cord-268140-s5lailkp	77	9	studies	study	NNS
cord-268140-s5lailkp	77	10	revealed	reveal	VBD
cord-268140-s5lailkp	77	11	2.9-fold	2.9-fold	CD
cord-268140-s5lailkp	77	12	higher	high	JJR
cord-268140-s5lailkp	77	13	mean	mean	NN
cord-268140-s5lailkp	77	14	IL-6	IL-6	NNP
cord-268140-s5lailkp	77	15	concentrations	concentration	NNS
cord-268140-s5lailkp	77	16	in	in	IN
cord-268140-s5lailkp	77	17	patients	patient	NNS
cord-268140-s5lailkp	77	18	with	with	IN
cord-268140-s5lailkp	77	19	complicated	complicated	JJ
cord-268140-s5lailkp	77	20	COVID-19	covid-19	CD
cord-268140-s5lailkp	77	21	than	than	IN
cord-268140-s5lailkp	77	22	non	non	JJ
cord-268140-s5lailkp	77	23	-	-	JJ
cord-268140-s5lailkp	77	24	complicated	complicated	JJ
cord-268140-s5lailkp	77	25	disease	disease	NN
cord-268140-s5lailkp	77	26	[	[	-LRB-
cord-268140-s5lailkp	77	27	30	30	CD
cord-268140-s5lailkp	77	28	]	]	-RRB-
cord-268140-s5lailkp	77	29	.	.	.
cord-268140-s5lailkp	78	1	The	the	DT
cord-268140-s5lailkp	78	2	involvement	involvement	NN
cord-268140-s5lailkp	78	3	of	of	IN
cord-268140-s5lailkp	78	4	exaggerated	exaggerated	JJ
cord-268140-s5lailkp	78	5	host	host	NN
cord-268140-s5lailkp	78	6	immune	immune	JJ
cord-268140-s5lailkp	78	7	response	response	NN
cord-268140-s5lailkp	78	8	is	be	VBZ
cord-268140-s5lailkp	78	9	also	also	RB
cord-268140-s5lailkp	78	10	suggested	suggest	VBN
cord-268140-s5lailkp	78	11	by	by	IN
cord-268140-s5lailkp	78	12	findings	finding	NNS
cord-268140-s5lailkp	78	13	that	that	IN
cord-268140-s5lailkp	78	14	ARDS	ARDS	NNP
cord-268140-s5lailkp	78	15	occurs	occur	VBZ
cord-268140-s5lailkp	78	16	in	in	IN
cord-268140-s5lailkp	78	17	some	some	DT
cord-268140-s5lailkp	78	18	SARS	SARS	NNP
cord-268140-s5lailkp	78	19	patients	patient	NNS
cord-268140-s5lailkp	78	20	despite	despite	IN
cord-268140-s5lailkp	78	21	decreasing	decrease	VBG
cord-268140-s5lailkp	78	22	viral	viral	JJ
cord-268140-s5lailkp	78	23	load	load	NN
cord-268140-s5lailkp	78	24	.	.	.
cord-268140-s5lailkp	79	1	Furthermore	furthermore	RB
cord-268140-s5lailkp	79	2	,	,	,
cord-268140-s5lailkp	79	3	tissue	tissue	NN
cord-268140-s5lailkp	79	4	necrosis	necrosis	NN
cord-268140-s5lailkp	79	5	and	and	CC
cord-268140-s5lailkp	79	6	interstitial	interstitial	JJ
cord-268140-s5lailkp	79	7	macrophages	macrophage	NNS
cord-268140-s5lailkp	79	8	and	and	CC
cord-268140-s5lailkp	79	9	monocyte	monocyte	NNP
cord-268140-s5lailkp	79	10	infiltrations	infiltration	NNS
cord-268140-s5lailkp	79	11	in	in	IN
cord-268140-s5lailkp	79	12	the	the	DT
cord-268140-s5lailkp	79	13	lungs	lung	NNS
cord-268140-s5lailkp	79	14	,	,	,
cord-268140-s5lailkp	79	15	heart	heart	NN
cord-268140-s5lailkp	79	16	and	and	CC
cord-268140-s5lailkp	79	17	gastrointestinal	gastrointestinal	JJ
cord-268140-s5lailkp	79	18	mucosa	mucosa	NN
cord-268140-s5lailkp	79	19	have	have	VBP
cord-268140-s5lailkp	79	20	been	be	VBN
cord-268140-s5lailkp	79	21	demonstrated	demonstrate	VBN
cord-268140-s5lailkp	79	22	in	in	IN
cord-268140-s5lailkp	79	23	postmortem	postmortem	JJ
cord-268140-s5lailkp	79	24	pathology	pathology	NN
cord-268140-s5lailkp	79	25	in	in	IN
cord-268140-s5lailkp	79	26	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	79	27	patients	patient	NNS
cord-268140-s5lailkp	79	28	[	[	-LRB-
cord-268140-s5lailkp	79	29	25	25	CD
cord-268140-s5lailkp	79	30	,	,	,
cord-268140-s5lailkp	79	31	31	31	CD
cord-268140-s5lailkp	79	32	]	]	-RRB-
cord-268140-s5lailkp	79	33	.	.	.
cord-268140-s5lailkp	80	1	IL-6	IL-6	NNP
cord-268140-s5lailkp	81	1	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	81	2	thus	thus	RB
cord-268140-s5lailkp	81	3	have	have	VBP
cord-268140-s5lailkp	81	4	potential	potential	NN
cord-268140-s5lailkp	81	5	to	to	TO
cord-268140-s5lailkp	81	6	be	be	VB
cord-268140-s5lailkp	81	7	effective	effective	JJ
cord-268140-s5lailkp	81	8	in	in	IN
cord-268140-s5lailkp	81	9	such	such	JJ
cord-268140-s5lailkp	81	10	serious	serious	JJ
cord-268140-s5lailkp	81	11	cases	case	NNS
cord-268140-s5lailkp	81	12	of	of	IN
cord-268140-s5lailkp	81	13	COVID-19	covid-19	JJ
cord-268140-s5lailkp	81	14	infections	infection	NNS
cord-268140-s5lailkp	81	15	by	by	IN
cord-268140-s5lailkp	81	16	preventing	prevent	VBG
cord-268140-s5lailkp	81	17	the	the	DT
cord-268140-s5lailkp	81	18	severe	severe	JJ
cord-268140-s5lailkp	81	19	damage	damage	NN
cord-268140-s5lailkp	81	20	to	to	IN
cord-268140-s5lailkp	81	21	lung	lung	NN
cord-268140-s5lailkp	81	22	tissue	tissue	NN
cord-268140-s5lailkp	81	23	caused	cause	VBN
cord-268140-s5lailkp	81	24	by	by	IN
cord-268140-s5lailkp	81	25	the	the	DT
cord-268140-s5lailkp	81	26	CRS	CRS	NNP
cord-268140-s5lailkp	81	27	[	[	-LRB-
cord-268140-s5lailkp	81	28	32	32	CD
cord-268140-s5lailkp	81	29	]	]	-RRB-
cord-268140-s5lailkp	81	30	.	.	.
cord-268140-s5lailkp	82	1	Figure	figure	NN
cord-268140-s5lailkp	82	2	1	1	CD
cord-268140-s5lailkp	82	3	shows	show	VBZ
cord-268140-s5lailkp	82	4	the	the	DT
cord-268140-s5lailkp	82	5	effect	effect	NN
cord-268140-s5lailkp	82	6	of	of	IN
cord-268140-s5lailkp	82	7	viral	viral	JJ
cord-268140-s5lailkp	82	8	infection	infection	NN
cord-268140-s5lailkp	82	9	on	on	IN
cord-268140-s5lailkp	82	10	various	various	JJ
cord-268140-s5lailkp	82	11	cells	cell	NNS
cord-268140-s5lailkp	82	12	and	and	CC
cord-268140-s5lailkp	82	13	the	the	DT
cord-268140-s5lailkp	82	14	possible	possible	JJ
cord-268140-s5lailkp	82	15	role	role	NN
cord-268140-s5lailkp	82	16	of	of	IN
cord-268140-s5lailkp	82	17	cytokine	cytokine	NN
cord-268140-s5lailkp	82	18	blockade	blockade	NN
cord-268140-s5lailkp	82	19	through	through	IN
cord-268140-s5lailkp	82	20	drugs	drug	NNS
cord-268140-s5lailkp	82	21	like	like	IN
cord-268140-s5lailkp	82	22	IL-6	IL-6	NNP
cord-268140-s5lailkp	82	23	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	82	24	.	.	.
cord-268140-s5lailkp	83	1	Published	publish	VBN
cord-268140-s5lailkp	83	2	preclinical	preclinical	JJ
cord-268140-s5lailkp	83	3	data	datum	NNS
cord-268140-s5lailkp	83	4	regarding	regard	VBG
cord-268140-s5lailkp	83	5	efficacy	efficacy	NN
cord-268140-s5lailkp	83	6	of	of	IN
cord-268140-s5lailkp	83	7	IL-6	IL-6	NNP
cord-268140-s5lailkp	83	8	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	83	9	against	against	IN
cord-268140-s5lailkp	83	10	SARS	SARS	NNP
cord-268140-s5lailkp	83	11	-	-	HYPH
cord-268140-s5lailkp	83	12	CoV2	CoV2	NNP
cord-268140-s5lailkp	83	13	are	be	VBP
cord-268140-s5lailkp	83	14	not	not	RB
cord-268140-s5lailkp	83	15	readily	readily	RB
cord-268140-s5lailkp	83	16	available	available	JJ
cord-268140-s5lailkp	83	17	.	.	.
cord-268140-s5lailkp	84	1	However	however	RB
cord-268140-s5lailkp	84	2	,	,	,
cord-268140-s5lailkp	84	3	previous	previous	JJ
cord-268140-s5lailkp	84	4	evidence	evidence	NN
cord-268140-s5lailkp	84	5	from	from	IN
cord-268140-s5lailkp	84	6	preclinical	preclinical	JJ
cord-268140-s5lailkp	84	7	studies	study	NNS
cord-268140-s5lailkp	84	8	on	on	IN
cord-268140-s5lailkp	84	9	SARS	SARS	NNP
cord-268140-s5lailkp	84	10	-	-	HYPH
cord-268140-s5lailkp	84	11	CoV	CoV	NNP
cord-268140-s5lailkp	84	12	has	have	VBZ
cord-268140-s5lailkp	84	13	demonstrated	demonstrate	VBN
cord-268140-s5lailkp	84	14	that	that	IN
cord-268140-s5lailkp	84	15	inhibiting	inhibit	VBG
cord-268140-s5lailkp	84	16	nuclear	nuclear	JJ
cord-268140-s5lailkp	84	17	factor	factor	NN
cord-268140-s5lailkp	84	18	kappa	kappa	NN
cord-268140-s5lailkp	84	19	-	-	HYPH
cord-268140-s5lailkp	84	20	B	B	NNP
cord-268140-s5lailkp	84	21	(	(	-LRB-
cord-268140-s5lailkp	84	22	NF	nf	NN
cord-268140-s5lailkp	84	23	-	-	HYPH
cord-268140-s5lailkp	84	24	κB	κB	NNP
cord-268140-s5lailkp	84	25	)	)	-RRB-
cord-268140-s5lailkp	84	26	,	,	,
cord-268140-s5lailkp	84	27	a	a	DT
cord-268140-s5lailkp	84	28	key	key	JJ
cord-268140-s5lailkp	84	29	transcription	transcription	NN
cord-268140-s5lailkp	84	30	factor	factor	NN
cord-268140-s5lailkp	84	31	of	of	IN
cord-268140-s5lailkp	84	32	IL-6	IL-6	NNP
cord-268140-s5lailkp	84	33	,	,	,
cord-268140-s5lailkp	84	34	or	or	CC
cord-268140-s5lailkp	84	35	infecting	infect	VBG
cord-268140-s5lailkp	84	36	animals	animal	NNS
cord-268140-s5lailkp	84	37	with	with	IN
cord-268140-s5lailkp	84	38	SARS	SARS	NNP
cord-268140-s5lailkp	84	39	-	-	HYPH
cord-268140-s5lailkp	84	40	CoV	CoV	NNP
cord-268140-s5lailkp	84	41	lacking	lack	VBG
cord-268140-s5lailkp	84	42	the	the	DT
cord-268140-s5lailkp	84	43	coronavirus	coronavirus	NN
cord-268140-s5lailkp	84	44	envelope	envelope	NN
cord-268140-s5lailkp	84	45	(	(	-LRB-
cord-268140-s5lailkp	84	46	E	e	NN
cord-268140-s5lailkp	84	47	)	)	-RRB-
cord-268140-s5lailkp	84	48	protein	protein	NN
cord-268140-s5lailkp	84	49	,	,	,
cord-268140-s5lailkp	84	50	which	which	WDT
cord-268140-s5lailkp	84	51	is	be	VBZ
cord-268140-s5lailkp	84	52	a	a	DT
cord-268140-s5lailkp	84	53	strong	strong	JJ
cord-268140-s5lailkp	84	54	stimulus	stimulus	NN
cord-268140-s5lailkp	84	55	to	to	IN
cord-268140-s5lailkp	84	56	NF	nf	NN
cord-268140-s5lailkp	84	57	-	-	HYPH
cord-268140-s5lailkp	84	58	κB	κB	NNP
cord-268140-s5lailkp	84	59	signaling	signaling	NN
cord-268140-s5lailkp	84	60	,	,	,
cord-268140-s5lailkp	84	61	increased	increase	VBN
cord-268140-s5lailkp	84	62	animal	animal	NN
cord-268140-s5lailkp	84	63	survival	survival	NN
cord-268140-s5lailkp	84	64	and	and	CC
cord-268140-s5lailkp	84	65	resulted	result	VBD
cord-268140-s5lailkp	84	66	in	in	IN
cord-268140-s5lailkp	84	67	reduced	reduce	VBN
cord-268140-s5lailkp	84	68	IL-6	IL-6	NNP
cord-268140-s5lailkp	84	69	levels	level	NNS
cord-268140-s5lailkp	84	70	[	[	-LRB-
cord-268140-s5lailkp	84	71	33	33	CD
cord-268140-s5lailkp	84	72	]	]	-RRB-
cord-268140-s5lailkp	84	73	.	.	.
cord-268140-s5lailkp	85	1	IL-6	IL-6	NNP
cord-268140-s5lailkp	86	1	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	86	2	are	be	VBP
cord-268140-s5lailkp	86	3	categorized	categorize	VBN
cord-268140-s5lailkp	86	4	under	under	IN
cord-268140-s5lailkp	86	5	immune	immune	NN
cord-268140-s5lailkp	86	6	-	-	HYPH
cord-268140-s5lailkp	86	7	based	base	VBN
cord-268140-s5lailkp	86	8	therapies	therapy	NNS
cord-268140-s5lailkp	86	9	,	,	,
cord-268140-s5lailkp	86	10	separate	separate	JJ
cord-268140-s5lailkp	86	11	from	from	IN
cord-268140-s5lailkp	86	12	the	the	DT
cord-268140-s5lailkp	86	13	antiviral	antiviral	JJ
cord-268140-s5lailkp	86	14	therapies	therapy	NNS
cord-268140-s5lailkp	86	15	[	[	-LRB-
cord-268140-s5lailkp	86	16	11	11	CD
cord-268140-s5lailkp	86	17	]	]	-RRB-
cord-268140-s5lailkp	86	18	.	.	.
cord-268140-s5lailkp	87	1	Evidence	evidence	NN
cord-268140-s5lailkp	87	2	from	from	IN
cord-268140-s5lailkp	87	3	previous	previous	JJ
cord-268140-s5lailkp	87	4	pandemics	pandemic	NNS
cord-268140-s5lailkp	87	5	of	of	IN
cord-268140-s5lailkp	87	6	SARS	SARS	NNP
cord-268140-s5lailkp	87	7	and	and	CC
cord-268140-s5lailkp	87	8	MERS	MERS	NNP
cord-268140-s5lailkp	87	9	reported	report	VBD
cord-268140-s5lailkp	87	10	no	no	DT
cord-268140-s5lailkp	87	11	survival	survival	NN
cord-268140-s5lailkp	87	12	benefits	benefit	NNS
cord-268140-s5lailkp	87	13	with	with	IN
cord-268140-s5lailkp	87	14	corticosteroids	corticosteroid	NNS
cord-268140-s5lailkp	87	15	;	;	:
cord-268140-s5lailkp	87	16	in	in	IN
cord-268140-s5lailkp	87	17	fact	fact	NN
cord-268140-s5lailkp	87	18	delayed	delay	VBN
cord-268140-s5lailkp	87	19	viral	viral	JJ
cord-268140-s5lailkp	87	20	clearance	clearance	NN
cord-268140-s5lailkp	87	21	was	be	VBD
cord-268140-s5lailkp	87	22	observed	observe	VBN
cord-268140-s5lailkp	87	23	from	from	IN
cord-268140-s5lailkp	87	24	the	the	DT
cord-268140-s5lailkp	87	25	respiratory	respiratory	JJ
cord-268140-s5lailkp	87	26	tract	tract	NN
cord-268140-s5lailkp	87	27	and	and	CC
cord-268140-s5lailkp	87	28	blood	blood	NN
cord-268140-s5lailkp	87	29	with	with	IN
cord-268140-s5lailkp	87	30	high	high	JJ
cord-268140-s5lailkp	87	31	rates	rate	NNS
cord-268140-s5lailkp	87	32	of	of	IN
cord-268140-s5lailkp	87	33	complications	complication	NNS
cord-268140-s5lailkp	87	34	including	include	VBG
cord-268140-s5lailkp	87	35	hyperglycemia	hyperglycemia	NN
cord-268140-s5lailkp	87	36	,	,	,
cord-268140-s5lailkp	87	37	psychosis	psychosis	NN
cord-268140-s5lailkp	87	38	,	,	,
cord-268140-s5lailkp	87	39	and	and	CC
cord-268140-s5lailkp	87	40	avascular	avascular	JJ
cord-268140-s5lailkp	87	41	necrosis	necrosis	NN
cord-268140-s5lailkp	87	42	with	with	IN
cord-268140-s5lailkp	87	43	use	use	NN
cord-268140-s5lailkp	87	44	of	of	IN
cord-268140-s5lailkp	87	45	corticosteroids	corticosteroid	NNS
cord-268140-s5lailkp	87	46	[	[	-LRB-
cord-268140-s5lailkp	87	47	34	34	CD
cord-268140-s5lailkp	87	48	]	]	-RRB-
cord-268140-s5lailkp	87	49	.	.	.
cord-268140-s5lailkp	88	1	Hence	hence	RB
cord-268140-s5lailkp	88	2	,	,	,
cord-268140-s5lailkp	88	3	corticosteroids	corticosteroid	NNS
cord-268140-s5lailkp	88	4	are	be	VBP
cord-268140-s5lailkp	88	5	generally	generally	RB
cord-268140-s5lailkp	88	6	reserved	reserve	VBN
cord-268140-s5lailkp	88	7	for	for	IN
cord-268140-s5lailkp	88	8	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	88	9	in	in	IN
cord-268140-s5lailkp	88	10	specific	specific	JJ
cord-268140-s5lailkp	88	11	situations	situation	NNS
cord-268140-s5lailkp	88	12	like	like	IN
cord-268140-s5lailkp	88	13	refractory	refractory	JJ
cord-268140-s5lailkp	88	14	septic	septic	JJ
cord-268140-s5lailkp	88	15	shock	shock	NN
cord-268140-s5lailkp	88	16	[	[	-LRB-
cord-268140-s5lailkp	88	17	11	11	CD
cord-268140-s5lailkp	88	18	,	,	,
cord-268140-s5lailkp	88	19	35	35	CD
cord-268140-s5lailkp	88	20	]	]	-RRB-
cord-268140-s5lailkp	88	21	.	.	.
cord-268140-s5lailkp	89	1	However	however	RB
cord-268140-s5lailkp	89	2	,	,	,
cord-268140-s5lailkp	89	3	selective	selective	JJ
cord-268140-s5lailkp	89	4	immunosuppression	immunosuppression	NN
cord-268140-s5lailkp	89	5	is	be	VBZ
cord-268140-s5lailkp	89	6	likely	likely	JJ
cord-268140-s5lailkp	89	7	to	to	TO
cord-268140-s5lailkp	89	8	be	be	VB
cord-268140-s5lailkp	89	9	beneficial	beneficial	JJ
cord-268140-s5lailkp	89	10	in	in	IN
cord-268140-s5lailkp	89	11	the	the	DT
cord-268140-s5lailkp	89	12	COVID-19-associated	covid-19-associated	JJ
cord-268140-s5lailkp	89	13	states	state	NNS
cord-268140-s5lailkp	89	14	of	of	IN
cord-268140-s5lailkp	89	15	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	89	16	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	89	17	.	.	.
cord-268140-s5lailkp	90	1	The	the	DT
cord-268140-s5lailkp	90	2	targeted	target	VBN
cord-268140-s5lailkp	90	3	monoclonal	monoclonal	JJ
cord-268140-s5lailkp	90	4	antibodies	antibody	NNS
cord-268140-s5lailkp	90	5	against	against	IN
cord-268140-s5lailkp	90	6	IL-6	IL-6	NNP
cord-268140-s5lailkp	90	7	can	can	MD
cord-268140-s5lailkp	90	8	selectively	selectively	RB
cord-268140-s5lailkp	90	9	dampen	dampen	VB
cord-268140-s5lailkp	90	10	this	this	DT
cord-268140-s5lailkp	90	11	process	process	NN
cord-268140-s5lailkp	90	12	and	and	CC
cord-268140-s5lailkp	90	13	improve	improve	VB
cord-268140-s5lailkp	90	14	clinical	clinical	JJ
cord-268140-s5lailkp	90	15	outcomes	outcome	NNS
cord-268140-s5lailkp	90	16	in	in	IN
cord-268140-s5lailkp	90	17	patients	patient	NNS
cord-268140-s5lailkp	90	18	with	with	IN
cord-268140-s5lailkp	90	19	evident	evident	JJ
cord-268140-s5lailkp	90	20	features	feature	NNS
cord-268140-s5lailkp	90	21	of	of	IN
cord-268140-s5lailkp	90	22	cytokine	cytokine	NN
cord-268140-s5lailkp	90	23	driven	drive	VBN
cord-268140-s5lailkp	90	24	inflammation	inflammation	NN
cord-268140-s5lailkp	90	25	like	like	IN
cord-268140-s5lailkp	90	26	persistent	persistent	JJ
cord-268140-s5lailkp	90	27	fever	fever	NN
cord-268140-s5lailkp	90	28	,	,	,
cord-268140-s5lailkp	90	29	dyspnea	dyspnea	NN
cord-268140-s5lailkp	90	30	,	,	,
cord-268140-s5lailkp	90	31	and	and	CC
cord-268140-s5lailkp	90	32	elevated	elevate	VBD
cord-268140-s5lailkp	90	33	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	90	34	markers	marker	NNS
cord-268140-s5lailkp	90	35	.	.	.
cord-268140-s5lailkp	91	1	A	a	DT
cord-268140-s5lailkp	91	2	further	further	JJ
cord-268140-s5lailkp	91	3	rationale	rationale	NN
cord-268140-s5lailkp	91	4	has	have	VBZ
cord-268140-s5lailkp	91	5	been	be	VBN
cord-268140-s5lailkp	91	6	provided	provide	VBN
cord-268140-s5lailkp	91	7	by	by	IN
cord-268140-s5lailkp	91	8	research	research	NN
cord-268140-s5lailkp	91	9	indicating	indicate	VBG
cord-268140-s5lailkp	91	10	that	that	IN
cord-268140-s5lailkp	91	11	viral	viral	JJ
cord-268140-s5lailkp	91	12	load	load	NN
cord-268140-s5lailkp	91	13	is	be	VBZ
cord-268140-s5lailkp	91	14	associated	associate	VBN
cord-268140-s5lailkp	91	15	with	with	IN
cord-268140-s5lailkp	91	16	elevated	elevated	JJ
cord-268140-s5lailkp	91	17	IL-6	IL-6	NNP
cord-268140-s5lailkp	91	18	levels	level	NNS
cord-268140-s5lailkp	91	19	in	in	IN
cord-268140-s5lailkp	91	20	severely	severely	RB
cord-268140-s5lailkp	91	21	ill	ill	JJ
cord-268140-s5lailkp	92	1	COVID-19	covid-19	JJ
cord-268140-s5lailkp	92	2	patients	patient	NNS
cord-268140-s5lailkp	92	3	[	[	-LRB-
cord-268140-s5lailkp	92	4	36	36	CD
cord-268140-s5lailkp	92	5	]	]	-RRB-
cord-268140-s5lailkp	92	6	.	.	.
cord-268140-s5lailkp	93	1	It	-PRON-	PRP
cord-268140-s5lailkp	93	2	has	have	VBZ
cord-268140-s5lailkp	93	3	been	be	VBN
cord-268140-s5lailkp	93	4	proposed	propose	VBN
cord-268140-s5lailkp	93	5	that	that	IN
cord-268140-s5lailkp	93	6	early	early	JJ
cord-268140-s5lailkp	93	7	diagnosis	diagnosis	NN
cord-268140-s5lailkp	93	8	of	of	IN
cord-268140-s5lailkp	93	9	CRS	CRS	NNP
cord-268140-s5lailkp	93	10	in	in	IN
cord-268140-s5lailkp	93	11	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	93	12	patients	patient	NNS
cord-268140-s5lailkp	93	13	through	through	IN
cord-268140-s5lailkp	93	14	screening	screening	NN
cord-268140-s5lailkp	93	15	tools	tool	NNS
cord-268140-s5lailkp	93	16	like	like	IN
cord-268140-s5lailkp	93	17	the	the	DT
cord-268140-s5lailkp	93	18	H	h	NN
cord-268140-s5lailkp	93	19	-	-	HYPH
cord-268140-s5lailkp	93	20	score	score	NN
cord-268140-s5lailkp	93	21	used	use	VBN
cord-268140-s5lailkp	93	22	for	for	IN
cord-268140-s5lailkp	93	23	HLH	HLH	NNP
cord-268140-s5lailkp	93	24	,	,	,
cord-268140-s5lailkp	93	25	and	and	CC
cord-268140-s5lailkp	93	26	prompt	prompt	JJ
cord-268140-s5lailkp	93	27	immunomodulation	immunomodulation	NN
cord-268140-s5lailkp	93	28	with	with	IN
cord-268140-s5lailkp	93	29	IL-6	IL-6	NNP
cord-268140-s5lailkp	93	30	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	93	31	may	may	MD
cord-268140-s5lailkp	93	32	be	be	VB
cord-268140-s5lailkp	93	33	beneficial	beneficial	JJ
cord-268140-s5lailkp	93	34	,	,	,
cord-268140-s5lailkp	93	35	as	as	IN
cord-268140-s5lailkp	93	36	in	in	IN
cord-268140-s5lailkp	93	37	HLH	HLH	NNP
cord-268140-s5lailkp	93	38	[	[	-LRB-
cord-268140-s5lailkp	93	39	37	37	CD
cord-268140-s5lailkp	93	40	]	]	-RRB-
cord-268140-s5lailkp	93	41	.	.	.
cord-268140-s5lailkp	94	1	A	a	DT
cord-268140-s5lailkp	94	2	recent	recent	JJ
cord-268140-s5lailkp	94	3	consensus	consensus	NN
cord-268140-s5lailkp	94	4	published	publish	VBN
cord-268140-s5lailkp	94	5	by	by	IN
cord-268140-s5lailkp	94	6	international	international	JJ
cord-268140-s5lailkp	94	7	pulmonologists	pulmonologist	NNS
cord-268140-s5lailkp	94	8	supported	support	VBD
cord-268140-s5lailkp	94	9	the	the	DT
cord-268140-s5lailkp	94	10	consideration	consideration	NN
cord-268140-s5lailkp	94	11	of	of	IN
cord-268140-s5lailkp	94	12	these	these	DT
cord-268140-s5lailkp	94	13	drugs	drug	NNS
cord-268140-s5lailkp	94	14	in	in	IN
cord-268140-s5lailkp	94	15	critical	critical	JJ
cord-268140-s5lailkp	94	16	illnessrespiratory	illnessrespiratory	NN
cord-268140-s5lailkp	94	17	failure	failure	NN
cord-268140-s5lailkp	94	18	,	,	,
cord-268140-s5lailkp	94	19	shock	shock	NN
cord-268140-s5lailkp	94	20	,	,	,
cord-268140-s5lailkp	94	21	multiorgan	multiorgan	NN
cord-268140-s5lailkp	94	22	involvement	involvement	NN
cord-268140-s5lailkp	94	23	[	[	-LRB-
cord-268140-s5lailkp	94	24	38	38	CD
cord-268140-s5lailkp	94	25	]	]	-RRB-
cord-268140-s5lailkp	94	26	.	.	.
cord-268140-s5lailkp	95	1	China	China	NNP
cord-268140-s5lailkp	95	2	's	's	POS
cord-268140-s5lailkp	95	3	National	National	NNP
cord-268140-s5lailkp	95	4	Health	Health	NNP
cord-268140-s5lailkp	95	5	Commission	Commission	NNP
cord-268140-s5lailkp	95	6	(	(	-LRB-
cord-268140-s5lailkp	95	7	NHC	NHC	NNP
cord-268140-s5lailkp	95	8	)	)	-RRB-
cord-268140-s5lailkp	95	9	also	also	RB
cord-268140-s5lailkp	95	10	included	include	VBD
cord-268140-s5lailkp	95	11	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	95	12	in	in	IN
cord-268140-s5lailkp	95	13	its	-PRON-	PRP$
cord-268140-s5lailkp	95	14	7th	7th	JJ
cord-268140-s5lailkp	95	15	updated	update	VBN
cord-268140-s5lailkp	95	16	diagnosis	diagnosis	NN
cord-268140-s5lailkp	95	17	and	and	CC
cord-268140-s5lailkp	95	18	treatment	treatment	NN
cord-268140-s5lailkp	95	19	plan	plan	NN
cord-268140-s5lailkp	95	20	for	for	IN
cord-268140-s5lailkp	95	21	COVID-19	covid-19	CD
cord-268140-s5lailkp	95	22	2020	2020	CD
cord-268140-s5lailkp	95	23	[	[	-LRB-
cord-268140-s5lailkp	95	24	39	39	CD
cord-268140-s5lailkp	95	25	]	]	-RRB-
cord-268140-s5lailkp	95	26	.	.	.
cord-268140-s5lailkp	96	1	They	-PRON-	PRP
cord-268140-s5lailkp	96	2	are	be	VBP
cord-268140-s5lailkp	96	3	also	also	RB
cord-268140-s5lailkp	96	4	mentioned	mention	VBN
cord-268140-s5lailkp	96	5	in	in	IN
cord-268140-s5lailkp	96	6	the	the	DT
cord-268140-s5lailkp	96	7	NIH	NIH	NNP
cord-268140-s5lailkp	96	8	treatment	treatment	NN
cord-268140-s5lailkp	96	9	guidelines	guideline	NNS
cord-268140-s5lailkp	96	10	and	and	CC
cord-268140-s5lailkp	96	11	the	the	DT
cord-268140-s5lailkp	96	12	WHO	WHO	NNP
cord-268140-s5lailkp	96	13	interim	interim	JJ
cord-268140-s5lailkp	96	14	guidance	guidance	NN
cord-268140-s5lailkp	96	15	,	,	,
cord-268140-s5lailkp	96	16	both	both	DT
cord-268140-s5lailkp	96	17	of	of	IN
cord-268140-s5lailkp	96	18	which	which	WDT
cord-268140-s5lailkp	96	19	cite	cite	VBP
cord-268140-s5lailkp	96	20	insufficient	insufficient	JJ
cord-268140-s5lailkp	96	21	clinical	clinical	JJ
cord-268140-s5lailkp	96	22	data	datum	NNS
cord-268140-s5lailkp	96	23	to	to	TO
cord-268140-s5lailkp	96	24	recommend	recommend	VB
cord-268140-s5lailkp	96	25	either	either	CC
cord-268140-s5lailkp	96	26	for	for	IN
cord-268140-s5lailkp	96	27	or	or	CC
cord-268140-s5lailkp	96	28	against	against	IN
cord-268140-s5lailkp	96	29	the	the	DT
cord-268140-s5lailkp	96	30	use	use	NN
cord-268140-s5lailkp	96	31	of	of	IN
cord-268140-s5lailkp	96	32	these	these	DT
cord-268140-s5lailkp	96	33	drugs	drug	NNS
cord-268140-s5lailkp	96	34	-	-	:
cord-268140-s5lailkp	96	35	the	the	DT
cord-268140-s5lailkp	96	36	same	same	JJ
cord-268140-s5lailkp	96	37	as	as	IN
cord-268140-s5lailkp	96	38	for	for	IN
cord-268140-s5lailkp	96	39	other	other	JJ
cord-268140-s5lailkp	96	40	drugs	drug	NNS
cord-268140-s5lailkp	96	41	[	[	-LRB-
cord-268140-s5lailkp	96	42	11	11	CD
cord-268140-s5lailkp	96	43	,	,	,
cord-268140-s5lailkp	96	44	13	13	CD
cord-268140-s5lailkp	96	45	]	]	-RRB-
cord-268140-s5lailkp	96	46	.	.	.
cord-268140-s5lailkp	97	1	Tocilizumab	Tocilizumab	NNP
cord-268140-s5lailkp	97	2	(	(	-LRB-
cord-268140-s5lailkp	97	3	Actemra	Actemra	NNP
cord-268140-s5lailkp	97	4	)	)	-RRB-
cord-268140-s5lailkp	97	5	and	and	CC
cord-268140-s5lailkp	97	6	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	97	7	(	(	-LRB-
cord-268140-s5lailkp	97	8	Kevzara	Kevzara	NNP
cord-268140-s5lailkp	97	9	)	)	-RRB-
cord-268140-s5lailkp	97	10	are	be	VBP
cord-268140-s5lailkp	97	11	antagonists	antagonist	NNS
cord-268140-s5lailkp	97	12	of	of	IN
cord-268140-s5lailkp	97	13	the	the	DT
cord-268140-s5lailkp	97	14	IL-6	IL-6	NNP
cord-268140-s5lailkp	97	15	receptors	receptor	NNS
cord-268140-s5lailkp	97	16	,	,	,
cord-268140-s5lailkp	97	17	with	with	IN
cord-268140-s5lailkp	97	18	FDA	FDA	NNP
cord-268140-s5lailkp	97	19	approval	approval	NN
cord-268140-s5lailkp	97	20	to	to	TO
cord-268140-s5lailkp	97	21	treat	treat	VB
cord-268140-s5lailkp	97	22	moderate	moderate	JJ
cord-268140-s5lailkp	97	23	-	-	HYPH
cord-268140-s5lailkp	97	24	to	to	IN
cord-268140-s5lailkp	97	25	-	-	HYPH
cord-268140-s5lailkp	97	26	severe	severe	JJ
cord-268140-s5lailkp	97	27	rheumatoid	rheumatoid	NN
cord-268140-s5lailkp	97	28	arthritis	arthritis	NN
cord-268140-s5lailkp	97	29	not	not	RB
cord-268140-s5lailkp	97	30	responding	respond	VBG
cord-268140-s5lailkp	97	31	to	to	IN
cord-268140-s5lailkp	97	32	disease	disease	NN
cord-268140-s5lailkp	97	33	-	-	HYPH
cord-268140-s5lailkp	97	34	modifying	modify	VBG
cord-268140-s5lailkp	97	35	anti	anti	JJ
cord-268140-s5lailkp	97	36	-	-	JJ
cord-268140-s5lailkp	97	37	rheumatic	rheumatic	JJ
cord-268140-s5lailkp	97	38	drugs	drug	NNS
cord-268140-s5lailkp	97	39	(	(	-LRB-
cord-268140-s5lailkp	97	40	DMARDs	dmard	NNS
cord-268140-s5lailkp	97	41	)	)	-RRB-
cord-268140-s5lailkp	97	42	,	,	,
cord-268140-s5lailkp	97	43	the	the	DT
cord-268140-s5lailkp	97	44	former	former	JJ
cord-268140-s5lailkp	97	45	also	also	RB
cord-268140-s5lailkp	97	46	approved	approve	VBN
cord-268140-s5lailkp	97	47	for	for	IN
cord-268140-s5lailkp	97	48	giant	giant	JJ
cord-268140-s5lailkp	97	49	cell	cell	NN
cord-268140-s5lailkp	97	50	arteritis	arteritis	NN
cord-268140-s5lailkp	97	51	,	,	,
cord-268140-s5lailkp	97	52	polyarticular	polyarticular	JJ
cord-268140-s5lailkp	97	53	juvenile	juvenile	JJ
cord-268140-s5lailkp	97	54	idiopathic	idiopathic	JJ
cord-268140-s5lailkp	97	55	arthritis	arthritis	NN
cord-268140-s5lailkp	97	56	,	,	,
cord-268140-s5lailkp	97	57	systemic	systemic	JJ
cord-268140-s5lailkp	97	58	juvenile	juvenile	JJ
cord-268140-s5lailkp	97	59	idiopathic	idiopathic	JJ
cord-268140-s5lailkp	97	60	arthritis	arthritis	NN
cord-268140-s5lailkp	97	61	,	,	,
cord-268140-s5lailkp	97	62	and	and	CC
cord-268140-s5lailkp	97	63	CAR	car	NN
cord-268140-s5lailkp	97	64	-	-	HYPH
cord-268140-s5lailkp	97	65	T	t	NN
cord-268140-s5lailkp	97	66	cell	cell	NN
cord-268140-s5lailkp	97	67	-	-	HYPH
cord-268140-s5lailkp	97	68	induced	induce	VBN
cord-268140-s5lailkp	97	69	CRS	CRS	NNP
cord-268140-s5lailkp	97	70	[	[	-LRB-
cord-268140-s5lailkp	97	71	40	40	CD
cord-268140-s5lailkp	97	72	,	,	,
cord-268140-s5lailkp	97	73	41	41	CD
cord-268140-s5lailkp	97	74	]	]	-RRB-
cord-268140-s5lailkp	97	75	.	.	.
cord-268140-s5lailkp	98	1	Another	another	DT
cord-268140-s5lailkp	98	2	FDA	FDA	NNP
cord-268140-s5lailkp	98	3	-	-	HYPH
cord-268140-s5lailkp	98	4	approved	approve	VBN
cord-268140-s5lailkp	98	5	IL-6	IL-6	NNP
cord-268140-s5lailkp	98	6	receptor	receptor	NN
cord-268140-s5lailkp	98	7	antagonist	antagonist	NN
cord-268140-s5lailkp	98	8	is	be	VBZ
cord-268140-s5lailkp	98	9	siltuximab	siltuximab	JJ
cord-268140-s5lailkp	98	10	(	(	-LRB-
cord-268140-s5lailkp	98	11	Sylvant	Sylvant	NNP
cord-268140-s5lailkp	98	12	)	)	-RRB-
cord-268140-s5lailkp	98	13	,	,	,
cord-268140-s5lailkp	98	14	which	which	WDT
cord-268140-s5lailkp	98	15	is	be	VBZ
cord-268140-s5lailkp	98	16	indicated	indicate	VBN
cord-268140-s5lailkp	98	17	for	for	IN
cord-268140-s5lailkp	98	18	the	the	DT
cord-268140-s5lailkp	98	19	treatment	treatment	NN
cord-268140-s5lailkp	98	20	of	of	IN
cord-268140-s5lailkp	98	21	patients	patient	NNS
cord-268140-s5lailkp	98	22	with	with	IN
cord-268140-s5lailkp	98	23	multicentric	multicentric	NNP
cord-268140-s5lailkp	98	24	Castleman	Castleman	NNP
cord-268140-s5lailkp	98	25	's	's	POS
cord-268140-s5lailkp	98	26	disease	disease	NN
cord-268140-s5lailkp	98	27	(	(	-LRB-
cord-268140-s5lailkp	98	28	MCD	MCD	NNP
cord-268140-s5lailkp	98	29	)	)	-RRB-
cord-268140-s5lailkp	98	30	who	who	WP
cord-268140-s5lailkp	98	31	are	be	VBP
cord-268140-s5lailkp	98	32	HIV	HIV	NNP
cord-268140-s5lailkp	98	33	negative	negative	JJ
cord-268140-s5lailkp	98	34	and	and	CC
cord-268140-s5lailkp	98	35	human	human	JJ
cord-268140-s5lailkp	98	36	herpesvirus-8	herpesvirus-8	NNP
cord-268140-s5lailkp	98	37	(	(	-LRB-
cord-268140-s5lailkp	98	38	HHV-8	HHV-8	NNP
cord-268140-s5lailkp	98	39	)	)	-RRB-
cord-268140-s5lailkp	99	1	negative	negative	JJ
cord-268140-s5lailkp	99	2	[	[	-LRB-
cord-268140-s5lailkp	99	3	42	42	CD
cord-268140-s5lailkp	99	4	]	]	-RRB-
cord-268140-s5lailkp	99	5	.	.	.
cord-268140-s5lailkp	100	1	Preliminary	preliminary	JJ
cord-268140-s5lailkp	100	2	evidence	evidence	NN
cord-268140-s5lailkp	100	3	of	of	IN
cord-268140-s5lailkp	100	4	efficacy	efficacy	NN
cord-268140-s5lailkp	100	5	in	in	IN
cord-268140-s5lailkp	100	6	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	100	7	is	be	VBZ
cord-268140-s5lailkp	100	8	available	available	JJ
cord-268140-s5lailkp	100	9	for	for	IN
cord-268140-s5lailkp	100	10	tocilizumab	tocilizumab	NN
cord-268140-s5lailkp	100	11	through	through	IN
cord-268140-s5lailkp	100	12	small	small	JJ
cord-268140-s5lailkp	100	13	studies	study	NNS
cord-268140-s5lailkp	100	14	.	.	.
cord-268140-s5lailkp	101	1	One	one	CD
cord-268140-s5lailkp	101	2	study	study	NN
cord-268140-s5lailkp	101	3	in	in	IN
cord-268140-s5lailkp	101	4	severe	severe	JJ
cord-268140-s5lailkp	101	5	COVID-19	covid-19	JJ
cord-268140-s5lailkp	101	6	patients	patient	NNS
cord-268140-s5lailkp	101	7	showed	show	VBD
cord-268140-s5lailkp	101	8	successful	successful	JJ
cord-268140-s5lailkp	101	9	outcomes	outcome	NNS
cord-268140-s5lailkp	101	10	in	in	IN
cord-268140-s5lailkp	101	11	21	21	CD
cord-268140-s5lailkp	101	12	patients	patient	NNS
cord-268140-s5lailkp	101	13	,	,	,
cord-268140-s5lailkp	101	14	with	with	IN
cord-268140-s5lailkp	101	15	most	most	JJS
cord-268140-s5lailkp	101	16	receiving	receive	VBG
cord-268140-s5lailkp	101	17	only	only	RB
cord-268140-s5lailkp	101	18	one	one	CD
cord-268140-s5lailkp	101	19	dose	dose	NN
cord-268140-s5lailkp	101	20	of	of	IN
cord-268140-s5lailkp	101	21	tocilizumab	tocilizumab	NN
cord-268140-s5lailkp	101	22	400	400	CD
cord-268140-s5lailkp	101	23	mg	mg	NNS
cord-268140-s5lailkp	101	24	along	along	RB
cord-268140-s5lailkp	101	25	with	with	IN
cord-268140-s5lailkp	101	26	standard	standard	NN
cord-268140-s5lailkp	101	27	of	of	IN
cord-268140-s5lailkp	101	28	care	care	NN
cord-268140-s5lailkp	101	29	,	,	,
cord-268140-s5lailkp	101	30	including	include	VBG
cord-268140-s5lailkp	101	31	lopinavir	lopinavir	NNS
cord-268140-s5lailkp	101	32	and	and	CC
cord-268140-s5lailkp	101	33	methylprednisolone	methylprednisolone	NNP
cord-268140-s5lailkp	101	34	.	.	.
cord-268140-s5lailkp	102	1	It	-PRON-	PRP
cord-268140-s5lailkp	102	2	showed	show	VBD
cord-268140-s5lailkp	102	3	improved	improved	JJ
cord-268140-s5lailkp	102	4	clinical	clinical	JJ
cord-268140-s5lailkp	102	5	outcomes	outcome	NNS
cord-268140-s5lailkp	102	6	in	in	IN
cord-268140-s5lailkp	102	7	91	91	CD
cord-268140-s5lailkp	102	8	%	%	NN
cord-268140-s5lailkp	102	9	of	of	IN
cord-268140-s5lailkp	102	10	patients	patient	NNS
cord-268140-s5lailkp	102	11	in	in	IN
cord-268140-s5lailkp	102	12	terms	term	NNS
cord-268140-s5lailkp	102	13	of	of	IN
cord-268140-s5lailkp	102	14	improvement	improvement	NN
cord-268140-s5lailkp	102	15	in	in	IN
cord-268140-s5lailkp	102	16	lung	lung	NN
cord-268140-s5lailkp	102	17	function	function	NN
cord-268140-s5lailkp	102	18	and	and	CC
cord-268140-s5lailkp	102	19	successful	successful	JJ
cord-268140-s5lailkp	102	20	discharge	discharge	NN
cord-268140-s5lailkp	102	21	with	with	IN
cord-268140-s5lailkp	102	22	a	a	DT
cord-268140-s5lailkp	102	23	mean	mean	NN
cord-268140-s5lailkp	102	24	of	of	IN
cord-268140-s5lailkp	102	25	15.5	15.5	CD
cord-268140-s5lailkp	102	26	days	day	NNS
cord-268140-s5lailkp	102	27	;	;	:
cord-268140-s5lailkp	102	28	however	however	RB
cord-268140-s5lailkp	102	29	,	,	,
cord-268140-s5lailkp	102	30	lack	lack	NN
cord-268140-s5lailkp	102	31	of	of	IN
cord-268140-s5lailkp	102	32	a	a	DT
cord-268140-s5lailkp	102	33	comparator	comparator	NN
cord-268140-s5lailkp	102	34	group	group	NN
cord-268140-s5lailkp	102	35	and	and	CC
cord-268140-s5lailkp	102	36	blinding	blind	VBG
cord-268140-s5lailkp	102	37	were	be	VBD
cord-268140-s5lailkp	102	38	important	important	JJ
cord-268140-s5lailkp	102	39	limitations	limitation	NNS
cord-268140-s5lailkp	102	40	[	[	-LRB-
cord-268140-s5lailkp	102	41	6	6	CD
cord-268140-s5lailkp	102	42	]	]	-RRB-
cord-268140-s5lailkp	102	43	.	.	.
cord-268140-s5lailkp	103	1	Further	further	RB
cord-268140-s5lailkp	103	2	,	,	,
cord-268140-s5lailkp	103	3	a	a	DT
cord-268140-s5lailkp	103	4	retrospective	retrospective	JJ
cord-268140-s5lailkp	103	5	observational	observational	JJ
cord-268140-s5lailkp	103	6	study	study	NN
cord-268140-s5lailkp	103	7	in	in	IN
cord-268140-s5lailkp	103	8	15	15	CD
cord-268140-s5lailkp	104	1	COVID-19	covid-19	JJ
cord-268140-s5lailkp	104	2	patients	patient	NNS
cord-268140-s5lailkp	104	3	reported	report	VBD
cord-268140-s5lailkp	104	4	a	a	DT
cord-268140-s5lailkp	104	5	good	good	JJ
cord-268140-s5lailkp	104	6	response	response	NN
cord-268140-s5lailkp	104	7	in	in	IN
cord-268140-s5lailkp	104	8	patients	patient	NNS
cord-268140-s5lailkp	104	9	treated	treat	VBN
cord-268140-s5lailkp	104	10	with	with	IN
cord-268140-s5lailkp	104	11	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	104	12	and	and	CC
cord-268140-s5lailkp	104	13	recommend	recommend	VB
cord-268140-s5lailkp	104	14	repeated	repeat	VBN
cord-268140-s5lailkp	104	15	doses	dose	NNS
cord-268140-s5lailkp	104	16	of	of	IN
cord-268140-s5lailkp	104	17	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	104	18	in	in	IN
cord-268140-s5lailkp	104	19	critically	critically	RB
cord-268140-s5lailkp	104	20	ill	ill	JJ
cord-268140-s5lailkp	104	21	COVID-19	covid-19	CD
cord-268140-s5lailkp	104	22	patients	patient	NNS
cord-268140-s5lailkp	104	23	[	[	-LRB-
cord-268140-s5lailkp	104	24	43	43	CD
cord-268140-s5lailkp	104	25	]	]	-RRB-
cord-268140-s5lailkp	104	26	.	.	.
cord-268140-s5lailkp	105	1	However	however	RB
cord-268140-s5lailkp	105	2	,	,	,
cord-268140-s5lailkp	105	3	the	the	DT
cord-268140-s5lailkp	105	4	number	number	NN
cord-268140-s5lailkp	105	5	of	of	IN
cord-268140-s5lailkp	105	6	cases	case	NNS
cord-268140-s5lailkp	105	7	reported	report	VBN
cord-268140-s5lailkp	105	8	was	be	VBD
cord-268140-s5lailkp	105	9	again	again	RB
cord-268140-s5lailkp	105	10	small	small	JJ
cord-268140-s5lailkp	105	11	and	and	CC
cord-268140-s5lailkp	105	12	the	the	DT
cord-268140-s5lailkp	105	13	duration	duration	NN
cord-268140-s5lailkp	105	14	of	of	IN
cord-268140-s5lailkp	105	15	treatment	treatment	NN
cord-268140-s5lailkp	105	16	studied	study	VBD
cord-268140-s5lailkp	105	17	might	may	MD
cord-268140-s5lailkp	105	18	not	not	RB
cord-268140-s5lailkp	105	19	have	have	VB
cord-268140-s5lailkp	105	20	been	be	VBN
cord-268140-s5lailkp	105	21	sufficient	sufficient	JJ
cord-268140-s5lailkp	105	22	.	.	.
cord-268140-s5lailkp	105	23	 	 	_SP
cord-268140-s5lailkp	106	1	Several	several	JJ
cord-268140-s5lailkp	106	2	randomized	randomize	VBN
cord-268140-s5lailkp	106	3	controlled	control	VBN
cord-268140-s5lailkp	106	4	trials	trial	NNS
cord-268140-s5lailkp	106	5	or	or	CC
cord-268140-s5lailkp	106	6	'	'	``
cord-268140-s5lailkp	106	7	RCTs	rct	NNS
cord-268140-s5lailkp	106	8	'	'	''
cord-268140-s5lailkp	107	1	(	(	-LRB-
cord-268140-s5lailkp	107	2	in	in	IN
cord-268140-s5lailkp	107	3	excess	excess	NN
cord-268140-s5lailkp	107	4	of	of	IN
cord-268140-s5lailkp	107	5	50	50	CD
cord-268140-s5lailkp	107	6	in	in	IN
cord-268140-s5lailkp	107	7	number	number	NN
cord-268140-s5lailkp	107	8	)	)	-RRB-
cord-268140-s5lailkp	107	9	of	of	IN
cord-268140-s5lailkp	107	10	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	107	11	,	,	,
cord-268140-s5lailkp	107	12	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	107	13	and	and	CC
cord-268140-s5lailkp	107	14	siltuximab	siltuximab	NNP
cord-268140-s5lailkp	107	15	,	,	,
cord-268140-s5lailkp	107	16	alone	alone	JJ
cord-268140-s5lailkp	107	17	or	or	CC
cord-268140-s5lailkp	107	18	in	in	IN
cord-268140-s5lailkp	107	19	combination	combination	NN
cord-268140-s5lailkp	107	20	,	,	,
cord-268140-s5lailkp	107	21	are	be	VBP
cord-268140-s5lailkp	107	22	now	now	RB
cord-268140-s5lailkp	107	23	proposed	propose	VBN
cord-268140-s5lailkp	107	24	in	in	IN
cord-268140-s5lailkp	107	25	patients	patient	NNS
cord-268140-s5lailkp	107	26	with	with	IN
cord-268140-s5lailkp	107	27	severe	severe	JJ
cord-268140-s5lailkp	107	28	COVID-19	covid-19	NN
cord-268140-s5lailkp	107	29	,	,	,
cord-268140-s5lailkp	107	30	and	and	CC
cord-268140-s5lailkp	107	31	are	be	VBP
cord-268140-s5lailkp	107	32	underway	underway	JJ
cord-268140-s5lailkp	107	33	mainly	mainly	RB
cord-268140-s5lailkp	107	34	in	in	IN
cord-268140-s5lailkp	107	35	China	China	NNP
cord-268140-s5lailkp	107	36	,	,	,
cord-268140-s5lailkp	107	37	Western	Western	NNP
cord-268140-s5lailkp	107	38	Europe	Europe	NNP
cord-268140-s5lailkp	107	39	,	,	,
cord-268140-s5lailkp	107	40	USA	USA	NNP
cord-268140-s5lailkp	107	41	,	,	,
cord-268140-s5lailkp	107	42	Russia	Russia	NNP
cord-268140-s5lailkp	107	43	,	,	,
cord-268140-s5lailkp	107	44	Malaysia	Malaysia	NNP
cord-268140-s5lailkp	107	45	,	,	,
cord-268140-s5lailkp	107	46	and	and	CC
cord-268140-s5lailkp	107	47	Australia	Australia	NNP
cord-268140-s5lailkp	107	48	[	[	-LRB-
cord-268140-s5lailkp	107	49	44	44	CD
cord-268140-s5lailkp	107	50	]	]	-RRB-
cord-268140-s5lailkp	108	1	[	[	-LRB-
cord-268140-s5lailkp	108	2	45	45	CD
cord-268140-s5lailkp	108	3	]	]	-RRB-
cord-268140-s5lailkp	108	4	[	[	-LRB-
cord-268140-s5lailkp	108	5	46	46	CD
cord-268140-s5lailkp	108	6	]	]	-RRB-
cord-268140-s5lailkp	108	7	.	.	.
cord-268140-s5lailkp	109	1	Some	some	DT
cord-268140-s5lailkp	109	2	of	of	IN
cord-268140-s5lailkp	109	3	the	the	DT
cord-268140-s5lailkp	109	4	early	early	JJ
cord-268140-s5lailkp	109	5	initiated	initiate	VBN
cord-268140-s5lailkp	109	6	studies	study	NNS
cord-268140-s5lailkp	109	7	include	include	VBP
cord-268140-s5lailkp	109	8	a	a	DT
cord-268140-s5lailkp	109	9	multicenter	multicenter	JJ
cord-268140-s5lailkp	109	10	RCT	RCT	NNP
cord-268140-s5lailkp	109	11	of	of	IN
cord-268140-s5lailkp	109	12	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	109	13	alone	alone	RB
cord-268140-s5lailkp	109	14	in	in	IN
cord-268140-s5lailkp	109	15	patients	patient	NNS
cord-268140-s5lailkp	109	16	with	with	IN
cord-268140-s5lailkp	109	17	COVID-19	covid-19	JJ
cord-268140-s5lailkp	109	18	pneumonia	pneumonia	NN
cord-268140-s5lailkp	109	19	and	and	CC
cord-268140-s5lailkp	109	20	elevated	elevate	VBN
cord-268140-s5lailkp	109	21	IL-6	IL-6	NNP
cord-268140-s5lailkp	109	22	in	in	IN
cord-268140-s5lailkp	109	23	China	China	NNP
cord-268140-s5lailkp	109	24	(	(	-LRB-
cord-268140-s5lailkp	109	25	ChiCTR2000029765	chictr2000029765	NN
cord-268140-s5lailkp	109	26	)	)	-RRB-
cord-268140-s5lailkp	109	27	targeting	target	VBG
cord-268140-s5lailkp	109	28	188	188	CD
cord-268140-s5lailkp	109	29	patients	patient	NNS
cord-268140-s5lailkp	109	30	[	[	-LRB-
cord-268140-s5lailkp	109	31	47	47	CD
cord-268140-s5lailkp	109	32	]	]	-RRB-
cord-268140-s5lailkp	109	33	and	and	CC
cord-268140-s5lailkp	109	34	another	another	DT
cord-268140-s5lailkp	109	35	Chinese	chinese	JJ
cord-268140-s5lailkp	109	36	trial	trial	NN
cord-268140-s5lailkp	109	37	on	on	IN
cord-268140-s5lailkp	109	38	150	150	CD
cord-268140-s5lailkp	109	39	patients	patient	NNS
cord-268140-s5lailkp	109	40	assessing	assess	VBG
cord-268140-s5lailkp	109	41	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	109	42	in	in	IN
cord-268140-s5lailkp	109	43	combination	combination	NN
cord-268140-s5lailkp	109	44	with	with	IN
cord-268140-s5lailkp	109	45	favipiravir	favipiravir	NNP
cord-268140-s5lailkp	109	46	,	,	,
cord-268140-s5lailkp	109	47	a	a	DT
cord-268140-s5lailkp	109	48	broad	broad	JJ
cord-268140-s5lailkp	109	49	spectrum	spectrum	JJ
cord-268140-s5lailkp	109	50	anti	anti	JJ
cord-268140-s5lailkp	109	51	-	-	JJ
cord-268140-s5lailkp	109	52	viral	viral	JJ
cord-268140-s5lailkp	109	53	agent	agent	NN
cord-268140-s5lailkp	109	54	(	(	-LRB-
cord-268140-s5lailkp	109	55	ChiCTR2000030894	chictr2000030894	UH
cord-268140-s5lailkp	109	56	,	,	,
cord-268140-s5lailkp	109	57	NCT04310228	NCT04310228	NNP
cord-268140-s5lailkp	109	58	)	)	-RRB-
cord-268140-s5lailkp	109	59	[	[	-LRB-
cord-268140-s5lailkp	109	60	48	48	CD
cord-268140-s5lailkp	109	61	]	]	-RRB-
cord-268140-s5lailkp	109	62	.	.	.
cord-268140-s5lailkp	110	1	Genentech	Genentech	NNP
cord-268140-s5lailkp	110	2	,	,	,
cord-268140-s5lailkp	110	3	the	the	DT
cord-268140-s5lailkp	110	4	innovator	innovator	NN
cord-268140-s5lailkp	110	5	company	company	NN
cord-268140-s5lailkp	110	6	of	of	IN
cord-268140-s5lailkp	110	7	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	110	8	,	,	,
cord-268140-s5lailkp	110	9	has	have	VBZ
cord-268140-s5lailkp	110	10	also	also	RB
cord-268140-s5lailkp	110	11	initiated	initiate	VBN
cord-268140-s5lailkp	110	12	a	a	DT
cord-268140-s5lailkp	110	13	randomized	randomized	JJ
cord-268140-s5lailkp	110	14	,	,	,
cord-268140-s5lailkp	110	15	double	double	JJ
cord-268140-s5lailkp	110	16	-	-	HYPH
cord-268140-s5lailkp	110	17	blind	blind	JJ
cord-268140-s5lailkp	110	18	,	,	,
cord-268140-s5lailkp	110	19	placebo	placebo	NN
cord-268140-s5lailkp	110	20	-	-	HYPH
cord-268140-s5lailkp	110	21	controlled	control	VBN
cord-268140-s5lailkp	110	22	Phase	Phase	NNP
cord-268140-s5lailkp	110	23	III	iii	CD
cord-268140-s5lailkp	110	24	clinical	clinical	JJ
cord-268140-s5lailkp	110	25	trial	trial	NN
cord-268140-s5lailkp	110	26	(	(	-LRB-
cord-268140-s5lailkp	110	27	COVACTA	COVACTA	NNP
cord-268140-s5lailkp	110	28	,	,	,
cord-268140-s5lailkp	110	29	NCT04320615	NCT04320615	NNP
cord-268140-s5lailkp	110	30	)	)	-RRB-
cord-268140-s5lailkp	110	31	to	to	TO
cord-268140-s5lailkp	110	32	evaluate	evaluate	VB
cord-268140-s5lailkp	110	33	the	the	DT
cord-268140-s5lailkp	110	34	safety	safety	NN
cord-268140-s5lailkp	110	35	and	and	CC
cord-268140-s5lailkp	110	36	efficacy	efficacy	NN
cord-268140-s5lailkp	110	37	of	of	IN
cord-268140-s5lailkp	110	38	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	110	39	plus	plus	CC
cord-268140-s5lailkp	110	40	standard	standard	NN
cord-268140-s5lailkp	110	41	of	of	IN
cord-268140-s5lailkp	110	42	care	care	NN
cord-268140-s5lailkp	110	43	in	in	IN
cord-268140-s5lailkp	110	44	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	110	45	adult	adult	NN
cord-268140-s5lailkp	110	46	patients	patient	NNS
cord-268140-s5lailkp	110	47	with	with	IN
cord-268140-s5lailkp	110	48	severe	severe	JJ
cord-268140-s5lailkp	110	49	COVID-19	covid-19	JJ
cord-268140-s5lailkp	110	50	pneumonia	pneumonia	NN
cord-268140-s5lailkp	110	51	compared	compare	VBN
cord-268140-s5lailkp	110	52	with	with	IN
cord-268140-s5lailkp	110	53	placebo	placebo	NN
cord-268140-s5lailkp	110	54	plus	plus	CC
cord-268140-s5lailkp	110	55	standard	standard	NN
cord-268140-s5lailkp	110	56	of	of	IN
cord-268140-s5lailkp	110	57	care	care	NN
cord-268140-s5lailkp	110	58	;	;	:
cord-268140-s5lailkp	110	59	it	-PRON-	PRP
cord-268140-s5lailkp	110	60	aims	aim	VBZ
cord-268140-s5lailkp	110	61	to	to	TO
cord-268140-s5lailkp	110	62	recruit	recruit	VB
cord-268140-s5lailkp	110	63	approximately	approximately	RB
cord-268140-s5lailkp	110	64	330	330	CD
cord-268140-s5lailkp	110	65	patients	patient	NNS
cord-268140-s5lailkp	110	66	globally	globally	RB
cord-268140-s5lailkp	110	67	[	[	-LRB-
cord-268140-s5lailkp	110	68	49	49	CD
cord-268140-s5lailkp	110	69	]	]	-RRB-
cord-268140-s5lailkp	110	70	.	.	.
cord-268140-s5lailkp	111	1	The	the	DT
cord-268140-s5lailkp	111	2	primary	primary	JJ
cord-268140-s5lailkp	111	3	and	and	CC
cord-268140-s5lailkp	111	4	secondary	secondary	JJ
cord-268140-s5lailkp	111	5	endpoints	endpoint	NNS
cord-268140-s5lailkp	111	6	of	of	IN
cord-268140-s5lailkp	111	7	the	the	DT
cord-268140-s5lailkp	111	8	study	study	NN
cord-268140-s5lailkp	111	9	include	include	VBP
cord-268140-s5lailkp	111	10	clinical	clinical	JJ
cord-268140-s5lailkp	111	11	status	status	NN
cord-268140-s5lailkp	111	12	,	,	,
cord-268140-s5lailkp	111	13	mortality	mortality	NN
cord-268140-s5lailkp	111	14	,	,	,
cord-268140-s5lailkp	111	15	mechanical	mechanical	JJ
cord-268140-s5lailkp	111	16	ventilation	ventilation	NN
cord-268140-s5lailkp	111	17	,	,	,
cord-268140-s5lailkp	111	18	and	and	CC
cord-268140-s5lailkp	111	19	ICU	ICU	NNP
cord-268140-s5lailkp	111	20	variables	variable	NNS
cord-268140-s5lailkp	111	21	.	.	.
cord-268140-s5lailkp	112	1	In	in	IN
cord-268140-s5lailkp	112	2	Italy	Italy	NNP
cord-268140-s5lailkp	112	3	,	,	,
cord-268140-s5lailkp	112	4	a	a	DT
cord-268140-s5lailkp	112	5	single	single	JJ
cord-268140-s5lailkp	112	6	-	-	HYPH
cord-268140-s5lailkp	112	7	arm	arm	NN
cord-268140-s5lailkp	112	8	Phase	Phase	NNP
cord-268140-s5lailkp	112	9	II	II	NNP
cord-268140-s5lailkp	112	10	trial	trial	NN
cord-268140-s5lailkp	112	11	(	(	-LRB-
cord-268140-s5lailkp	112	12	NCT04317092	NCT04317092	NNP
cord-268140-s5lailkp	112	13	)	)	-RRB-
cord-268140-s5lailkp	112	14	and	and	CC
cord-268140-s5lailkp	112	15	a	a	DT
cord-268140-s5lailkp	112	16	parallel	parallel	JJ
cord-268140-s5lailkp	112	17	observational	observational	JJ
cord-268140-s5lailkp	112	18	cohort	cohort	NN
cord-268140-s5lailkp	112	19	study	study	NN
cord-268140-s5lailkp	112	20	,	,	,
cord-268140-s5lailkp	112	21	is	be	VBZ
cord-268140-s5lailkp	112	22	enrolling	enrol	VBG
cord-268140-s5lailkp	112	23	patients	patient	NNS
cord-268140-s5lailkp	112	24	with	with	IN
cord-268140-s5lailkp	112	25	COVID-19	covid-19	JJ
cord-268140-s5lailkp	112	26	pneumonia	pneumonia	NN
cord-268140-s5lailkp	112	27	in	in	IN
cord-268140-s5lailkp	112	28	Naples	Naples	NNP
cord-268140-s5lailkp	112	29	to	to	TO
cord-268140-s5lailkp	112	30	study	study	VB
cord-268140-s5lailkp	112	31	efficacy	efficacy	NN
cord-268140-s5lailkp	112	32	of	of	IN
cord-268140-s5lailkp	112	33	a	a	DT
cord-268140-s5lailkp	112	34	single	single	JJ
cord-268140-s5lailkp	112	35	dose	dose	NN
cord-268140-s5lailkp	112	36	of	of	IN
cord-268140-s5lailkp	112	37	tocilizumab	tocilizumab	NN
cord-268140-s5lailkp	112	38	8	8	CD
cord-268140-s5lailkp	112	39	mg	mg	NNP
cord-268140-s5lailkp	112	40	/	/	SYM
cord-268140-s5lailkp	112	41	kg	kg	NNP
cord-268140-s5lailkp	112	42	[	[	-LRB-
cord-268140-s5lailkp	112	43	50	50	CD
cord-268140-s5lailkp	112	44	]	]	-RRB-
cord-268140-s5lailkp	112	45	.	.	.
cord-268140-s5lailkp	113	1	This	this	DT
cord-268140-s5lailkp	113	2	study	study	NN
cord-268140-s5lailkp	113	3	has	have	VBZ
cord-268140-s5lailkp	113	4	two	two	CD
cord-268140-s5lailkp	113	5	primary	primary	JJ
cord-268140-s5lailkp	113	6	outcome	outcome	NN
cord-268140-s5lailkp	113	7	measures	measure	NNS
cord-268140-s5lailkp	113	8	:	:	:
cord-268140-s5lailkp	113	9	arrest	arrest	VB
cord-268140-s5lailkp	113	10	in	in	IN
cord-268140-s5lailkp	113	11	deterioration	deterioration	NN
cord-268140-s5lailkp	113	12	of	of	IN
cord-268140-s5lailkp	113	13	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	113	14	function	function	NN
cord-268140-s5lailkp	113	15	,	,	,
cord-268140-s5lailkp	113	16	and	and	CC
cord-268140-s5lailkp	113	17	improvement	improvement	NN
cord-268140-s5lailkp	113	18	in	in	IN
cord-268140-s5lailkp	113	19	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	113	20	function	function	NN
cord-268140-s5lailkp	113	21	.	.	.
cord-268140-s5lailkp	114	1	Another	another	DT
cord-268140-s5lailkp	114	2	Italian	italian	JJ
cord-268140-s5lailkp	114	3	Phase	Phase	NNP
cord-268140-s5lailkp	114	4	II	II	NNP
cord-268140-s5lailkp	114	5	open	open	JJ
cord-268140-s5lailkp	114	6	-	-	HYPH
cord-268140-s5lailkp	114	7	label	label	NN
cord-268140-s5lailkp	114	8	trial	trial	NN
cord-268140-s5lailkp	114	9	(	(	-LRB-
cord-268140-s5lailkp	114	10	NCT04315480	NCT04315480	NNP
cord-268140-s5lailkp	114	11	)	)	-RRB-
cord-268140-s5lailkp	114	12	with	with	IN
cord-268140-s5lailkp	114	13	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	114	14	8	8	CD
cord-268140-s5lailkp	114	15	mg	mg	NNP
cord-268140-s5lailkp	114	16	/	/	SYM
cord-268140-s5lailkp	114	17	kg	kg	NN
cord-268140-s5lailkp	114	18	single	single	JJ
cord-268140-s5lailkp	114	19	dose	dose	NN
cord-268140-s5lailkp	114	20	is	be	VBZ
cord-268140-s5lailkp	114	21	being	be	VBG
cord-268140-s5lailkp	114	22	conducted	conduct	VBN
cord-268140-s5lailkp	114	23	in	in	IN
cord-268140-s5lailkp	114	24	patients	patient	NNS
cord-268140-s5lailkp	114	25	with	with	IN
cord-268140-s5lailkp	114	26	severe	severe	JJ
cord-268140-s5lailkp	114	27	multifocal	multifocal	JJ
cord-268140-s5lailkp	114	28	interstitial	interstitial	JJ
cord-268140-s5lailkp	114	29	pneumonia	pneumonia	NN
cord-268140-s5lailkp	114	30	due	due	IN
cord-268140-s5lailkp	114	31	to	to	IN
cord-268140-s5lailkp	114	32	COVID-19	covid-19	VB
cord-268140-s5lailkp	114	33	to	to	TO
cord-268140-s5lailkp	114	34	evaluate	evaluate	VB
cord-268140-s5lailkp	114	35	its	-PRON-	PRP$
cord-268140-s5lailkp	114	36	role	role	NN
cord-268140-s5lailkp	114	37	in	in	IN
cord-268140-s5lailkp	114	38	the	the	DT
cord-268140-s5lailkp	114	39	virus	virus	NN
cord-268140-s5lailkp	114	40	-	-	HYPH
cord-268140-s5lailkp	114	41	induced	induce	VBN
cord-268140-s5lailkp	114	42	cytokine	cytokine	NN
cord-268140-s5lailkp	114	43	storm	storm	NN
cord-268140-s5lailkp	114	44	,	,	,
cord-268140-s5lailkp	114	45	in	in	IN
cord-268140-s5lailkp	114	46	blocking	block	VBG
cord-268140-s5lailkp	114	47	deterioration	deterioration	NN
cord-268140-s5lailkp	114	48	of	of	IN
cord-268140-s5lailkp	114	49	lung	lung	NN
cord-268140-s5lailkp	114	50	function	function	NN
cord-268140-s5lailkp	114	51	or	or	CC
cord-268140-s5lailkp	114	52	even	even	RB
cord-268140-s5lailkp	114	53	promoting	promote	VBG
cord-268140-s5lailkp	114	54	a	a	DT
cord-268140-s5lailkp	114	55	rapid	rapid	JJ
cord-268140-s5lailkp	114	56	improvement	improvement	NN
cord-268140-s5lailkp	114	57	of	of	IN
cord-268140-s5lailkp	114	58	clinical	clinical	JJ
cord-268140-s5lailkp	114	59	conditions	condition	NNS
cord-268140-s5lailkp	114	60	,	,	,
cord-268140-s5lailkp	114	61	preventing	prevent	VBG
cord-268140-s5lailkp	114	62	naso	naso	JJ
cord-268140-s5lailkp	114	63	-	-	HYPH
cord-268140-s5lailkp	114	64	tracheal	tracheal	JJ
cord-268140-s5lailkp	114	65	intubation	intubation	NN
cord-268140-s5lailkp	114	66	and/or	and/or	CC
cord-268140-s5lailkp	114	67	death	death	NN
cord-268140-s5lailkp	114	68	[	[	-LRB-
cord-268140-s5lailkp	114	69	51	51	CD
cord-268140-s5lailkp	114	70	]	]	-RRB-
cord-268140-s5lailkp	114	71	.	.	.
cord-268140-s5lailkp	115	1	In	in	IN
cord-268140-s5lailkp	115	2	Denmark	Denmark	NNP
cord-268140-s5lailkp	115	3	,	,	,
cord-268140-s5lailkp	115	4	there	there	EX
cord-268140-s5lailkp	115	5	is	be	VBZ
cord-268140-s5lailkp	115	6	an	an	DT
cord-268140-s5lailkp	115	7	open	open	JJ
cord-268140-s5lailkp	115	8	-	-	HYPH
cord-268140-s5lailkp	115	9	label	label	NN
cord-268140-s5lailkp	115	10	,	,	,
cord-268140-s5lailkp	115	11	multicenter	multicenter	JJ
cord-268140-s5lailkp	115	12	sequential	sequential	JJ
cord-268140-s5lailkp	115	13	and	and	CC
cord-268140-s5lailkp	115	14	cluster	cluster	NN
cord-268140-s5lailkp	115	15	randomized	randomized	JJ
cord-268140-s5lailkp	115	16	trial	trial	NN
cord-268140-s5lailkp	115	17	(	(	-LRB-
cord-268140-s5lailkp	115	18	TOCIVID	TOCIVID	NNP
cord-268140-s5lailkp	115	19	,	,	,
cord-268140-s5lailkp	115	20	NCT04322773	NCT04322773	NNP
cord-268140-s5lailkp	115	21	)	)	-RRB-
cord-268140-s5lailkp	115	22	to	to	TO
cord-268140-s5lailkp	115	23	compare	compare	VB
cord-268140-s5lailkp	115	24	the	the	DT
cord-268140-s5lailkp	115	25	effect	effect	NN
cord-268140-s5lailkp	115	26	of	of	IN
cord-268140-s5lailkp	115	27	either	either	DT
cord-268140-s5lailkp	115	28	one	one	CD
cord-268140-s5lailkp	115	29	of	of	IN
cord-268140-s5lailkp	115	30	three	three	CD
cord-268140-s5lailkp	115	31	IL-6	IL-6	NNP
cord-268140-s5lailkp	115	32	inhibitor	inhibitor	NN
cord-268140-s5lailkp	115	33	administrations	administration	NNS
cord-268140-s5lailkp	115	34	(	(	-LRB-
cord-268140-s5lailkp	115	35	i.e.	i.e.	FW
cord-268140-s5lailkp	115	36	intravenous	intravenous	JJ
cord-268140-s5lailkp	115	37	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	115	38	,	,	,
cord-268140-s5lailkp	115	39	subcutaneous	subcutaneous	JJ
cord-268140-s5lailkp	115	40	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	115	41	,	,	,
cord-268140-s5lailkp	115	42	and	and	CC
cord-268140-s5lailkp	115	43	subcutaneous	subcutaneous	JJ
cord-268140-s5lailkp	115	44	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	115	45	)	)	-RRB-
cord-268140-s5lailkp	115	46	,	,	,
cord-268140-s5lailkp	115	47	relative	relative	JJ
cord-268140-s5lailkp	115	48	to	to	IN
cord-268140-s5lailkp	115	49	the	the	DT
cord-268140-s5lailkp	115	50	standard	standard	NN
cord-268140-s5lailkp	115	51	of	of	IN
cord-268140-s5lailkp	115	52	care	care	NN
cord-268140-s5lailkp	115	53	,	,	,
cord-268140-s5lailkp	115	54	in	in	IN
cord-268140-s5lailkp	115	55	patients	patient	NNS
cord-268140-s5lailkp	115	56	with	with	IN
cord-268140-s5lailkp	115	57	severe	severe	JJ
cord-268140-s5lailkp	115	58	SARS	SARS	NNP
cord-268140-s5lailkp	115	59	-	-	HYPH
cord-268140-s5lailkp	115	60	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	115	61	pneumonia	pneumonia	NN
cord-268140-s5lailkp	115	62	[	[	-LRB-
cord-268140-s5lailkp	115	63	52	52	CD
cord-268140-s5lailkp	115	64	]	]	-RRB-
cord-268140-s5lailkp	115	65	.	.	.
cord-268140-s5lailkp	116	1	In	in	IN
cord-268140-s5lailkp	116	2	France	France	NNP
cord-268140-s5lailkp	116	3	,	,	,
cord-268140-s5lailkp	116	4	an	an	DT
cord-268140-s5lailkp	116	5	open	open	JJ
cord-268140-s5lailkp	116	6	-	-	HYPH
cord-268140-s5lailkp	116	7	label	label	NN
cord-268140-s5lailkp	116	8	Phase	Phase	NNP
cord-268140-s5lailkp	116	9	II	II	NNP
cord-268140-s5lailkp	116	10	RCT	RCT	NNP
cord-268140-s5lailkp	116	11	(	(	-LRB-
cord-268140-s5lailkp	116	12	CORIMUNO	CORIMUNO	NNP
cord-268140-s5lailkp	116	13	-	-	HYPH
cord-268140-s5lailkp	116	14	TOCI	TOCI	NNP
cord-268140-s5lailkp	116	15	,	,	,
cord-268140-s5lailkp	116	16	NCT04331808	NCT04331808	NNP
cord-268140-s5lailkp	116	17	)	)	-RRB-
cord-268140-s5lailkp	116	18	is	be	VBZ
cord-268140-s5lailkp	116	19	being	be	VBG
cord-268140-s5lailkp	116	20	conducted	conduct	VBN
cord-268140-s5lailkp	116	21	by	by	IN
cord-268140-s5lailkp	116	22	the	the	DT
cord-268140-s5lailkp	116	23	public	public	JJ
cord-268140-s5lailkp	116	24	assistance	assistance	NN
cord-268140-s5lailkp	116	25	-	-	HYPH
cord-268140-s5lailkp	116	26	hospitals	hospital	NNS
cord-268140-s5lailkp	116	27	of	of	IN
cord-268140-s5lailkp	116	28	Paris	Paris	NNP
cord-268140-s5lailkp	116	29	.	.	.
cord-268140-s5lailkp	117	1	Although	although	IN
cord-268140-s5lailkp	117	2	unpublished	unpublished	JJ
cord-268140-s5lailkp	117	3	yet	yet	RB
cord-268140-s5lailkp	117	4	,	,	,
cord-268140-s5lailkp	117	5	the	the	DT
cord-268140-s5lailkp	117	6	interim	interim	JJ
cord-268140-s5lailkp	117	7	results	result	NNS
cord-268140-s5lailkp	117	8	of	of	IN
cord-268140-s5lailkp	117	9	this	this	DT
cord-268140-s5lailkp	117	10	study	study	NN
cord-268140-s5lailkp	117	11	were	be	VBD
cord-268140-s5lailkp	117	12	released	release	VBN
cord-268140-s5lailkp	117	13	recently	recently	RB
cord-268140-s5lailkp	117	14	through	through	IN
cord-268140-s5lailkp	117	15	a	a	DT
cord-268140-s5lailkp	117	16	press	press	NN
cord-268140-s5lailkp	117	17	release	release	NN
cord-268140-s5lailkp	117	18	.	.	.
cord-268140-s5lailkp	118	1	Sixty	sixty	CD
cord-268140-s5lailkp	118	2	-	-	HYPH
cord-268140-s5lailkp	118	3	five	five	CD
cord-268140-s5lailkp	118	4	of	of	IN
cord-268140-s5lailkp	118	5	the	the	DT
cord-268140-s5lailkp	118	6	129	129	CD
cord-268140-s5lailkp	118	7	patients	patient	NNS
cord-268140-s5lailkp	118	8	were	be	VBD
cord-268140-s5lailkp	118	9	randomized	randomize	VBN
cord-268140-s5lailkp	118	10	to	to	TO
cord-268140-s5lailkp	118	11	receive	receive	VB
cord-268140-s5lailkp	118	12	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	118	13	8	8	CD
cord-268140-s5lailkp	118	14	mg	mg	NNP
cord-268140-s5lailkp	118	15	/	/	SYM
cord-268140-s5lailkp	118	16	kg	kg	NN
cord-268140-s5lailkp	118	17	(	(	-LRB-
cord-268140-s5lailkp	118	18	1	1	CD
cord-268140-s5lailkp	118	19	-	-	SYM
cord-268140-s5lailkp	118	20	2	2	CD
cord-268140-s5lailkp	118	21	injections	injection	NNS
cord-268140-s5lailkp	118	22	)	)	-RRB-
cord-268140-s5lailkp	118	23	along	along	IN
cord-268140-s5lailkp	118	24	with	with	IN
cord-268140-s5lailkp	118	25	standard	standard	NN
cord-268140-s5lailkp	118	26	of	of	IN
cord-268140-s5lailkp	118	27	care	care	NN
cord-268140-s5lailkp	118	28	,	,	,
cord-268140-s5lailkp	118	29	and	and	CC
cord-268140-s5lailkp	118	30	64	64	CD
cord-268140-s5lailkp	118	31	received	receive	VBN
cord-268140-s5lailkp	118	32	standard	standard	NN
cord-268140-s5lailkp	118	33	of	of	IN
cord-268140-s5lailkp	118	34	care	care	NN
cord-268140-s5lailkp	118	35	alone	alone	JJ
cord-268140-s5lailkp	118	36	.	.	.
cord-268140-s5lailkp	119	1	A	a	DT
cord-268140-s5lailkp	119	2	significantly	significantly	RB
cord-268140-s5lailkp	119	3	lower	low	JJR
cord-268140-s5lailkp	119	4	proportion	proportion	NN
cord-268140-s5lailkp	119	5	of	of	IN
cord-268140-s5lailkp	119	6	the	the	DT
cord-268140-s5lailkp	119	7	patients	patient	NNS
cord-268140-s5lailkp	119	8	in	in	IN
cord-268140-s5lailkp	119	9	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	119	10	arm	arm	NN
cord-268140-s5lailkp	119	11	attained	attain	VBD
cord-268140-s5lailkp	119	12	the	the	DT
cord-268140-s5lailkp	119	13	primary	primary	JJ
cord-268140-s5lailkp	119	14	outcome	outcome	NN
cord-268140-s5lailkp	119	15	of	of	IN
cord-268140-s5lailkp	119	16	need	need	NN
cord-268140-s5lailkp	119	17	for	for	IN
cord-268140-s5lailkp	119	18	ventilation	ventilation	NN
cord-268140-s5lailkp	119	19	or	or	CC
cord-268140-s5lailkp	119	20	death	death	NN
cord-268140-s5lailkp	119	21	at	at	IN
cord-268140-s5lailkp	119	22	.	.	.
cord-268140-s5lailkp	120	1	As	as	IN
cord-268140-s5lailkp	120	2	for	for	IN
cord-268140-s5lailkp	120	3	all	all	DT
cord-268140-s5lailkp	120	4	other	other	JJ
cord-268140-s5lailkp	120	5	potential	potential	JJ
cord-268140-s5lailkp	120	6	COVID-19	covid-19	CD
cord-268140-s5lailkp	120	7	treatments	treatment	NNS
cord-268140-s5lailkp	120	8	,	,	,
cord-268140-s5lailkp	120	9	more	more	JJR
cord-268140-s5lailkp	120	10	evidence	evidence	NN
cord-268140-s5lailkp	120	11	is	be	VBZ
cord-268140-s5lailkp	120	12	desired	desire	VBN
cord-268140-s5lailkp	120	13	at	at	IN
cord-268140-s5lailkp	120	14	this	this	DT
cord-268140-s5lailkp	120	15	point	point	NN
cord-268140-s5lailkp	120	16	of	of	IN
cord-268140-s5lailkp	120	17	time	time	NN
cord-268140-s5lailkp	120	18	and	and	CC
cord-268140-s5lailkp	120	19	further	far	RBR
cord-268140-s5lailkp	120	20	rigorous	rigorous	JJ
cord-268140-s5lailkp	120	21	clinical	clinical	JJ
cord-268140-s5lailkp	120	22	studies	study	NNS
cord-268140-s5lailkp	120	23	are	be	VBP
cord-268140-s5lailkp	120	24	warranted	warrant	VBN
cord-268140-s5lailkp	120	25	.	.	.
cord-268140-s5lailkp	121	1	For	for	IN
cord-268140-s5lailkp	121	2	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	121	3	,	,	,
cord-268140-s5lailkp	121	4	a	a	DT
cord-268140-s5lailkp	121	5	Phase	Phase	NNP
cord-268140-s5lailkp	121	6	II	II	NNP
cord-268140-s5lailkp	121	7	/	/	SYM
cord-268140-s5lailkp	121	8	III	iii	CD
cord-268140-s5lailkp	121	9	trial	trial	NN
cord-268140-s5lailkp	121	10	of	of	IN
cord-268140-s5lailkp	121	11	the	the	DT
cord-268140-s5lailkp	121	12	intravenous	intravenous	JJ
cord-268140-s5lailkp	121	13	formulation	formulation	NN
cord-268140-s5lailkp	121	14	has	have	VBZ
cord-268140-s5lailkp	121	15	been	be	VBN
cord-268140-s5lailkp	121	16	initiated	initiate	VBN
cord-268140-s5lailkp	121	17	in	in	IN
cord-268140-s5lailkp	121	18	March	March	NNP
cord-268140-s5lailkp	121	19	2020	2020	CD
cord-268140-s5lailkp	121	20	by	by	IN
cord-268140-s5lailkp	121	21	Sanofi	Sanofi	NNP
cord-268140-s5lailkp	121	22	and	and	CC
cord-268140-s5lailkp	121	23	Regeneron	Regeneron	NNP
cord-268140-s5lailkp	121	24	,	,	,
cord-268140-s5lailkp	121	25	for	for	IN
cord-268140-s5lailkp	121	26	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	121	27	patients	patient	NNS
cord-268140-s5lailkp	121	28	with	with	IN
cord-268140-s5lailkp	121	29	severe	severe	JJ
cord-268140-s5lailkp	121	30	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	121	31	(	(	-LRB-
cord-268140-s5lailkp	121	32	NCT04315298	NCT04315298	NNP
cord-268140-s5lailkp	121	33	)	)	-RRB-
cord-268140-s5lailkp	121	34	in	in	IN
cord-268140-s5lailkp	121	35	USA	USA	NNP
cord-268140-s5lailkp	121	36	,	,	,
cord-268140-s5lailkp	121	37	Italy	Italy	NNP
cord-268140-s5lailkp	121	38	,	,	,
cord-268140-s5lailkp	121	39	Spain	Spain	NNP
cord-268140-s5lailkp	121	40	,	,	,
cord-268140-s5lailkp	121	41	Germany	Germany	NNP
cord-268140-s5lailkp	121	42	,	,	,
cord-268140-s5lailkp	121	43	France	France	NNP
cord-268140-s5lailkp	121	44	,	,	,
cord-268140-s5lailkp	121	45	Japan	Japan	NNP
cord-268140-s5lailkp	121	46	,	,	,
cord-268140-s5lailkp	121	47	Canada	Canada	NNP
cord-268140-s5lailkp	121	48	and	and	CC
cord-268140-s5lailkp	121	49	Russia	Russia	NNP
cord-268140-s5lailkp	121	50	[	[	-LRB-
cord-268140-s5lailkp	121	51	56	56	CD
cord-268140-s5lailkp	121	52	]	]	-RRB-
cord-268140-s5lailkp	121	53	.	.	.
cord-268140-s5lailkp	122	1	The	the	DT
cord-268140-s5lailkp	122	2	double	double	JJ
cord-268140-s5lailkp	122	3	-	-	HYPH
cord-268140-s5lailkp	122	4	blind	blind	JJ
cord-268140-s5lailkp	122	5	trial	trial	NN
cord-268140-s5lailkp	122	6	has	have	VBZ
cord-268140-s5lailkp	122	7	an	an	DT
cord-268140-s5lailkp	122	8	adaptive	adaptive	JJ
cord-268140-s5lailkp	122	9	design	design	NN
cord-268140-s5lailkp	122	10	with	with	IN
cord-268140-s5lailkp	122	11	two	two	CD
cord-268140-s5lailkp	122	12	parts	part	NNS
cord-268140-s5lailkp	122	13	and	and	CC
cord-268140-s5lailkp	122	14	is	be	VBZ
cord-268140-s5lailkp	122	15	anticipated	anticipate	VBN
cord-268140-s5lailkp	122	16	to	to	TO
cord-268140-s5lailkp	122	17	enroll	enroll	VB
cord-268140-s5lailkp	122	18	up	up	IN
cord-268140-s5lailkp	122	19	to	to	TO
cord-268140-s5lailkp	122	20	400	400	CD
cord-268140-s5lailkp	122	21	patients	patient	NNS
cord-268140-s5lailkp	122	22	.	.	.
cord-268140-s5lailkp	123	1	The	the	DT
cord-268140-s5lailkp	123	2	first	first	JJ
cord-268140-s5lailkp	123	3	part	part	NN
cord-268140-s5lailkp	123	4	is	be	VBZ
cord-268140-s5lailkp	123	5	recruiting	recruit	VBG
cord-268140-s5lailkp	123	6	patients	patient	NNS
cord-268140-s5lailkp	123	7	across	across	IN
cord-268140-s5lailkp	123	8	multiple	multiple	JJ
cord-268140-s5lailkp	123	9	sites	site	NNS
cord-268140-s5lailkp	123	10	in	in	IN
cord-268140-s5lailkp	123	11	the	the	DT
cord-268140-s5lailkp	123	12	USA	USA	NNP
cord-268140-s5lailkp	123	13	and	and	CC
cord-268140-s5lailkp	123	14	will	will	MD
cord-268140-s5lailkp	123	15	evaluate	evaluate	VB
cord-268140-s5lailkp	123	16	the	the	DT
cord-268140-s5lailkp	123	17	effect	effect	NN
cord-268140-s5lailkp	123	18	of	of	IN
cord-268140-s5lailkp	123	19	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	123	20	on	on	IN
cord-268140-s5lailkp	123	21	fever	fever	NN
cord-268140-s5lailkp	123	22	and	and	CC
cord-268140-s5lailkp	123	23	need	need	NN
cord-268140-s5lailkp	123	24	for	for	IN
cord-268140-s5lailkp	123	25	supplemental	supplemental	JJ
cord-268140-s5lailkp	123	26	oxygen	oxygen	NN
cord-268140-s5lailkp	123	27	.	.	.
cord-268140-s5lailkp	124	1	The	the	DT
cord-268140-s5lailkp	124	2	second	second	JJ
cord-268140-s5lailkp	124	3	,	,	,
cord-268140-s5lailkp	124	4	larger	large	JJR
cord-268140-s5lailkp	124	5	,	,	,
cord-268140-s5lailkp	124	6	part	part	NN
cord-268140-s5lailkp	124	7	of	of	IN
cord-268140-s5lailkp	124	8	the	the	DT
cord-268140-s5lailkp	124	9	trial	trial	NN
cord-268140-s5lailkp	124	10	will	will	MD
cord-268140-s5lailkp	124	11	evaluate	evaluate	VB
cord-268140-s5lailkp	124	12	improvement	improvement	NN
cord-268140-s5lailkp	124	13	in	in	IN
cord-268140-s5lailkp	124	14	longer	long	JJR
cord-268140-s5lailkp	124	15	-	-	HYPH
cord-268140-s5lailkp	124	16	term	term	NN
cord-268140-s5lailkp	124	17	outcomes	outcome	NNS
cord-268140-s5lailkp	124	18	,	,	,
cord-268140-s5lailkp	124	19	including	include	VBG
cord-268140-s5lailkp	124	20	prevention	prevention	NN
cord-268140-s5lailkp	124	21	of	of	IN
cord-268140-s5lailkp	124	22	mortality	mortality	NN
cord-268140-s5lailkp	124	23	and	and	CC
cord-268140-s5lailkp	124	24	reduction	reduction	NN
cord-268140-s5lailkp	124	25	in	in	IN
cord-268140-s5lailkp	124	26	need	need	NN
cord-268140-s5lailkp	124	27	for	for	IN
cord-268140-s5lailkp	124	28	mechanical	mechanical	JJ
cord-268140-s5lailkp	124	29	ventilation	ventilation	NN
cord-268140-s5lailkp	124	30	,	,	,
cord-268140-s5lailkp	124	31	supplemental	supplemental	JJ
cord-268140-s5lailkp	124	32	oxygen	oxygen	NN
cord-268140-s5lailkp	124	33	,	,	,
cord-268140-s5lailkp	124	34	and/or	and/or	CC
cord-268140-s5lailkp	124	35	hospitalization	hospitalization	NN
cord-268140-s5lailkp	124	36	.	.	.
cord-268140-s5lailkp	125	1	The	the	DT
cord-268140-s5lailkp	125	2	early	early	JJ
cord-268140-s5lailkp	125	3	results	result	NNS
cord-268140-s5lailkp	125	4	from	from	IN
cord-268140-s5lailkp	125	5	this	this	DT
cord-268140-s5lailkp	125	6	study	study	NN
cord-268140-s5lailkp	125	7	seem	seem	VBP
cord-268140-s5lailkp	125	8	to	to	TO
cord-268140-s5lailkp	125	9	show	show	VB
cord-268140-s5lailkp	125	10	that	that	IN
cord-268140-s5lailkp	125	11	its	-PRON-	PRP$
cord-268140-s5lailkp	125	12	utility	utility	NN
cord-268140-s5lailkp	125	13	may	may	MD
cord-268140-s5lailkp	125	14	be	be	VB
cord-268140-s5lailkp	125	15	reserved	reserve	VBN
cord-268140-s5lailkp	125	16	for	for	IN
cord-268140-s5lailkp	125	17	the	the	DT
cord-268140-s5lailkp	125	18	'	'	``
cord-268140-s5lailkp	125	19	critically	critically	RB
cord-268140-s5lailkp	125	20	'	'	``
cord-268140-s5lailkp	125	21	ill	ill	JJ
cord-268140-s5lailkp	125	22	patients	patient	NNS
cord-268140-s5lailkp	125	23	[	[	-LRB-
cord-268140-s5lailkp	125	24	57	57	CD
cord-268140-s5lailkp	125	25	]	]	-RRB-
cord-268140-s5lailkp	125	26	.	.	.
cord-268140-s5lailkp	126	1	Another	another	DT
cord-268140-s5lailkp	126	2	openlabel	openlabel	NN
cord-268140-s5lailkp	126	3	randomized	randomize	VBD
cord-268140-s5lailkp	126	4	Phase	Phase	NNP
cord-268140-s5lailkp	126	5	II	II	NNP
cord-268140-s5lailkp	126	6	/	/	SYM
cord-268140-s5lailkp	126	7	III	iii	CD
cord-268140-s5lailkp	126	8	clinical	clinical	JJ
cord-268140-s5lailkp	126	9	trial	trial	NN
cord-268140-s5lailkp	126	10	(	(	-LRB-
cord-268140-s5lailkp	126	11	CORIMUNO	CORIMUNO	NNP
cord-268140-s5lailkp	126	12	-	-	HYPH
cord-268140-s5lailkp	126	13	SARI	SARI	NNP
cord-268140-s5lailkp	126	14	,	,	,
cord-268140-s5lailkp	126	15	NCT04324073	NCT04324073	NNP
cord-268140-s5lailkp	126	16	)	)	-RRB-
cord-268140-s5lailkp	126	17	with	with	IN
cord-268140-s5lailkp	126	18	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	126	19	in	in	IN
cord-268140-s5lailkp	126	20	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	126	21	patients	patient	NNS
cord-268140-s5lailkp	126	22	with	with	IN
cord-268140-s5lailkp	126	23	moderate	moderate	JJ
cord-268140-s5lailkp	126	24	,	,	,
cord-268140-s5lailkp	126	25	severe	severe	JJ
cord-268140-s5lailkp	126	26	or	or	CC
cord-268140-s5lailkp	126	27	critical	critical	JJ
cord-268140-s5lailkp	126	28	pneumonia	pneumonia	NN
cord-268140-s5lailkp	126	29	aims	aim	VBZ
cord-268140-s5lailkp	126	30	to	to	TO
cord-268140-s5lailkp	126	31	compare	compare	VB
cord-268140-s5lailkp	126	32	the	the	DT
cord-268140-s5lailkp	126	33	outcomes	outcome	NNS
cord-268140-s5lailkp	126	34	of	of	IN
cord-268140-s5lailkp	126	35	sarilumab	sarilumab	NN
cord-268140-s5lailkp	126	36	-	-	HYPH
cord-268140-s5lailkp	126	37	treated	treat	VBN
cord-268140-s5lailkp	126	38	patients	patient	NNS
cord-268140-s5lailkp	126	39	with	with	IN
cord-268140-s5lailkp	126	40	those	those	DT
cord-268140-s5lailkp	126	41	receiving	receive	VBG
cord-268140-s5lailkp	126	42	outcomes	outcome	NNS
cord-268140-s5lailkp	126	43	of	of	IN
cord-268140-s5lailkp	126	44	standard	standard	NN
cord-268140-s5lailkp	126	45	of	of	IN
cord-268140-s5lailkp	126	46	care	care	NN
cord-268140-s5lailkp	126	47	as	as	RB
cord-268140-s5lailkp	126	48	well	well	RB
cord-268140-s5lailkp	126	49	as	as	IN
cord-268140-s5lailkp	126	50	with	with	IN
cord-268140-s5lailkp	126	51	patients	patient	NNS
cord-268140-s5lailkp	126	52	being	be	VBG
cord-268140-s5lailkp	126	53	treated	treat	VBN
cord-268140-s5lailkp	126	54	with	with	IN
cord-268140-s5lailkp	126	55	other	other	JJ
cord-268140-s5lailkp	126	56	immunomodulators	immunomodulator	NNS
cord-268140-s5lailkp	126	57	[	[	-LRB-
cord-268140-s5lailkp	126	58	58	58	CD
cord-268140-s5lailkp	126	59	]	]	-RRB-
cord-268140-s5lailkp	126	60	.	.	.
cord-268140-s5lailkp	127	1	More	More	JJR
cord-268140-s5lailkp	127	2	studies	study	NNS
cord-268140-s5lailkp	127	3	have	have	VBP
cord-268140-s5lailkp	127	4	since	since	IN
cord-268140-s5lailkp	127	5	been	be	VBN
cord-268140-s5lailkp	127	6	registered	register	VBN
cord-268140-s5lailkp	127	7	or	or	CC
cord-268140-s5lailkp	127	8	initiated	initiate	VBN
cord-268140-s5lailkp	127	9	for	for	IN
cord-268140-s5lailkp	127	10	assessing	assess	VBG
cord-268140-s5lailkp	127	11	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	127	12	.	.	.
cord-268140-s5lailkp	128	1	For	for	IN
cord-268140-s5lailkp	128	2	siltuximab	siltuximab	NNS
cord-268140-s5lailkp	128	3	a	a	DT
cord-268140-s5lailkp	128	4	Phase	Phase	NNP
cord-268140-s5lailkp	128	5	II	II	NNP
cord-268140-s5lailkp	128	6	,	,	,
cord-268140-s5lailkp	128	7	randomized	randomized	JJ
cord-268140-s5lailkp	128	8	,	,	,
cord-268140-s5lailkp	128	9	open	open	JJ
cord-268140-s5lailkp	128	10	-	-	HYPH
cord-268140-s5lailkp	128	11	label	label	NN
cord-268140-s5lailkp	128	12	study	study	NN
cord-268140-s5lailkp	128	13	to	to	TO
cord-268140-s5lailkp	128	14	compare	compare	VB
cord-268140-s5lailkp	128	15	the	the	DT
cord-268140-s5lailkp	128	16	efficacy	efficacy	NN
cord-268140-s5lailkp	128	17	and	and	CC
cord-268140-s5lailkp	128	18	safety	safety	NN
cord-268140-s5lailkp	128	19	of	of	IN
cord-268140-s5lailkp	128	20	siltuximab	siltuximab	NNP
cord-268140-s5lailkp	128	21	versus	versus	IN
cord-268140-s5lailkp	128	22	methylprednisolone	methylprednisolone	NN
cord-268140-s5lailkp	128	23	in	in	IN
cord-268140-s5lailkp	128	24	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	128	25	patients	patient	NNS
cord-268140-s5lailkp	128	26	with	with	IN
cord-268140-s5lailkp	128	27	COVID	COVID	NNP
cord-268140-s5lailkp	128	28	19	19	CD
cord-268140-s5lailkp	128	29	pneumonia	pneumonia	NN
cord-268140-s5lailkp	128	30	has	have	VBZ
cord-268140-s5lailkp	128	31	begun	begin	VBN
cord-268140-s5lailkp	128	32	recruiting	recruit	VBG
cord-268140-s5lailkp	128	33	patients	patient	NNS
cord-268140-s5lailkp	128	34	in	in	IN
cord-268140-s5lailkp	128	35	Spain	Spain	NNP
cord-268140-s5lailkp	128	36	(	(	-LRB-
cord-268140-s5lailkp	128	37	NCT04329650	NCT04329650	NNP
cord-268140-s5lailkp	128	38	)	)	-RRB-
cord-268140-s5lailkp	128	39	[	[	-LRB-
cord-268140-s5lailkp	128	40	46	46	CD
cord-268140-s5lailkp	128	41	]	]	-RRB-
cord-268140-s5lailkp	128	42	.	.	.
cord-268140-s5lailkp	129	1	A	a	DT
cord-268140-s5lailkp	129	2	retrospective	retrospective	JJ
cord-268140-s5lailkp	129	3	observational	observational	JJ
cord-268140-s5lailkp	129	4	case	case	NN
cord-268140-s5lailkp	129	5	-	-	HYPH
cord-268140-s5lailkp	129	6	control	control	NN
cord-268140-s5lailkp	129	7	study	study	NN
cord-268140-s5lailkp	129	8	evaluating	evaluate	VBG
cord-268140-s5lailkp	129	9	the	the	DT
cord-268140-s5lailkp	129	10	use	use	NN
cord-268140-s5lailkp	129	11	of	of	IN
cord-268140-s5lailkp	129	12	siltuximab	siltuximab	NNP
cord-268140-s5lailkp	129	13	in	in	IN
cord-268140-s5lailkp	129	14	patients	patient	NNS
cord-268140-s5lailkp	129	15	diagnosed	diagnose	VBN
cord-268140-s5lailkp	129	16	with	with	IN
cord-268140-s5lailkp	129	17	COVID-19	covid-19	JJ
cord-268140-s5lailkp	129	18	infection	infection	NN
cord-268140-s5lailkp	129	19	who	who	WP
cord-268140-s5lailkp	129	20	have	have	VBP
cord-268140-s5lailkp	129	21	developed	develop	VBN
cord-268140-s5lailkp	129	22	serious	serious	JJ
cord-268140-s5lailkp	129	23	respiratory	respiratory	JJ
cord-268140-s5lailkp	129	24	complications	complication	NNS
cord-268140-s5lailkp	129	25	is	be	VBZ
cord-268140-s5lailkp	129	26	also	also	RB
cord-268140-s5lailkp	129	27	registered	register	VBN
cord-268140-s5lailkp	129	28	in	in	IN
cord-268140-s5lailkp	129	29	Italy	Italy	NNP
cord-268140-s5lailkp	129	30	(	(	-LRB-
cord-268140-s5lailkp	129	31	NCT04322188	NCT04322188	NNP
cord-268140-s5lailkp	129	32	)	)	-RRB-
cord-268140-s5lailkp	130	1	[	[	-LRB-
cord-268140-s5lailkp	130	2	46	46	CD
cord-268140-s5lailkp	130	3	]	]	-RRB-
cord-268140-s5lailkp	130	4	.	.	.
cord-268140-s5lailkp	131	1	SAR	SAR	NNP
cord-268140-s5lailkp	131	2	-	-	HYPH
cord-268140-s5lailkp	131	3	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	131	4	infects	infect	VBZ
cord-268140-s5lailkp	131	5	the	the	DT
cord-268140-s5lailkp	131	6	human	human	JJ
cord-268140-s5lailkp	131	7	airway	airway	NN
cord-268140-s5lailkp	131	8	,	,	,
cord-268140-s5lailkp	131	9	vascular	vascular	JJ
cord-268140-s5lailkp	131	10	and	and	CC
cord-268140-s5lailkp	131	11	immune	immune	JJ
cord-268140-s5lailkp	131	12	cells	cell	NNS
cord-268140-s5lailkp	131	13	,	,	,
cord-268140-s5lailkp	131	14	and	and	CC
cord-268140-s5lailkp	131	15	may	may	MD
cord-268140-s5lailkp	131	16	cause	cause	VB
cord-268140-s5lailkp	131	17	serious	serious	JJ
cord-268140-s5lailkp	131	18	damage	damage	NN
cord-268140-s5lailkp	131	19	to	to	IN
cord-268140-s5lailkp	131	20	the	the	DT
cord-268140-s5lailkp	131	21	respiratory	respiratory	JJ
cord-268140-s5lailkp	131	22	tract	tract	NN
cord-268140-s5lailkp	131	23	,	,	,
cord-268140-s5lailkp	131	24	particularly	particularly	RB
cord-268140-s5lailkp	131	25	the	the	DT
cord-268140-s5lailkp	131	26	lungs	lung	NNS
cord-268140-s5lailkp	131	27	.	.	.
cord-268140-s5lailkp	132	1	The	the	DT
cord-268140-s5lailkp	132	2	severity	severity	NN
cord-268140-s5lailkp	132	3	of	of	IN
cord-268140-s5lailkp	132	4	the	the	DT
cord-268140-s5lailkp	132	5	disease	disease	NN
cord-268140-s5lailkp	132	6	depends	depend	VBZ
cord-268140-s5lailkp	132	7	on	on	IN
cord-268140-s5lailkp	132	8	the	the	DT
cord-268140-s5lailkp	132	9	efficiency	efficiency	NN
cord-268140-s5lailkp	132	10	of	of	IN
cord-268140-s5lailkp	132	11	the	the	DT
cord-268140-s5lailkp	132	12	immune	immune	JJ
cord-268140-s5lailkp	132	13	system	system	NN
cord-268140-s5lailkp	132	14	[	[	-LRB-
cord-268140-s5lailkp	132	15	5	5	CD
cord-268140-s5lailkp	132	16	]	]	-RRB-
cord-268140-s5lailkp	132	17	.	.	.
cord-268140-s5lailkp	133	1	The	the	DT
cord-268140-s5lailkp	133	2	data	datum	NNS
cord-268140-s5lailkp	133	3	so	so	RB
cord-268140-s5lailkp	133	4	far	far	RB
cord-268140-s5lailkp	133	5	available	available	JJ
cord-268140-s5lailkp	133	6	indicate	indicate	VBP
cord-268140-s5lailkp	133	7	that	that	IN
cord-268140-s5lailkp	133	8	the	the	DT
cord-268140-s5lailkp	133	9	viral	viral	JJ
cord-268140-s5lailkp	133	10	infection	infection	NN
cord-268140-s5lailkp	133	11	can	can	MD
cord-268140-s5lailkp	133	12	lead	lead	VB
cord-268140-s5lailkp	133	13	to	to	IN
cord-268140-s5lailkp	133	14	an	an	DT
cord-268140-s5lailkp	133	15	excessive	excessive	JJ
cord-268140-s5lailkp	133	16	immune	immune	JJ
cord-268140-s5lailkp	133	17	reaction	reaction	NN
cord-268140-s5lailkp	133	18	in	in	IN
cord-268140-s5lailkp	133	19	the	the	DT
cord-268140-s5lailkp	133	20	host	host	NN
cord-268140-s5lailkp	133	21	in	in	IN
cord-268140-s5lailkp	133	22	some	some	DT
cord-268140-s5lailkp	133	23	cases	case	NNS
cord-268140-s5lailkp	133	24	so	so	RB
cord-268140-s5lailkp	133	25	severe	severe	JJ
cord-268140-s5lailkp	133	26	to	to	TO
cord-268140-s5lailkp	133	27	be	be	VB
cord-268140-s5lailkp	133	28	labelled	label	VBN
cord-268140-s5lailkp	133	29	as	as	IN
cord-268140-s5lailkp	133	30	CRS	CRS	NNP
cord-268140-s5lailkp	133	31	,	,	,
cord-268140-s5lailkp	133	32	which	which	WDT
cord-268140-s5lailkp	133	33	is	be	VBZ
cord-268140-s5lailkp	133	34	a	a	DT
cord-268140-s5lailkp	133	35	hyperinflammatory	hyperinflammatory	JJ
cord-268140-s5lailkp	133	36	state	state	NN
cord-268140-s5lailkp	133	37	.	.	.
cord-268140-s5lailkp	134	1	SAR	SAR	NNP
cord-268140-s5lailkp	134	2	-	-	HYPH
cord-268140-s5lailkp	134	3	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	134	4	is	be	VBZ
cord-268140-s5lailkp	134	5	primarily	primarily	RB
cord-268140-s5lailkp	134	6	attacked	attack	VBN
cord-268140-s5lailkp	134	7	by	by	IN
cord-268140-s5lailkp	134	8	immune	immune	JJ
cord-268140-s5lailkp	134	9	cells	cell	NNS
cord-268140-s5lailkp	134	10	including	include	VBG
cord-268140-s5lailkp	134	11	mast	mast	NN
cord-268140-s5lailkp	134	12	cells	cell	NNS
cord-268140-s5lailkp	134	13	(	(	-LRB-
cord-268140-s5lailkp	134	14	MCs	MCs	NNP
cord-268140-s5lailkp	134	15	)	)	-RRB-
cord-268140-s5lailkp	134	16	,	,	,
cord-268140-s5lailkp	134	17	present	present	JJ
cord-268140-s5lailkp	134	18	in	in	IN
cord-268140-s5lailkp	134	19	the	the	DT
cord-268140-s5lailkp	134	20	respiratory	respiratory	JJ
cord-268140-s5lailkp	134	21	tract	tract	NN
cord-268140-s5lailkp	134	22	and	and	CC
cord-268140-s5lailkp	134	23	in	in	IN
cord-268140-s5lailkp	134	24	the	the	DT
cord-268140-s5lailkp	134	25	nasal	nasal	NN
cord-268140-s5lailkp	134	26	cavity	cavity	NN
cord-268140-s5lailkp	134	27	[	[	-LRB-
cord-268140-s5lailkp	134	28	59	59	CD
cord-268140-s5lailkp	134	29	]	]	-RRB-
cord-268140-s5lailkp	134	30	.	.	.
cord-268140-s5lailkp	135	1	When	when	WRB
cord-268140-s5lailkp	135	2	the	the	DT
cord-268140-s5lailkp	135	3	virus	virus	NN
cord-268140-s5lailkp	135	4	infects	infect	VBZ
cord-268140-s5lailkp	135	5	the	the	DT
cord-268140-s5lailkp	135	6	respiratory	respiratory	JJ
cord-268140-s5lailkp	135	7	tract	tract	NN
cord-268140-s5lailkp	135	8	,	,	,
cord-268140-s5lailkp	135	9	it	-PRON-	PRP
cord-268140-s5lailkp	135	10	causes	cause	VBZ
cord-268140-s5lailkp	135	11	a	a	DT
cord-268140-s5lailkp	135	12	respiratory	respiratory	JJ
cord-268140-s5lailkp	135	13	syndrome	syndrome	NN
cord-268140-s5lailkp	135	14	with	with	IN
cord-268140-s5lailkp	135	15	consequent	consequent	JJ
cord-268140-s5lailkp	135	16	release	release	NN
cord-268140-s5lailkp	135	17	of	of	IN
cord-268140-s5lailkp	135	18	cytokines	cytokine	NNS
cord-268140-s5lailkp	135	19	like	like	IN
cord-268140-s5lailkp	136	1	interleukin	interleukin	NNP
cord-268140-s5lailkp	136	2	IL-1	IL-1	NNP
cord-268140-s5lailkp	136	3	and	and	CC
cord-268140-s5lailkp	136	4	IL-6	IL-6	NNP
cord-268140-s5lailkp	136	5	.	.	.
cord-268140-s5lailkp	137	1	These	these	DT
cord-268140-s5lailkp	137	2	in	in	IN
cord-268140-s5lailkp	137	3	turn	turn	NN
cord-268140-s5lailkp	137	4	are	be	VBP
cord-268140-s5lailkp	137	5	mediators	mediator	NNS
cord-268140-s5lailkp	137	6	of	of	IN
cord-268140-s5lailkp	137	7	further	further	JJ
cord-268140-s5lailkp	137	8	lung	lung	NN
cord-268140-s5lailkp	137	9	inflammation	inflammation	NN
cord-268140-s5lailkp	137	10	,	,	,
cord-268140-s5lailkp	137	11	fever	fever	NN
cord-268140-s5lailkp	137	12	,	,	,
cord-268140-s5lailkp	137	13	and	and	CC
cord-268140-s5lailkp	137	14	fibrosis	fibrosis	NN
cord-268140-s5lailkp	137	15	[	[	-LRB-
cord-268140-s5lailkp	137	16	60	60	CD
cord-268140-s5lailkp	137	17	]	]	-RRB-
cord-268140-s5lailkp	137	18	.	.	.
cord-268140-s5lailkp	138	1	Suppression	suppression	NN
cord-268140-s5lailkp	138	2	of	of	IN
cord-268140-s5lailkp	138	3	these	these	DT
cord-268140-s5lailkp	138	4	pro	pro	JJ
cord-268140-s5lailkp	138	5	-	-	JJ
cord-268140-s5lailkp	138	6	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	138	7	cytokines	cytokine	NNS
cord-268140-s5lailkp	138	8	has	have	VBZ
cord-268140-s5lailkp	138	9	been	be	VBN
cord-268140-s5lailkp	138	10	beneficial	beneficial	JJ
cord-268140-s5lailkp	138	11	therapeutically	therapeutically	RB
cord-268140-s5lailkp	138	12	in	in	IN
cord-268140-s5lailkp	138	13	many	many	JJ
cord-268140-s5lailkp	138	14	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	138	15	conditions	condition	NNS
cord-268140-s5lailkp	138	16	,	,	,
cord-268140-s5lailkp	138	17	including	include	VBG
cord-268140-s5lailkp	138	18	viral	viral	JJ
cord-268140-s5lailkp	138	19	infections	infection	NNS
cord-268140-s5lailkp	138	20	.	.	.
cord-268140-s5lailkp	139	1	Considering	consider	VBG
cord-268140-s5lailkp	139	2	the	the	DT
cord-268140-s5lailkp	139	3	proven	prove	VBN
cord-268140-s5lailkp	139	4	role	role	NN
cord-268140-s5lailkp	139	5	of	of	IN
cord-268140-s5lailkp	139	6	CRS	CRS	NNP
cord-268140-s5lailkp	139	7	in	in	IN
cord-268140-s5lailkp	139	8	serious	serious	JJ
cord-268140-s5lailkp	139	9	COVID-19	covid-19	JJ
cord-268140-s5lailkp	139	10	,	,	,
cord-268140-s5lailkp	139	11	early	early	JJ
cord-268140-s5lailkp	139	12	identification	identification	NN
cord-268140-s5lailkp	139	13	of	of	IN
cord-268140-s5lailkp	139	14	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	139	15	,	,	,
cord-268140-s5lailkp	139	16	and	and	CC
cord-268140-s5lailkp	139	17	its	-PRON-	PRP$
cord-268140-s5lailkp	139	18	management	management	NN
cord-268140-s5lailkp	139	19	using	use	VBG
cord-268140-s5lailkp	139	20	existing	exist	VBG
cord-268140-s5lailkp	139	21	,	,	,
cord-268140-s5lailkp	139	22	approved	approve	VBD
cord-268140-s5lailkp	139	23	therapies	therapy	NNS
cord-268140-s5lailkp	139	24	such	such	JJ
cord-268140-s5lailkp	139	25	as	as	IN
cord-268140-s5lailkp	139	26	steroids	steroid	NNS
cord-268140-s5lailkp	139	27	,	,	,
cord-268140-s5lailkp	139	28	intravenous	intravenous	JJ
cord-268140-s5lailkp	139	29	immunoglobulins	immunoglobulin	NNS
cord-268140-s5lailkp	139	30	,	,	,
cord-268140-s5lailkp	139	31	selective	selective	JJ
cord-268140-s5lailkp	139	32	cytokine	cytokine	NN
cord-268140-s5lailkp	139	33	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	139	34	should	should	MD
cord-268140-s5lailkp	139	35	be	be	VB
cord-268140-s5lailkp	139	36	done	do	VBN
cord-268140-s5lailkp	139	37	to	to	TO
cord-268140-s5lailkp	139	38	prevent	prevent	VB
cord-268140-s5lailkp	139	39	mortality	mortality	NN
cord-268140-s5lailkp	139	40	in	in	IN
cord-268140-s5lailkp	139	41	serious	serious	JJ
cord-268140-s5lailkp	139	42	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	139	43	,	,	,
cord-268140-s5lailkp	139	44	has	have	VBZ
cord-268140-s5lailkp	139	45	been	be	VBN
cord-268140-s5lailkp	139	46	recommended	recommend	VBN
cord-268140-s5lailkp	139	47	[	[	-LRB-
cord-268140-s5lailkp	139	48	32	32	CD
cord-268140-s5lailkp	139	49	]	]	-RRB-
cord-268140-s5lailkp	139	50	.	.	.
cord-268140-s5lailkp	140	1	Whilst	whilst	IN
cord-268140-s5lailkp	140	2	the	the	DT
cord-268140-s5lailkp	140	3	currently	currently	RB
cord-268140-s5lailkp	140	4	ongoing	ongoing	JJ
cord-268140-s5lailkp	140	5	multiple	multiple	JJ
cord-268140-s5lailkp	140	6	trials	trial	NNS
cord-268140-s5lailkp	140	7	for	for	IN
cord-268140-s5lailkp	140	8	IL-6	IL-6	NNP
cord-268140-s5lailkp	140	9	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	140	10	will	will	MD
cord-268140-s5lailkp	140	11	answer	answer	VB
cord-268140-s5lailkp	140	12	important	important	JJ
cord-268140-s5lailkp	140	13	questions	question	NNS
cord-268140-s5lailkp	140	14	regarding	regard	VBG
cord-268140-s5lailkp	140	15	the	the	DT
cord-268140-s5lailkp	140	16	clinical	clinical	JJ
cord-268140-s5lailkp	140	17	usefulness	usefulness	NN
cord-268140-s5lailkp	140	18	of	of	IN
cord-268140-s5lailkp	140	19	this	this	DT
cord-268140-s5lailkp	140	20	class	class	NN
cord-268140-s5lailkp	140	21	of	of	IN
cord-268140-s5lailkp	140	22	drugs	drug	NNS
cord-268140-s5lailkp	140	23	,	,	,
cord-268140-s5lailkp	140	24	the	the	DT
cord-268140-s5lailkp	140	25	number	number	NN
cord-268140-s5lailkp	140	26	of	of	IN
cord-268140-s5lailkp	140	27	these	these	DT
cord-268140-s5lailkp	140	28	studies	study	NNS
cord-268140-s5lailkp	140	29	is	be	VBZ
cord-268140-s5lailkp	140	30	still	still	RB
cord-268140-s5lailkp	140	31	proportionately	proportionately	RB
cord-268140-s5lailkp	140	32	lower	low	JJR
cord-268140-s5lailkp	140	33	than	than	IN
cord-268140-s5lailkp	140	34	the	the	DT
cord-268140-s5lailkp	140	35	clinical	clinical	JJ
cord-268140-s5lailkp	140	36	trials	trial	NNS
cord-268140-s5lailkp	140	37	underway	underway	RB
cord-268140-s5lailkp	140	38	or	or	CC
cord-268140-s5lailkp	140	39	announced	announce	VBD
cord-268140-s5lailkp	140	40	for	for	IN
cord-268140-s5lailkp	140	41	drugs	drug	NNS
cord-268140-s5lailkp	140	42	like	like	IN
cord-268140-s5lailkp	140	43	hydroxycholorquine	hydroxycholorquine	NN
cord-268140-s5lailkp	140	44	.	.	.
cord-268140-s5lailkp	141	1	This	this	DT
cord-268140-s5lailkp	141	2	is	be	VBZ
cord-268140-s5lailkp	141	3	despite	despite	IN
cord-268140-s5lailkp	141	4	the	the	DT
cord-268140-s5lailkp	141	5	fact	fact	NN
cord-268140-s5lailkp	141	6	that	that	IN
cord-268140-s5lailkp	141	7	most	most	JJS
cord-268140-s5lailkp	141	8	of	of	IN
cord-268140-s5lailkp	141	9	the	the	DT
cord-268140-s5lailkp	141	10	recently	recently	RB
cord-268140-s5lailkp	141	11	published	publish	VBN
cord-268140-s5lailkp	141	12	data	datum	NNS
cord-268140-s5lailkp	141	13	for	for	IN
cord-268140-s5lailkp	141	14	this	this	DT
cord-268140-s5lailkp	141	15	drug	drug	NN
cord-268140-s5lailkp	141	16	have	have	VBP
cord-268140-s5lailkp	141	17	not	not	RB
cord-268140-s5lailkp	141	18	been	be	VBN
cord-268140-s5lailkp	141	19	encouraging	encouraging	JJ
cord-268140-s5lailkp	141	20	.	.	.
cord-268140-s5lailkp	142	1	A	a	DT
cord-268140-s5lailkp	142	2	retrospective	retrospective	JJ
cord-268140-s5lailkp	142	3	analysis	analysis	NN
cord-268140-s5lailkp	142	4	of	of	IN
cord-268140-s5lailkp	142	5	368	368	CD
cord-268140-s5lailkp	142	6	patients	patient	NNS
cord-268140-s5lailkp	142	7	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	142	8	with	with	IN
cord-268140-s5lailkp	142	9	confirmed	confirm	VBN
cord-268140-s5lailkp	142	10	COVID-19	covid-19	CD
cord-268140-s5lailkp	142	11	infection	infection	NN
cord-268140-s5lailkp	142	12	in	in	IN
cord-268140-s5lailkp	142	13	all	all	DT
cord-268140-s5lailkp	142	14	US	US	NNP
cord-268140-s5lailkp	142	15	Veterans	Veterans	NNPS
cord-268140-s5lailkp	142	16	Health	Health	NNP
cord-268140-s5lailkp	142	17	Administration	Administration	NNP
cord-268140-s5lailkp	142	18	medical	medical	JJ
cord-268140-s5lailkp	142	19	centers	center	NNS
cord-268140-s5lailkp	142	20	during	during	IN
cord-268140-s5lailkp	142	21	one	one	CD
cord-268140-s5lailkp	142	22	month	month	NN
cord-268140-s5lailkp	142	23	,	,	,
cord-268140-s5lailkp	142	24	showed	show	VBD
cord-268140-s5lailkp	142	25	no	no	DT
cord-268140-s5lailkp	142	26	evidence	evidence	NN
cord-268140-s5lailkp	142	27	of	of	IN
cord-268140-s5lailkp	142	28	benefit	benefit	NN
cord-268140-s5lailkp	142	29	with	with	IN
cord-268140-s5lailkp	142	30	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	142	31	[	[	-LRB-
cord-268140-s5lailkp	142	32	61	61	CD
cord-268140-s5lailkp	142	33	]	]	-RRB-
cord-268140-s5lailkp	142	34	.	.	.
cord-268140-s5lailkp	143	1	Similar	similar	JJ
cord-268140-s5lailkp	143	2	disappointing	disappointing	JJ
cord-268140-s5lailkp	143	3	results	result	NNS
cord-268140-s5lailkp	143	4	and	and	CC
cord-268140-s5lailkp	143	5	opposing	oppose	VBG
cord-268140-s5lailkp	143	6	conclusions	conclusion	NNS
cord-268140-s5lailkp	143	7	have	have	VBP
cord-268140-s5lailkp	143	8	also	also	RB
cord-268140-s5lailkp	143	9	been	be	VBN
cord-268140-s5lailkp	143	10	obtained	obtain	VBN
cord-268140-s5lailkp	143	11	in	in	IN
cord-268140-s5lailkp	143	12	other	other	JJ
cord-268140-s5lailkp	143	13	studies	study	NNS
cord-268140-s5lailkp	143	14	[	[	-LRB-
cord-268140-s5lailkp	143	15	62	62	CD
cord-268140-s5lailkp	143	16	,	,	,
cord-268140-s5lailkp	143	17	63	63	CD
cord-268140-s5lailkp	143	18	]	]	-RRB-
cord-268140-s5lailkp	143	19	.	.	.
cord-268140-s5lailkp	144	1	In	in	IN
cord-268140-s5lailkp	144	2	fact	fact	NN
cord-268140-s5lailkp	144	3	,	,	,
cord-268140-s5lailkp	144	4	safety	safety	NN
cord-268140-s5lailkp	144	5	concerns	concern	NNS
cord-268140-s5lailkp	144	6	related	relate	VBN
cord-268140-s5lailkp	144	7	to	to	IN
cord-268140-s5lailkp	144	8	the	the	DT
cord-268140-s5lailkp	144	9	use	use	NN
cord-268140-s5lailkp	144	10	of	of	IN
cord-268140-s5lailkp	144	11	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	144	12	or	or	CC
cord-268140-s5lailkp	144	13	chloroquine	chloroquine	NN
cord-268140-s5lailkp	144	14	in	in	IN
cord-268140-s5lailkp	144	15	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	144	16	patients	patient	NNS
cord-268140-s5lailkp	144	17	had	have	VBD
cord-268140-s5lailkp	144	18	been	be	VBN
cord-268140-s5lailkp	144	19	incited	incite	VBN
cord-268140-s5lailkp	144	20	by	by	IN
cord-268140-s5lailkp	144	21	a	a	DT
cord-268140-s5lailkp	144	22	recently	recently	RB
cord-268140-s5lailkp	144	23	published	publish	VBN
cord-268140-s5lailkp	144	24	large	large	JJ
cord-268140-s5lailkp	144	25	observational	observational	JJ
cord-268140-s5lailkp	144	26	analysis	analysis	NN
cord-268140-s5lailkp	144	27	,	,	,
cord-268140-s5lailkp	144	28	in	in	IN
cord-268140-s5lailkp	144	29	response	response	NN
cord-268140-s5lailkp	144	30	to	to	TO
cord-268140-s5lailkp	144	31	which	which	WDT
cord-268140-s5lailkp	144	32	the	the	DT
cord-268140-s5lailkp	144	33	WHO	who	WP
cord-268140-s5lailkp	144	34	temporarily	temporarily	RB
cord-268140-s5lailkp	144	35	suspended	suspend	VBD
cord-268140-s5lailkp	144	36	the	the	DT
cord-268140-s5lailkp	144	37	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	144	38	arm	arm	NN
cord-268140-s5lailkp	144	39	within	within	IN
cord-268140-s5lailkp	144	40	the	the	DT
cord-268140-s5lailkp	144	41	Solidarity	Solidarity	NNP
cord-268140-s5lailkp	144	42	trial	trial	NN
cord-268140-s5lailkp	144	43	while	while	IN
cord-268140-s5lailkp	144	44	the	the	DT
cord-268140-s5lailkp	144	45	safety	safety	NN
cord-268140-s5lailkp	144	46	data	datum	NNS
cord-268140-s5lailkp	144	47	was	be	VBD
cord-268140-s5lailkp	144	48	reviewed	review	VBN
cord-268140-s5lailkp	144	49	by	by	IN
cord-268140-s5lailkp	144	50	the	the	DT
cord-268140-s5lailkp	144	51	Data	Data	NNP
cord-268140-s5lailkp	144	52	Safety	Safety	NNP
cord-268140-s5lailkp	144	53	Monitoring	Monitoring	NNP
cord-268140-s5lailkp	144	54	Board	Board	NNP
cord-268140-s5lailkp	144	55	;	;	:
cord-268140-s5lailkp	144	56	the	the	DT
cord-268140-s5lailkp	144	57	hydroxycholorquine	hydroxycholorquine	NN
cord-268140-s5lailkp	144	58	arm	arm	NN
cord-268140-s5lailkp	144	59	has	have	VBZ
cord-268140-s5lailkp	144	60	now	now	RB
cord-268140-s5lailkp	144	61	been	be	VBN
cord-268140-s5lailkp	144	62	reinstated	reinstate	VBN
cord-268140-s5lailkp	144	63	and	and	CC
cord-268140-s5lailkp	144	64	the	the	DT
cord-268140-s5lailkp	144	65	registry	registry	NN
cord-268140-s5lailkp	144	66	analysis	analysis	NN
cord-268140-s5lailkp	144	67	retracted	retract	VBN
cord-268140-s5lailkp	144	68	since	since	IN
cord-268140-s5lailkp	144	69	[	[	-LRB-
cord-268140-s5lailkp	144	70	7	7	CD
cord-268140-s5lailkp	144	71	,	,	,
cord-268140-s5lailkp	144	72	10	10	CD
cord-268140-s5lailkp	144	73	]	]	-RRB-
cord-268140-s5lailkp	144	74	.	.	.
cord-268140-s5lailkp	145	1	This	this	DT
cord-268140-s5lailkp	145	2	overwhelming	overwhelming	JJ
cord-268140-s5lailkp	145	3	fascination	fascination	NN
cord-268140-s5lailkp	145	4	with	with	IN
cord-268140-s5lailkp	145	5	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	145	6	until	until	IN
cord-268140-s5lailkp	145	7	recently	recently	RB
cord-268140-s5lailkp	145	8	has	have	VBZ
cord-268140-s5lailkp	145	9	continued	continue	VBN
cord-268140-s5lailkp	145	10	across	across	IN
cord-268140-s5lailkp	145	11	the	the	DT
cord-268140-s5lailkp	145	12	globe	globe	NN
cord-268140-s5lailkp	145	13	from	from	IN
cord-268140-s5lailkp	145	14	USA	USA	NNP
cord-268140-s5lailkp	145	15	,	,	,
cord-268140-s5lailkp	145	16	Europe	Europe	NNP
cord-268140-s5lailkp	145	17	to	to	IN
cord-268140-s5lailkp	145	18	China	China	NNP
cord-268140-s5lailkp	145	19	and	and	CC
cord-268140-s5lailkp	145	20	India	India	NNP
cord-268140-s5lailkp	145	21	,	,	,
cord-268140-s5lailkp	145	22	perhaps	perhaps	RB
cord-268140-s5lailkp	145	23	due	due	IN
cord-268140-s5lailkp	145	24	to	to	IN
cord-268140-s5lailkp	145	25	the	the	DT
cord-268140-s5lailkp	145	26	drug	drug	NN
cord-268140-s5lailkp	145	27	being	be	VBG
cord-268140-s5lailkp	145	28	inexpensive	inexpensive	JJ
cord-268140-s5lailkp	145	29	?	?	.
cord-268140-s5lailkp	146	1	Currently	currently	RB
cord-268140-s5lailkp	146	2	,	,	,
cord-268140-s5lailkp	146	3	remdesivir	remdesivir	NNP
cord-268140-s5lailkp	146	4	has	have	VBZ
cord-268140-s5lailkp	146	5	been	be	VBN
cord-268140-s5lailkp	146	6	proven	prove	VBN
cord-268140-s5lailkp	146	7	to	to	TO
cord-268140-s5lailkp	146	8	be	be	VB
cord-268140-s5lailkp	146	9	successful	successful	JJ
cord-268140-s5lailkp	146	10	treatment	treatment	NN
cord-268140-s5lailkp	146	11	for	for	IN
cord-268140-s5lailkp	146	12	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	146	13	with	with	IN
cord-268140-s5lailkp	146	14	the	the	DT
cord-268140-s5lailkp	146	15	announcement	announcement	NN
cord-268140-s5lailkp	146	16	of	of	IN
cord-268140-s5lailkp	146	17	its	-PRON-	PRP$
cord-268140-s5lailkp	146	18	encouraging	encouraging	JJ
cord-268140-s5lailkp	146	19	results	result	NNS
cord-268140-s5lailkp	146	20	[	[	-LRB-
cord-268140-s5lailkp	146	21	9	9	CD
cord-268140-s5lailkp	146	22	]	]	-RRB-
cord-268140-s5lailkp	146	23	.	.	.
cord-268140-s5lailkp	147	1	But	but	CC
cord-268140-s5lailkp	147	2	it	-PRON-	PRP
cord-268140-s5lailkp	147	3	has	have	VBZ
cord-268140-s5lailkp	147	4	to	to	TO
cord-268140-s5lailkp	147	5	be	be	VB
cord-268140-s5lailkp	147	6	borne	bear	VBN
cord-268140-s5lailkp	147	7	in	in	IN
cord-268140-s5lailkp	147	8	mind	mind	NN
cord-268140-s5lailkp	147	9	that	that	IN
cord-268140-s5lailkp	147	10	this	this	DT
cord-268140-s5lailkp	147	11	is	be	VBZ
cord-268140-s5lailkp	147	12	still	still	RB
cord-268140-s5lailkp	147	13	an	an	DT
cord-268140-s5lailkp	147	14	investigational	investigational	JJ
cord-268140-s5lailkp	147	15	agent	agent	NN
cord-268140-s5lailkp	147	16	,	,	,
cord-268140-s5lailkp	147	17	with	with	IN
cord-268140-s5lailkp	147	18	safety	safety	NN
cord-268140-s5lailkp	147	19	and	and	CC
cord-268140-s5lailkp	147	20	long	long	JJ
cord-268140-s5lailkp	147	21	-	-	HYPH
cord-268140-s5lailkp	147	22	term	term	NN
cord-268140-s5lailkp	147	23	effects	effect	NNS
cord-268140-s5lailkp	147	24	being	be	VBG
cord-268140-s5lailkp	147	25	much	much	RB
cord-268140-s5lailkp	147	26	less	less	RBR
cord-268140-s5lailkp	147	27	explored	explore	VBN
cord-268140-s5lailkp	147	28	;	;	:
cord-268140-s5lailkp	147	29	the	the	DT
cord-268140-s5lailkp	147	30	global	global	JJ
cord-268140-s5lailkp	147	31	availability	availability	NN
cord-268140-s5lailkp	147	32	also	also	RB
cord-268140-s5lailkp	147	33	remains	remain	VBZ
cord-268140-s5lailkp	147	34	a	a	DT
cord-268140-s5lailkp	147	35	contentious	contentious	JJ
cord-268140-s5lailkp	147	36	issue	issue	NN
cord-268140-s5lailkp	147	37	,	,	,
cord-268140-s5lailkp	147	38	although	although	IN
cord-268140-s5lailkp	147	39	the	the	DT
cord-268140-s5lailkp	147	40	innovator	innovator	NN
cord-268140-s5lailkp	147	41	company	company	NN
cord-268140-s5lailkp	147	42	has	have	VBZ
cord-268140-s5lailkp	147	43	entered	enter	VBN
cord-268140-s5lailkp	147	44	into	into	IN
cord-268140-s5lailkp	147	45	collaboration	collaboration	NN
cord-268140-s5lailkp	147	46	with	with	IN
cord-268140-s5lailkp	147	47	multiple	multiple	JJ
cord-268140-s5lailkp	147	48	local	local	JJ
cord-268140-s5lailkp	147	49	manufacturers	manufacturer	NNS
cord-268140-s5lailkp	147	50	in	in	IN
cord-268140-s5lailkp	147	51	key	key	JJ
cord-268140-s5lailkp	147	52	regions	region	NNS
cord-268140-s5lailkp	147	53	of	of	IN
cord-268140-s5lailkp	147	54	the	the	DT
cord-268140-s5lailkp	147	55	world	world	NN
cord-268140-s5lailkp	147	56	.	.	.
cord-268140-s5lailkp	148	1	With	with	IN
cord-268140-s5lailkp	148	2	the	the	DT
cord-268140-s5lailkp	148	3	dangerously	dangerously	RB
cord-268140-s5lailkp	148	4	rising	rise	VBG
cord-268140-s5lailkp	148	5	death	death	NN
cord-268140-s5lailkp	148	6	toll	toll	NN
cord-268140-s5lailkp	148	7	of	of	IN
cord-268140-s5lailkp	148	8	this	this	DT
cord-268140-s5lailkp	148	9	pandemic	pandemic	NN
cord-268140-s5lailkp	148	10	,	,	,
cord-268140-s5lailkp	148	11	it	-PRON-	PRP
cord-268140-s5lailkp	148	12	is	be	VBZ
cord-268140-s5lailkp	148	13	very	very	RB
cord-268140-s5lailkp	148	14	pertinent	pertinent	JJ
cord-268140-s5lailkp	148	15	to	to	TO
cord-268140-s5lailkp	148	16	look	look	VB
cord-268140-s5lailkp	148	17	at	at	IN
cord-268140-s5lailkp	148	18	treatment	treatment	NN
cord-268140-s5lailkp	148	19	options	option	NNS
cord-268140-s5lailkp	149	1	which	which	WDT
cord-268140-s5lailkp	149	2	can	can	MD
cord-268140-s5lailkp	149	3	literally	literally	RB
cord-268140-s5lailkp	149	4	'	'	``
cord-268140-s5lailkp	149	5	save	save	VB
cord-268140-s5lailkp	149	6	lives	life	NNS
cord-268140-s5lailkp	149	7	'	'	''
cord-268140-s5lailkp	149	8	among	among	IN
cord-268140-s5lailkp	149	9	the	the	DT
cord-268140-s5lailkp	149	10	critically	critically	RB
cord-268140-s5lailkp	149	11	ill	ill	JJ
cord-268140-s5lailkp	149	12	serious	serious	JJ
cord-268140-s5lailkp	149	13	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	149	14	patients	patient	NNS
cord-268140-s5lailkp	149	15	.	.	.
cord-268140-s5lailkp	150	1	Multiple	multiple	JJ
cord-268140-s5lailkp	150	2	new	new	JJ
cord-268140-s5lailkp	150	3	manifestations	manifestation	NNS
cord-268140-s5lailkp	150	4	of	of	IN
cord-268140-s5lailkp	150	5	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	150	6	are	be	VBP
cord-268140-s5lailkp	150	7	now	now	RB
cord-268140-s5lailkp	150	8	being	be	VBG
cord-268140-s5lailkp	150	9	recognized	recognize	VBN
cord-268140-s5lailkp	150	10	ranging	range	VBG
cord-268140-s5lailkp	150	11	from	from	IN
cord-268140-s5lailkp	150	12	gastrointestinal	gastrointestinal	JJ
cord-268140-s5lailkp	150	13	symptoms	symptom	NNS
cord-268140-s5lailkp	150	14	to	to	IN
cord-268140-s5lailkp	150	15	neurological	neurological	JJ
cord-268140-s5lailkp	150	16	dysfunctions	dysfunction	NNS
cord-268140-s5lailkp	150	17	,	,	,
cord-268140-s5lailkp	150	18	including	include	VBG
cord-268140-s5lailkp	150	19	stroke	stroke	NN
cord-268140-s5lailkp	150	20	,	,	,
cord-268140-s5lailkp	150	21	but	but	CC
cord-268140-s5lailkp	150	22	the	the	DT
cord-268140-s5lailkp	150	23	predominant	predominant	JJ
cord-268140-s5lailkp	150	24	cause	cause	NN
cord-268140-s5lailkp	150	25	of	of	IN
cord-268140-s5lailkp	150	26	death	death	NN
cord-268140-s5lailkp	150	27	still	still	RB
cord-268140-s5lailkp	150	28	remains	remain	VBZ
cord-268140-s5lailkp	150	29	respiratory	respiratory	JJ
cord-268140-s5lailkp	150	30	failure	failure	NN
cord-268140-s5lailkp	150	31	,	,	,
cord-268140-s5lailkp	150	32	which	which	WDT
cord-268140-s5lailkp	150	33	to	to	IN
cord-268140-s5lailkp	150	34	a	a	DT
cord-268140-s5lailkp	150	35	large	large	JJ
cord-268140-s5lailkp	150	36	extent	extent	NN
cord-268140-s5lailkp	150	37	is	be	VBZ
cord-268140-s5lailkp	150	38	due	due	JJ
cord-268140-s5lailkp	150	39	to	to	IN
cord-268140-s5lailkp	150	40	the	the	DT
cord-268140-s5lailkp	150	41	hypoxemic	hypoxemic	JJ
cord-268140-s5lailkp	150	42	effect	effect	NN
cord-268140-s5lailkp	150	43	of	of	IN
cord-268140-s5lailkp	150	44	the	the	DT
cord-268140-s5lailkp	150	45	virus	virus	NN
cord-268140-s5lailkp	150	46	with	with	IN
cord-268140-s5lailkp	150	47	an	an	DT
cord-268140-s5lailkp	150	48	accompanying	accompanying	JJ
cord-268140-s5lailkp	150	49	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	150	50	in	in	IN
cord-268140-s5lailkp	150	51	many	many	JJ
cord-268140-s5lailkp	150	52	patients	patient	NNS
cord-268140-s5lailkp	150	53	.	.	.
cord-268140-s5lailkp	151	1	This	this	DT
cord-268140-s5lailkp	151	2	is	be	VBZ
cord-268140-s5lailkp	151	3	where	where	WRB
cord-268140-s5lailkp	151	4	the	the	DT
cord-268140-s5lailkp	151	5	IL-6	IL-6	NNP
cord-268140-s5lailkp	151	6	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	151	7	can	can	MD
cord-268140-s5lailkp	151	8	play	play	VB
cord-268140-s5lailkp	151	9	a	a	DT
cord-268140-s5lailkp	151	10	crucial	crucial	JJ
cord-268140-s5lailkp	151	11	role	role	NN
cord-268140-s5lailkp	151	12	.	.	.
cord-268140-s5lailkp	152	1	The	the	DT
cord-268140-s5lailkp	152	2	repurposed	repurpose	VBN
cord-268140-s5lailkp	152	3	use	use	NN
cord-268140-s5lailkp	152	4	of	of	IN
cord-268140-s5lailkp	152	5	these	these	DT
cord-268140-s5lailkp	152	6	FDA	FDA	NNP
cord-268140-s5lailkp	152	7	-	-	HYPH
cord-268140-s5lailkp	152	8	approved	approve	VBN
cord-268140-s5lailkp	152	9	agents	agent	NNS
cord-268140-s5lailkp	152	10	may	may	MD
cord-268140-s5lailkp	152	11	score	score	VB
cord-268140-s5lailkp	152	12	over	over	IN
cord-268140-s5lailkp	152	13	the	the	DT
cord-268140-s5lailkp	152	14	highly	highly	RB
cord-268140-s5lailkp	152	15	promising	promising	JJ
cord-268140-s5lailkp	152	16	investigational	investigational	JJ
cord-268140-s5lailkp	152	17	new	new	JJ
cord-268140-s5lailkp	152	18	drug	drug	NN
cord-268140-s5lailkp	152	19	such	such	JJ
cord-268140-s5lailkp	152	20	as	as	IN
cord-268140-s5lailkp	152	21	Gilead	Gilead	NNP
cord-268140-s5lailkp	152	22	's	's	POS
cord-268140-s5lailkp	152	23	remdesivir	remdesivir	NNS
cord-268140-s5lailkp	152	24	,	,	,
cord-268140-s5lailkp	152	25	due	due	IN
cord-268140-s5lailkp	152	26	to	to	IN
cord-268140-s5lailkp	152	27	widespread	widespread	JJ
cord-268140-s5lailkp	152	28	experience	experience	NN
cord-268140-s5lailkp	152	29	with	with	IN
cord-268140-s5lailkp	152	30	their	-PRON-	PRP$
cord-268140-s5lailkp	152	31	clinical	clinical	JJ
cord-268140-s5lailkp	152	32	use	use	NN
cord-268140-s5lailkp	152	33	in	in	IN
cord-268140-s5lailkp	152	34	rheumatological	rheumatological	JJ
cord-268140-s5lailkp	152	35	conditions	condition	NNS
cord-268140-s5lailkp	152	36	,	,	,
cord-268140-s5lailkp	152	37	and	and	CC
cord-268140-s5lailkp	152	38	their	-PRON-	PRP$
cord-268140-s5lailkp	152	39	known	know	VBN
cord-268140-s5lailkp	152	40	acute	acute	NN
cord-268140-s5lailkp	152	41	as	as	RB
cord-268140-s5lailkp	152	42	well	well	RB
cord-268140-s5lailkp	152	43	as	as	IN
cord-268140-s5lailkp	152	44	long	long	JJ
cord-268140-s5lailkp	152	45	-	-	HYPH
cord-268140-s5lailkp	152	46	term	term	NN
cord-268140-s5lailkp	152	47	safety	safety	NN
cord-268140-s5lailkp	152	48	profile	profile	NN
cord-268140-s5lailkp	152	49	.	.	.
cord-268140-s5lailkp	153	1	Their	-PRON-	PRP$
cord-268140-s5lailkp	153	2	off	off	JJ
cord-268140-s5lailkp	153	3	-	-	HYPH
cord-268140-s5lailkp	153	4	label	label	NN
cord-268140-s5lailkp	153	5	use	use	NN
cord-268140-s5lailkp	153	6	may	may	MD
cord-268140-s5lailkp	153	7	also	also	RB
cord-268140-s5lailkp	153	8	be	be	VB
cord-268140-s5lailkp	153	9	relatively	relatively	RB
cord-268140-s5lailkp	153	10	more	more	RBR
cord-268140-s5lailkp	153	11	feasible	feasible	JJ
cord-268140-s5lailkp	153	12	across	across	IN
cord-268140-s5lailkp	153	13	the	the	DT
cord-268140-s5lailkp	153	14	globe	globe	NN
cord-268140-s5lailkp	153	15	due	due	JJ
cord-268140-s5lailkp	153	16	to	to	IN
cord-268140-s5lailkp	153	17	ready	ready	JJ
cord-268140-s5lailkp	153	18	availability	availability	NN
cord-268140-s5lailkp	153	19	with	with	IN
cord-268140-s5lailkp	153	20	production	production	NN
cord-268140-s5lailkp	153	21	and	and	CC
cord-268140-s5lailkp	153	22	distribution	distribution	NN
cord-268140-s5lailkp	153	23	capabilities	capability	NNS
cord-268140-s5lailkp	153	24	being	be	VBG
cord-268140-s5lailkp	153	25	already	already	RB
cord-268140-s5lailkp	153	26	in	in	IN
cord-268140-s5lailkp	153	27	place	place	NN
cord-268140-s5lailkp	153	28	.	.	.
cord-268140-s5lailkp	154	1	Safety	safety	NN
cord-268140-s5lailkp	154	2	could	could	MD
cord-268140-s5lailkp	154	3	actually	actually	RB
cord-268140-s5lailkp	154	4	be	be	VB
cord-268140-s5lailkp	154	5	one	one	CD
cord-268140-s5lailkp	154	6	of	of	IN
cord-268140-s5lailkp	154	7	the	the	DT
cord-268140-s5lailkp	154	8	main	main	JJ
cord-268140-s5lailkp	154	9	deterrents	deterrent	NNS
cord-268140-s5lailkp	154	10	in	in	IN
cord-268140-s5lailkp	154	11	the	the	DT
cord-268140-s5lailkp	154	12	use	use	NN
cord-268140-s5lailkp	154	13	of	of	IN
cord-268140-s5lailkp	154	14	these	these	DT
cord-268140-s5lailkp	154	15	drugs	drug	NNS
cord-268140-s5lailkp	154	16	.	.	.
cord-268140-s5lailkp	155	1	Serious	serious	JJ
cord-268140-s5lailkp	155	2	risk	risk	NN
cord-268140-s5lailkp	155	3	of	of	IN
cord-268140-s5lailkp	155	4	infections	infection	NNS
cord-268140-s5lailkp	155	5	has	have	VBZ
cord-268140-s5lailkp	155	6	been	be	VBN
cord-268140-s5lailkp	155	7	listed	list	VBN
cord-268140-s5lailkp	155	8	as	as	IN
cord-268140-s5lailkp	155	9	a	a	DT
cord-268140-s5lailkp	155	10	boxed	boxed	JJ
cord-268140-s5lailkp	155	11	warning	warning	NN
cord-268140-s5lailkp	155	12	,	,	,
cord-268140-s5lailkp	155	13	although	although	IN
cord-268140-s5lailkp	155	14	this	this	DT
cord-268140-s5lailkp	155	15	is	be	VBZ
cord-268140-s5lailkp	155	16	seen	see	VBN
cord-268140-s5lailkp	155	17	mainly	mainly	RB
cord-268140-s5lailkp	155	18	with	with	IN
cord-268140-s5lailkp	155	19	concomitant	concomitant	JJ
cord-268140-s5lailkp	155	20	use	use	NN
cord-268140-s5lailkp	155	21	of	of	IN
cord-268140-s5lailkp	155	22	immunosuppressants	immunosuppressant	NNS
cord-268140-s5lailkp	155	23	or	or	CC
cord-268140-s5lailkp	155	24	corticosteroids	corticosteroid	NNS
cord-268140-s5lailkp	155	25	.	.	.
cord-268140-s5lailkp	156	1	To	to	TO
cord-268140-s5lailkp	156	2	prevent	prevent	VB
cord-268140-s5lailkp	156	3	the	the	DT
cord-268140-s5lailkp	156	4	secondary	secondary	JJ
cord-268140-s5lailkp	156	5	infections	infection	NNS
cord-268140-s5lailkp	156	6	,	,	,
cord-268140-s5lailkp	156	7	prophylactic	prophylactic	JJ
cord-268140-s5lailkp	156	8	antibiotics	antibiotic	NNS
cord-268140-s5lailkp	156	9	may	may	MD
cord-268140-s5lailkp	156	10	be	be	VB
cord-268140-s5lailkp	156	11	indicated	indicate	VBN
cord-268140-s5lailkp	156	12	.	.	.
cord-268140-s5lailkp	157	1	The	the	DT
cord-268140-s5lailkp	157	2	drugs	drug	NNS
cord-268140-s5lailkp	157	3	are	be	VBP
cord-268140-s5lailkp	157	4	known	know	VBN
cord-268140-s5lailkp	157	5	to	to	TO
cord-268140-s5lailkp	157	6	cause	cause	VB
cord-268140-s5lailkp	157	7	hepatic	hepatic	JJ
cord-268140-s5lailkp	157	8	,	,	,
cord-268140-s5lailkp	157	9	endocrinological	endocrinological	JJ
cord-268140-s5lailkp	157	10	,	,	,
cord-268140-s5lailkp	157	11	metabolic	metabolic	JJ
cord-268140-s5lailkp	157	12	,	,	,
cord-268140-s5lailkp	157	13	hematological	hematological	JJ
cord-268140-s5lailkp	157	14	,	,	,
cord-268140-s5lailkp	157	15	gastrointestinal	gastrointestinal	JJ
cord-268140-s5lailkp	157	16	,	,	,
cord-268140-s5lailkp	157	17	cardiovascular	cardiovascular	JJ
cord-268140-s5lailkp	157	18	adverse	adverse	JJ
cord-268140-s5lailkp	157	19	effects	effect	NNS
cord-268140-s5lailkp	157	20	in	in	IN
cord-268140-s5lailkp	157	21	varying	vary	VBG
cord-268140-s5lailkp	157	22	frequencies	frequency	NNS
cord-268140-s5lailkp	157	23	[	[	-LRB-
cord-268140-s5lailkp	157	24	40	40	CD
cord-268140-s5lailkp	157	25	]	]	-RRB-
cord-268140-s5lailkp	157	26	[	[	-LRB-
cord-268140-s5lailkp	157	27	41	41	CD
cord-268140-s5lailkp	157	28	]	]	-RRB-
cord-268140-s5lailkp	157	29	[	[	-LRB-
cord-268140-s5lailkp	157	30	42	42	CD
cord-268140-s5lailkp	157	31	]	]	-RRB-
cord-268140-s5lailkp	157	32	.	.	.
cord-268140-s5lailkp	158	1	Similar	similar	JJ
cord-268140-s5lailkp	158	2	safety	safety	NN
cord-268140-s5lailkp	158	3	concerns	concern	NNS
cord-268140-s5lailkp	158	4	exist	exist	VBP
cord-268140-s5lailkp	158	5	for	for	IN
cord-268140-s5lailkp	158	6	all	all	DT
cord-268140-s5lailkp	158	7	other	other	JJ
cord-268140-s5lailkp	158	8	so	so	RB
cord-268140-s5lailkp	158	9	-	-	HYPH
cord-268140-s5lailkp	158	10	called	call	VBN
cord-268140-s5lailkp	158	11	promising	promising	JJ
cord-268140-s5lailkp	158	12	treatment	treatment	NN
cord-268140-s5lailkp	158	13	options	option	NNS
cord-268140-s5lailkp	158	14	for	for	IN
cord-268140-s5lailkp	158	15	COVID-19	covid-19	CD
cord-268140-s5lailkp	158	16	at	at	IN
cord-268140-s5lailkp	158	17	the	the	DT
cord-268140-s5lailkp	158	18	moment	moment	NN
cord-268140-s5lailkp	158	19	,	,	,
cord-268140-s5lailkp	158	20	albeit	albeit	IN
cord-268140-s5lailkp	158	21	in	in	IN
cord-268140-s5lailkp	158	22	differing	differ	VBG
cord-268140-s5lailkp	158	23	frequencies	frequency	NNS
cord-268140-s5lailkp	158	24	and	and	CC
cord-268140-s5lailkp	158	25	severity	severity	NN
cord-268140-s5lailkp	158	26	.	.	.
cord-268140-s5lailkp	159	1	The	the	DT
cord-268140-s5lailkp	159	2	risk	risk	NN
cord-268140-s5lailkp	159	3	-	-	HYPH
cord-268140-s5lailkp	159	4	benefit	benefit	NN
cord-268140-s5lailkp	159	5	ratio	ratio	NN
cord-268140-s5lailkp	159	6	has	have	VBZ
cord-268140-s5lailkp	159	7	to	to	TO
cord-268140-s5lailkp	159	8	be	be	VB
cord-268140-s5lailkp	159	9	constantly	constantly	RB
cord-268140-s5lailkp	159	10	assessed	assess	VBN
cord-268140-s5lailkp	159	11	,	,	,
cord-268140-s5lailkp	159	12	between	between	IN
cord-268140-s5lailkp	159	13	attenuation	attenuation	NN
cord-268140-s5lailkp	159	14	of	of	IN
cord-268140-s5lailkp	159	15	life	life	NN
cord-268140-s5lailkp	159	16	-	-	HYPH
cord-268140-s5lailkp	159	17	threatening	threaten	VBG
cord-268140-s5lailkp	159	18	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	159	19	and	and	CC
cord-268140-s5lailkp	159	20	serious	serious	JJ
cord-268140-s5lailkp	159	21	risk	risk	NN
cord-268140-s5lailkp	159	22	of	of	IN
cord-268140-s5lailkp	159	23	adverse	adverse	JJ
cord-268140-s5lailkp	159	24	effects	effect	NNS
cord-268140-s5lailkp	159	25	.	.	.
cord-268140-s5lailkp	160	1	At	at	IN
cord-268140-s5lailkp	160	2	a	a	DT
cord-268140-s5lailkp	160	3	time	time	NN
cord-268140-s5lailkp	160	4	when	when	WRB
cord-268140-s5lailkp	160	5	reducing	reduce	VBG
cord-268140-s5lailkp	160	6	mortality	mortality	NN
cord-268140-s5lailkp	160	7	due	due	IN
cord-268140-s5lailkp	160	8	to	to	IN
cord-268140-s5lailkp	160	9	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	160	10	is	be	VBZ
cord-268140-s5lailkp	160	11	unquestionably	unquestionably	RB
cord-268140-s5lailkp	160	12	one	one	CD
cord-268140-s5lailkp	160	13	of	of	IN
cord-268140-s5lailkp	160	14	the	the	DT
cord-268140-s5lailkp	160	15	primary	primary	JJ
cord-268140-s5lailkp	160	16	objectives	objective	NNS
cord-268140-s5lailkp	160	17	of	of	IN
cord-268140-s5lailkp	160	18	management	management	NN
cord-268140-s5lailkp	160	19	,	,	,
cord-268140-s5lailkp	160	20	these	these	DT
cord-268140-s5lailkp	160	21	drugs	drug	NNS
cord-268140-s5lailkp	160	22	may	may	MD
cord-268140-s5lailkp	160	23	prove	prove	VB
cord-268140-s5lailkp	160	24	to	to	TO
cord-268140-s5lailkp	160	25	be	be	VB
cord-268140-s5lailkp	160	26	a	a	DT
cord-268140-s5lailkp	160	27	life	life	NN
cord-268140-s5lailkp	160	28	-	-	HYPH
cord-268140-s5lailkp	160	29	saving	save	VBG
cord-268140-s5lailkp	160	30	adjunctive	adjunctive	JJ
cord-268140-s5lailkp	160	31	treatment	treatment	NN
cord-268140-s5lailkp	160	32	option	option	NN
cord-268140-s5lailkp	160	33	on	on	IN
cord-268140-s5lailkp	160	34	the	the	DT
cord-268140-s5lailkp	160	35	basis	basis	NN
cord-268140-s5lailkp	160	36	of	of	IN
cord-268140-s5lailkp	160	37	their	-PRON-	PRP$
cord-268140-s5lailkp	160	38	mechanism	mechanism	NN
cord-268140-s5lailkp	160	39	of	of	IN
cord-268140-s5lailkp	160	40	action	action	NN
cord-268140-s5lailkp	160	41	in	in	IN
cord-268140-s5lailkp	160	42	serious	serious	JJ
cord-268140-s5lailkp	160	43	or	or	CC
cord-268140-s5lailkp	160	44	critical	critical	JJ
cord-268140-s5lailkp	160	45	cases	case	NNS
cord-268140-s5lailkp	160	46	where	where	WRB
cord-268140-s5lailkp	160	47	chosen	choose	VBN
cord-268140-s5lailkp	160	48	to	to	TO
cord-268140-s5lailkp	160	49	be	be	VB
cord-268140-s5lailkp	160	50	used	use	VBN
cord-268140-s5lailkp	160	51	judiciously	judiciously	RB
cord-268140-s5lailkp	160	52	.	.	.
cord-268140-s5lailkp	161	1	A	a	DT
cord-268140-s5lailkp	161	2	significant	significant	JJ
cord-268140-s5lailkp	161	3	barrier	barrier	NN
cord-268140-s5lailkp	161	4	that	that	WDT
cord-268140-s5lailkp	161	5	may	may	MD
cord-268140-s5lailkp	161	6	be	be	VB
cord-268140-s5lailkp	161	7	holding	hold	VBG
cord-268140-s5lailkp	161	8	them	-PRON-	PRP
cord-268140-s5lailkp	161	9	back	back	RB
cord-268140-s5lailkp	161	10	from	from	IN
cord-268140-s5lailkp	161	11	being	be	VBG
cord-268140-s5lailkp	161	12	used	use	VBN
cord-268140-s5lailkp	161	13	or	or	CC
cord-268140-s5lailkp	161	14	tested	test	VBN
cord-268140-s5lailkp	161	15	as	as	RB
cord-268140-s5lailkp	161	16	extensively	extensively	RB
cord-268140-s5lailkp	161	17	as	as	IN
cord-268140-s5lailkp	161	18	some	some	DT
cord-268140-s5lailkp	161	19	of	of	IN
cord-268140-s5lailkp	161	20	the	the	DT
cord-268140-s5lailkp	161	21	other	other	JJ
cord-268140-s5lailkp	161	22	options	option	NNS
cord-268140-s5lailkp	161	23	is	be	VBZ
cord-268140-s5lailkp	161	24	probably	probably	RB
cord-268140-s5lailkp	161	25	the	the	DT
cord-268140-s5lailkp	161	26	very	very	RB
cord-268140-s5lailkp	161	27	high	high	JJ
cord-268140-s5lailkp	161	28	cost	cost	NN
cord-268140-s5lailkp	161	29	of	of	IN
cord-268140-s5lailkp	161	30	these	these	DT
cord-268140-s5lailkp	161	31	monoclonal	monoclonal	JJ
cord-268140-s5lailkp	161	32	antibodies	antibody	NNS
cord-268140-s5lailkp	161	33	,	,	,
cord-268140-s5lailkp	161	34	which	which	WDT
cord-268140-s5lailkp	161	35	are	be	VBP
cord-268140-s5lailkp	161	36	under	under	IN
cord-268140-s5lailkp	161	37	patent	patent	NN
cord-268140-s5lailkp	161	38	protection	protection	NN
cord-268140-s5lailkp	161	39	by	by	IN
cord-268140-s5lailkp	161	40	the	the	DT
cord-268140-s5lailkp	161	41	innovator	innovator	NN
cord-268140-s5lailkp	161	42	companies	company	NNS
cord-268140-s5lailkp	161	43	.	.	.
cord-268140-s5lailkp	162	1	The	the	DT
cord-268140-s5lailkp	162	2	Average	Average	NNP
cord-268140-s5lailkp	162	3	Wholesale	Wholesale	NNP
cord-268140-s5lailkp	162	4	Price	Price	NNP
cord-268140-s5lailkp	162	5	(	(	-LRB-
cord-268140-s5lailkp	162	6	AWP	AWP	NNP
cord-268140-s5lailkp	162	7	)	)	-RRB-
cord-268140-s5lailkp	162	8	in	in	IN
cord-268140-s5lailkp	162	9	the	the	DT
cord-268140-s5lailkp	162	10	USA	USA	NNP
cord-268140-s5lailkp	162	11	,	,	,
cord-268140-s5lailkp	162	12	as	as	RB
cord-268140-s5lailkp	162	13	available	available	JJ
cord-268140-s5lailkp	162	14	on	on	IN
cord-268140-s5lailkp	162	15	the	the	DT
cord-268140-s5lailkp	162	16	web	web	NN
cord-268140-s5lailkp	162	17	,	,	,
cord-268140-s5lailkp	162	18	for	for	IN
cord-268140-s5lailkp	162	19	400	400	CD
cord-268140-s5lailkp	162	20	mg	mg	NNP
cord-268140-s5lailkp	162	21	tocilizumab	tocilizumab	NN
cord-268140-s5lailkp	162	22	and	and	CC
cord-268140-s5lailkp	162	23	200	200	CD
cord-268140-s5lailkp	162	24	mg	mg	NN
cord-268140-s5lailkp	162	25	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	162	26	,	,	,
cord-268140-s5lailkp	162	27	400	400	CD
cord-268140-s5lailkp	162	28	mg	mg	NN
cord-268140-s5lailkp	162	29	is	be	VBZ
cord-268140-s5lailkp	162	30	$	$	$
cord-268140-s5lailkp	162	31	2765	2765	CD
cord-268140-s5lailkp	162	32	and	and	CC
cord-268140-s5lailkp	162	33	$	$	$
cord-268140-s5lailkp	162	34	1831.29	1831.29	CD
cord-268140-s5lailkp	162	35	,	,	,
cord-268140-s5lailkp	162	36	respectively	respectively	RB
cord-268140-s5lailkp	162	37	[	[	-LRB-
cord-268140-s5lailkp	162	38	6	6	CD
cord-268140-s5lailkp	162	39	]	]	-RRB-
cord-268140-s5lailkp	162	40	.	.	.
cord-268140-s5lailkp	163	1	Although	although	IN
cord-268140-s5lailkp	163	2	there	there	EX
cord-268140-s5lailkp	163	3	are	be	VBP
cord-268140-s5lailkp	163	4	numerous	numerous	JJ
cord-268140-s5lailkp	163	5	RCTs	rct	NNS
cord-268140-s5lailkp	163	6	currently	currently	RB
cord-268140-s5lailkp	163	7	underway	underway	JJ
cord-268140-s5lailkp	163	8	to	to	TO
cord-268140-s5lailkp	163	9	evaluate	evaluate	VB
cord-268140-s5lailkp	163	10	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	163	11	,	,	,
cord-268140-s5lailkp	163	12	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	163	13	and	and	CC
cord-268140-s5lailkp	163	14	siltuximab	siltuximab	NNP
cord-268140-s5lailkp	163	15	,	,	,
cord-268140-s5lailkp	163	16	more	more	RBR
cord-268140-s5lailkp	163	17	urgency	urgency	NN
cord-268140-s5lailkp	163	18	and	and	CC
cord-268140-s5lailkp	163	19	focus	focus	NN
cord-268140-s5lailkp	163	20	is	be	VBZ
cord-268140-s5lailkp	163	21	deserved	deserve	VBN
cord-268140-s5lailkp	163	22	by	by	IN
cord-268140-s5lailkp	163	23	these	these	DT
cord-268140-s5lailkp	163	24	drugs	drug	NNS
cord-268140-s5lailkp	163	25	due	due	JJ
cord-268140-s5lailkp	163	26	to	to	IN
cord-268140-s5lailkp	163	27	their	-PRON-	PRP$
cord-268140-s5lailkp	163	28	potential	potential	NN
cord-268140-s5lailkp	163	29	in	in	IN
cord-268140-s5lailkp	163	30	preventing	prevent	VBG
cord-268140-s5lailkp	163	31	mortality	mortality	NN
cord-268140-s5lailkp	163	32	in	in	IN
cord-268140-s5lailkp	163	33	serious	serious	JJ
cord-268140-s5lailkp	163	34	COVID-19	covid-19	NN
cord-268140-s5lailkp	163	35	.	.	.
cord-268140-s5lailkp	164	1	There	there	EX
cord-268140-s5lailkp	164	2	are	be	VBP
cord-268140-s5lailkp	164	3	still	still	RB
cord-268140-s5lailkp	164	4	countries	country	NNS
cord-268140-s5lailkp	164	5	in	in	IN
cord-268140-s5lailkp	164	6	the	the	DT
cord-268140-s5lailkp	164	7	world	world	NN
cord-268140-s5lailkp	164	8	that	that	WDT
cord-268140-s5lailkp	164	9	are	be	VBP
cord-268140-s5lailkp	164	10	significantly	significantly	RB
cord-268140-s5lailkp	164	11	affected	affect	VBN
cord-268140-s5lailkp	164	12	by	by	IN
cord-268140-s5lailkp	164	13	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	164	14	,	,	,
cord-268140-s5lailkp	164	15	where	where	WRB
cord-268140-s5lailkp	164	16	very	very	RB
cord-268140-s5lailkp	164	17	few	few	JJ
cord-268140-s5lailkp	164	18	ongoing	ongoing	JJ
cord-268140-s5lailkp	164	19	studies	study	NNS
cord-268140-s5lailkp	164	20	on	on	IN
cord-268140-s5lailkp	164	21	IL-6	IL-6	NNP
cord-268140-s5lailkp	164	22	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	164	23	can	can	MD
cord-268140-s5lailkp	164	24	be	be	VB
cord-268140-s5lailkp	164	25	found	find	VBN
cord-268140-s5lailkp	164	26	.	.	.
cord-268140-s5lailkp	165	1	Mechanical	mechanical	JJ
cord-268140-s5lailkp	165	2	ventilators	ventilator	NNS
cord-268140-s5lailkp	165	3	,	,	,
cord-268140-s5lailkp	165	4	which	which	WDT
cord-268140-s5lailkp	165	5	have	have	VBP
cord-268140-s5lailkp	165	6	been	be	VBN
cord-268140-s5lailkp	165	7	considered	consider	VBN
cord-268140-s5lailkp	165	8	the	the	DT
cord-268140-s5lailkp	165	9	last	last	JJ
cord-268140-s5lailkp	165	10	resort	resort	NN
cord-268140-s5lailkp	165	11	in	in	IN
cord-268140-s5lailkp	165	12	the	the	DT
cord-268140-s5lailkp	165	13	treatment	treatment	NN
cord-268140-s5lailkp	165	14	protocol	protocol	NN
cord-268140-s5lailkp	165	15	of	of	IN
cord-268140-s5lailkp	165	16	critically	critically	RB
cord-268140-s5lailkp	165	17	ill	ill	JJ
cord-268140-s5lailkp	165	18	patients	patient	NNS
cord-268140-s5lailkp	165	19	,	,	,
cord-268140-s5lailkp	165	20	have	have	VBP
cord-268140-s5lailkp	165	21	high	high	JJ
cord-268140-s5lailkp	165	22	costs	cost	NNS
cord-268140-s5lailkp	165	23	and	and	CC
cord-268140-s5lailkp	165	24	availability	availability	NN
cord-268140-s5lailkp	165	25	issues	issue	NNS
cord-268140-s5lailkp	165	26	.	.	.
cord-268140-s5lailkp	166	1	A	a	DT
cord-268140-s5lailkp	166	2	growing	grow	VBG
cord-268140-s5lailkp	166	3	body	body	NN
cord-268140-s5lailkp	166	4	of	of	IN
cord-268140-s5lailkp	166	5	evidence	evidence	NN
cord-268140-s5lailkp	166	6	is	be	VBZ
cord-268140-s5lailkp	166	7	also	also	RB
cord-268140-s5lailkp	166	8	indicating	indicate	VBG
cord-268140-s5lailkp	166	9	that	that	IN
cord-268140-s5lailkp	166	10	they	-PRON-	PRP
cord-268140-s5lailkp	166	11	may	may	MD
cord-268140-s5lailkp	166	12	not	not	RB
cord-268140-s5lailkp	166	13	be	be	VB
cord-268140-s5lailkp	166	14	very	very	RB
cord-268140-s5lailkp	166	15	useful	useful	JJ
cord-268140-s5lailkp	166	16	in	in	IN
cord-268140-s5lailkp	166	17	preventing	prevent	VBG
cord-268140-s5lailkp	166	18	mortality	mortality	NN
cord-268140-s5lailkp	166	19	in	in	IN
cord-268140-s5lailkp	166	20	serious	serious	JJ
cord-268140-s5lailkp	166	21	patients	patient	NNS
cord-268140-s5lailkp	166	22	,	,	,
cord-268140-s5lailkp	166	23	with	with	IN
cord-268140-s5lailkp	166	24	multiple	multiple	JJ
cord-268140-s5lailkp	166	25	reports	report	NNS
cord-268140-s5lailkp	166	26	suggesting	suggest	VBG
cord-268140-s5lailkp	166	27	overuse	overuse	NN
cord-268140-s5lailkp	166	28	of	of	IN
cord-268140-s5lailkp	166	29	ventilators	ventilator	NNS
cord-268140-s5lailkp	166	30	without	without	IN
cord-268140-s5lailkp	166	31	much	much	JJ
cord-268140-s5lailkp	166	32	benefit	benefit	NN
cord-268140-s5lailkp	166	33	and	and	CC
cord-268140-s5lailkp	166	34	increase	increase	NN
cord-268140-s5lailkp	166	35	in	in	IN
cord-268140-s5lailkp	166	36	harm	harm	NN
cord-268140-s5lailkp	166	37	[	[	-LRB-
cord-268140-s5lailkp	166	38	64	64	CD
cord-268140-s5lailkp	166	39	]	]	-RRB-
cord-268140-s5lailkp	166	40	.	.	.
cord-268140-s5lailkp	167	1	There	there	EX
cord-268140-s5lailkp	167	2	is	be	VBZ
cord-268140-s5lailkp	167	3	perhaps	perhaps	RB
cord-268140-s5lailkp	167	4	a	a	DT
cord-268140-s5lailkp	167	5	need	need	NN
cord-268140-s5lailkp	167	6	to	to	TO
cord-268140-s5lailkp	167	7	divert	divert	VB
cord-268140-s5lailkp	167	8	some	some	DT
cord-268140-s5lailkp	167	9	of	of	IN
cord-268140-s5lailkp	167	10	those	those	DT
cord-268140-s5lailkp	167	11	resources	resource	NNS
cord-268140-s5lailkp	167	12	to	to	TO
cord-268140-s5lailkp	167	13	procure	procure	VB
cord-268140-s5lailkp	167	14	these	these	DT
cord-268140-s5lailkp	167	15	drugs	drug	NNS
cord-268140-s5lailkp	167	16	for	for	IN
cord-268140-s5lailkp	167	17	wider	wide	JJR
cord-268140-s5lailkp	167	18	use	use	NN
cord-268140-s5lailkp	167	19	in	in	IN
cord-268140-s5lailkp	167	20	eligible	eligible	JJ
cord-268140-s5lailkp	167	21	critically	critically	RB
cord-268140-s5lailkp	167	22	ill	ill	JJ
cord-268140-s5lailkp	167	23	patients	patient	NNS
cord-268140-s5lailkp	167	24	.	.	.
cord-268140-s5lailkp	168	1	The	the	DT
cord-268140-s5lailkp	168	2	innovator	innovator	NN
cord-268140-s5lailkp	168	3	companies	company	NNS
cord-268140-s5lailkp	168	4	can	can	MD
cord-268140-s5lailkp	168	5	also	also	RB
cord-268140-s5lailkp	168	6	contribute	contribute	VB
cord-268140-s5lailkp	168	7	during	during	IN
cord-268140-s5lailkp	168	8	these	these	DT
cord-268140-s5lailkp	168	9	desperate	desperate	JJ
cord-268140-s5lailkp	168	10	times	time	NNS
cord-268140-s5lailkp	168	11	for	for	IN
cord-268140-s5lailkp	168	12	humanity	humanity	NN
cord-268140-s5lailkp	168	13	,	,	,
cord-268140-s5lailkp	168	14	by	by	IN
cord-268140-s5lailkp	168	15	making	make	VBG
cord-268140-s5lailkp	168	16	these	these	DT
cord-268140-s5lailkp	168	17	molecules	molecule	NNS
cord-268140-s5lailkp	168	18	available	available	JJ
cord-268140-s5lailkp	168	19	at	at	IN
cord-268140-s5lailkp	168	20	lowest	low	JJS
cord-268140-s5lailkp	168	21	possible	possible	JJ
cord-268140-s5lailkp	168	22	prices	price	NNS
cord-268140-s5lailkp	168	23	,	,	,
cord-268140-s5lailkp	168	24	thus	thus	RB
cord-268140-s5lailkp	168	25	allowing	allow	VBG
cord-268140-s5lailkp	168	26	more	more	JJR
cord-268140-s5lailkp	168	27	off	off	IN
cord-268140-s5lailkp	168	28	-	-	HYPH
cord-268140-s5lailkp	168	29	label	label	NN
cord-268140-s5lailkp	168	30	use	use	NN
cord-268140-s5lailkp	168	31	of	of	IN
cord-268140-s5lailkp	168	32	these	these	DT
cord-268140-s5lailkp	168	33	drugs	drug	NNS
cord-268140-s5lailkp	168	34	,	,	,
cord-268140-s5lailkp	168	35	thereby	thereby	RB
cord-268140-s5lailkp	168	36	generating	generate	VBG
cord-268140-s5lailkp	168	37	more	more	RBR
cord-268140-s5lailkp	168	38	preliminary	preliminary	JJ
cord-268140-s5lailkp	168	39	anecdotal	anecdotal	JJ
cord-268140-s5lailkp	168	40	and	and	CC
cord-268140-s5lailkp	168	41	scientific	scientific	JJ
cord-268140-s5lailkp	168	42	evidence	evidence	NN
cord-268140-s5lailkp	168	43	.	.	.
cord-268140-s5lailkp	169	1	To	to	TO
cord-268140-s5lailkp	169	2	conclude	conclude	VB
cord-268140-s5lailkp	169	3	,	,	,
cord-268140-s5lailkp	169	4	it	-PRON-	PRP
cord-268140-s5lailkp	169	5	seems	seem	VBZ
cord-268140-s5lailkp	169	6	that	that	IN
cord-268140-s5lailkp	169	7	in	in	IN
cord-268140-s5lailkp	169	8	the	the	DT
cord-268140-s5lailkp	169	9	race	race	NN
cord-268140-s5lailkp	169	10	for	for	IN
cord-268140-s5lailkp	169	11	a	a	DT
cord-268140-s5lailkp	169	12	successful	successful	JJ
cord-268140-s5lailkp	169	13	antiviral	antiviral	JJ
cord-268140-s5lailkp	169	14	treatment	treatment	NN
cord-268140-s5lailkp	169	15	for	for	IN
cord-268140-s5lailkp	169	16	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	169	17	,	,	,
cord-268140-s5lailkp	169	18	anti	anti	JJ
cord-268140-s5lailkp	169	19	-	-	JJ
cord-268140-s5lailkp	169	20	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	169	21	,	,	,
cord-268140-s5lailkp	169	22	immunomodulatory	immunomodulatory	JJ
cord-268140-s5lailkp	169	23	approaches	approach	NNS
cord-268140-s5lailkp	169	24	for	for	IN
cord-268140-s5lailkp	169	25	the	the	DT
cord-268140-s5lailkp	169	26	serious	serious	JJ
cord-268140-s5lailkp	169	27	patients	patient	NNS
cord-268140-s5lailkp	169	28	are	be	VBP
cord-268140-s5lailkp	169	29	now	now	RB
cord-268140-s5lailkp	169	30	being	be	VBG
cord-268140-s5lailkp	169	31	increasingly	increasingly	RB
cord-268140-s5lailkp	169	32	explored	explore	VBN
cord-268140-s5lailkp	169	33	,	,	,
cord-268140-s5lailkp	169	34	but	but	CC
cord-268140-s5lailkp	169	35	more	more	JJR
cord-268140-s5lailkp	169	36	evidence	evidence	NN
cord-268140-s5lailkp	169	37	remains	remain	VBZ
cord-268140-s5lailkp	169	38	to	to	TO
cord-268140-s5lailkp	169	39	be	be	VB
cord-268140-s5lailkp	169	40	generated	generate	VBN
cord-268140-s5lailkp	169	41	.	.	.
cord-268140-s5lailkp	170	1	The	the	DT
cord-268140-s5lailkp	170	2	IL-6	IL-6	NNP
cord-268140-s5lailkp	170	3	inhibitor	inhibitor	NN
cord-268140-s5lailkp	170	4	drugs	drug	NNS
cord-268140-s5lailkp	170	5	belong	belong	VBP
cord-268140-s5lailkp	170	6	to	to	IN
cord-268140-s5lailkp	170	7	this	this	DT
cord-268140-s5lailkp	170	8	category	category	NN
cord-268140-s5lailkp	170	9	of	of	IN
cord-268140-s5lailkp	170	10	treatment	treatment	NN
cord-268140-s5lailkp	170	11	options	option	NNS
cord-268140-s5lailkp	170	12	,	,	,
cord-268140-s5lailkp	170	13	available	available	JJ
cord-268140-s5lailkp	170	14	at	at	IN
cord-268140-s5lailkp	170	15	hand	hand	NN
cord-268140-s5lailkp	170	16	,	,	,
cord-268140-s5lailkp	170	17	yet	yet	CC
cord-268140-s5lailkp	170	18	whose	whose	WP$
cord-268140-s5lailkp	170	19	potential	potential	NN
cord-268140-s5lailkp	170	20	has	have	VBZ
cord-268140-s5lailkp	170	21	perhaps	perhaps	RB
cord-268140-s5lailkp	170	22	not	not	RB
cord-268140-s5lailkp	170	23	been	be	VBN
cord-268140-s5lailkp	170	24	fully	fully	RB
cord-268140-s5lailkp	170	25	assessed	assess	VBN
cord-268140-s5lailkp	170	26	and	and	CC
cord-268140-s5lailkp	170	27	understood	understand	VBN
cord-268140-s5lailkp	170	28	,	,	,
cord-268140-s5lailkp	170	29	with	with	IN
cord-268140-s5lailkp	170	30	clinical	clinical	JJ
cord-268140-s5lailkp	170	31	trials	trial	NNS
cord-268140-s5lailkp	170	32	still	still	RB
cord-268140-s5lailkp	170	33	limited	limited	JJ
cord-268140-s5lailkp	170	34	to	to	IN
cord-268140-s5lailkp	170	35	a	a	DT
cord-268140-s5lailkp	170	36	few	few	JJ
cord-268140-s5lailkp	170	37	countries	country	NNS
cord-268140-s5lailkp	170	38	.	.	.
cord-268140-s5lailkp	171	1	With	with	IN
cord-268140-s5lailkp	171	2	the	the	DT
cord-268140-s5lailkp	171	3	strong	strong	JJ
cord-268140-s5lailkp	171	4	rationale	rationale	NN
cord-268140-s5lailkp	171	5	for	for	IN
cord-268140-s5lailkp	171	6	their	-PRON-	PRP$
cord-268140-s5lailkp	171	7	use	use	NN
cord-268140-s5lailkp	171	8	in	in	IN
cord-268140-s5lailkp	171	9	serious	serious	JJ
cord-268140-s5lailkp	171	10	or	or	CC
cord-268140-s5lailkp	171	11	critically	critically	RB
cord-268140-s5lailkp	171	12	ill	ill	RB
cord-268140-s5lailkp	171	13	COVID-19	covid-19	JJ
cord-268140-s5lailkp	171	14	patients	patient	NNS
cord-268140-s5lailkp	171	15	with	with	IN
cord-268140-s5lailkp	171	16	predominant	predominant	JJ
cord-268140-s5lailkp	171	17	pulmonary	pulmonary	JJ
cord-268140-s5lailkp	171	18	involvement	involvement	NN
cord-268140-s5lailkp	171	19	,	,	,
cord-268140-s5lailkp	171	20	and	and	CC
cord-268140-s5lailkp	171	21	features	feature	NNS
cord-268140-s5lailkp	171	22	of	of	IN
cord-268140-s5lailkp	171	23	hyperinflammation	hyperinflammation	NN
cord-268140-s5lailkp	171	24	,	,	,
cord-268140-s5lailkp	171	25	it	-PRON-	PRP
cord-268140-s5lailkp	171	26	may	may	MD
cord-268140-s5lailkp	171	27	be	be	VB
cord-268140-s5lailkp	171	28	very	very	RB
cord-268140-s5lailkp	171	29	useful	useful	JJ
cord-268140-s5lailkp	171	30	to	to	TO
cord-268140-s5lailkp	171	31	widely	widely	RB
cord-268140-s5lailkp	171	32	explore	explore	VB
cord-268140-s5lailkp	171	33	IL-6	IL-6	NNP
cord-268140-s5lailkp	171	34	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	171	35	as	as	IN
cord-268140-s5lailkp	171	36	treatment	treatment	NN
cord-268140-s5lailkp	171	37	options	option	NNS
cord-268140-s5lailkp	171	38	in	in	IN
cord-268140-s5lailkp	171	39	clinical	clinical	JJ
cord-268140-s5lailkp	171	40	settings	setting	NNS
cord-268140-s5lailkp	171	41	for	for	IN
cord-268140-s5lailkp	171	42	serious	serious	JJ
cord-268140-s5lailkp	171	43	COVID-19	covid-19	NN
cord-268140-s5lailkp	171	44	,	,	,
cord-268140-s5lailkp	171	45	and	and	CC
cord-268140-s5lailkp	171	46	have	have	VBP
cord-268140-s5lailkp	171	47	more	more	RBR
cord-268140-s5lailkp	171	48	rigorous	rigorous	JJ
cord-268140-s5lailkp	171	49	systematic	systematic	JJ
cord-268140-s5lailkp	171	50	evaluation	evaluation	NN
cord-268140-s5lailkp	171	51	through	through	IN
cord-268140-s5lailkp	171	52	scientific	scientific	JJ
cord-268140-s5lailkp	171	53	studies	study	NNS
cord-268140-s5lailkp	171	54	.	.	.
cord-268140-s5lailkp	172	1	In	in	IN
cord-268140-s5lailkp	172	2	the	the	DT
cord-268140-s5lailkp	172	3	fight	fight	NN
cord-268140-s5lailkp	172	4	against	against	IN
cord-268140-s5lailkp	172	5	the	the	DT
cord-268140-s5lailkp	172	6	highly	highly	RB
cord-268140-s5lailkp	172	7	transmissible	transmissible	JJ
cord-268140-s5lailkp	172	8	and	and	CC
cord-268140-s5lailkp	172	9	deadly	deadly	JJ
cord-268140-s5lailkp	172	10	SARS	SARS	NNP
cord-268140-s5lailkp	172	11	-	-	HYPH
cord-268140-s5lailkp	172	12	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	172	13	causing	cause	VBG
cord-268140-s5lailkp	172	14	COVID-19	covid-19	CD
cord-268140-s5lailkp	172	15	,	,	,
cord-268140-s5lailkp	172	16	these	these	DT
cord-268140-s5lailkp	172	17	drugs	drug	NNS
cord-268140-s5lailkp	172	18	can	can	MD
cord-268140-s5lailkp	172	19	help	help	VB
cord-268140-s5lailkp	172	20	save	save	VB
cord-268140-s5lailkp	172	21	lives	life	NNS
cord-268140-s5lailkp	172	22	if	if	IN
cord-268140-s5lailkp	172	23	used	use	VBN
cord-268140-s5lailkp	172	24	judiciously	judiciously	RB
cord-268140-s5lailkp	172	25	in	in	IN
cord-268140-s5lailkp	172	26	appropriate	appropriate	JJ
cord-268140-s5lailkp	172	27	cases	case	NNS
cord-268140-s5lailkp	172	28	.	.	.
cord-268140-s5lailkp	173	1	Author	author	NN
cord-268140-s5lailkp	173	2	contributions	contribution	NNS
cord-268140-s5lailkp	174	1	Both	both	DT
cord-268140-s5lailkp	174	2	the	the	DT
cord-268140-s5lailkp	174	3	authors	author	NNS
cord-268140-s5lailkp	174	4	have	have	VBP
cord-268140-s5lailkp	174	5	contributed	contribute	VBN
cord-268140-s5lailkp	174	6	to	to	IN
cord-268140-s5lailkp	174	7	the	the	DT
cord-268140-s5lailkp	174	8	conception	conception	NN
cord-268140-s5lailkp	174	9	,	,	,
cord-268140-s5lailkp	174	10	literature	literature	NN
cord-268140-s5lailkp	174	11	review	review	NN
cord-268140-s5lailkp	174	12	,	,	,
cord-268140-s5lailkp	174	13	drafting	drafting	NN
cord-268140-s5lailkp	174	14	,	,	,
cord-268140-s5lailkp	174	15	review	review	NN
cord-268140-s5lailkp	174	16	and	and	CC
cord-268140-s5lailkp	174	17	finalization	finalization	NN
cord-268140-s5lailkp	174	18	of	of	IN
cord-268140-s5lailkp	174	19	the	the	DT
cord-268140-s5lailkp	174	20	work	work	NN
cord-268140-s5lailkp	174	21	.	.	.
cord-268140-s5lailkp	175	1	Case	case	NN
cord-268140-s5lailkp	175	2	-	-	HYPH
cord-268140-s5lailkp	175	3	fatality	fatality	NN
cord-268140-s5lailkp	175	4	rate	rate	NN
cord-268140-s5lailkp	175	5	and	and	CC
cord-268140-s5lailkp	175	6	characteristics	characteristic	NNS
cord-268140-s5lailkp	175	7	of	of	IN
cord-268140-s5lailkp	175	8	patients	patient	NNS
cord-268140-s5lailkp	175	9	dying	die	VBG
cord-268140-s5lailkp	175	10	in	in	IN
cord-268140-s5lailkp	175	11	relation	relation	NN
cord-268140-s5lailkp	175	12	to	to	IN
cord-268140-s5lailkp	175	13	COVID-19	covid-19	VB
cord-268140-s5lailkp	175	14	in	in	IN
cord-268140-s5lailkp	175	15	Italy	Italy	NNP
cord-268140-s5lailkp	175	16	Clinical	clinical	JJ
cord-268140-s5lailkp	175	17	predictors	predictor	NNS
cord-268140-s5lailkp	175	18	of	of	IN
cord-268140-s5lailkp	175	19	mortality	mortality	NN
cord-268140-s5lailkp	175	20	due	due	IN
cord-268140-s5lailkp	175	21	to	to	IN
cord-268140-s5lailkp	175	22	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	175	23	based	base	VBN
cord-268140-s5lailkp	175	24	on	on	IN
cord-268140-s5lailkp	175	25	an	an	DT
cord-268140-s5lailkp	175	26	analysis	analysis	NN
cord-268140-s5lailkp	175	27	of	of	IN
cord-268140-s5lailkp	175	28	data	datum	NNS
cord-268140-s5lailkp	175	29	of	of	IN
cord-268140-s5lailkp	175	30	150	150	CD
cord-268140-s5lailkp	175	31	patients	patient	NNS
cord-268140-s5lailkp	175	32	from	from	IN
cord-268140-s5lailkp	175	33	Wuhan	Wuhan	NNP
cord-268140-s5lailkp	175	34	,	,	,
cord-268140-s5lailkp	175	35	China	China	NNP
cord-268140-s5lailkp	175	36	.	.	.
cord-268140-s5lailkp	176	1	Intensive	intensive	JJ
cord-268140-s5lailkp	176	2	Care	care	NN
cord-268140-s5lailkp	176	3	Med	Med	NNP
cord-268140-s5lailkp	177	1	How	how	WRB
cord-268140-s5lailkp	177	2	to	to	TO
cord-268140-s5lailkp	177	3	reduce	reduce	VB
cord-268140-s5lailkp	177	4	the	the	DT
cord-268140-s5lailkp	177	5	likelihood	likelihood	NN
cord-268140-s5lailkp	177	6	of	of	IN
cord-268140-s5lailkp	177	7	coronavirus-19	coronavirus-19	NNP
cord-268140-s5lailkp	177	8	(	(	-LRB-
cord-268140-s5lailkp	177	9	CoV-19	CoV-19	NNP
cord-268140-s5lailkp	177	10	or	or	CC
cord-268140-s5lailkp	177	11	SARS	SARS	NNP
cord-268140-s5lailkp	177	12	-	-	HYPH
cord-268140-s5lailkp	177	13	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	177	14	)	)	-RRB-
cord-268140-s5lailkp	177	15	infection	infection	NN
cord-268140-s5lailkp	177	16	and	and	CC
cord-268140-s5lailkp	177	17	lung	lung	NN
cord-268140-s5lailkp	177	18	inflammation	inflammation	NN
cord-268140-s5lailkp	177	19	mediated	mediate	VBN
cord-268140-s5lailkp	177	20	by	by	IN
cord-268140-s5lailkp	178	1	IL-1	IL-1	NNP
cord-268140-s5lailkp	178	2	Coronavirus	Coronavirus	NNP
cord-268140-s5lailkp	178	3	COV-19	COV-19	NNP
cord-268140-s5lailkp	178	4	/	/	SYM
cord-268140-s5lailkp	178	5	SARS	SARS	NNP
cord-268140-s5lailkp	178	6	-	-	HYPH
cord-268140-s5lailkp	178	7	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	178	8	affects	affect	VBZ
cord-268140-s5lailkp	178	9	women	woman	NNS
cord-268140-s5lailkp	178	10	less	less	JJR
cord-268140-s5lailkp	178	11	than	than	IN
cord-268140-s5lailkp	178	12	men	man	NNS
cord-268140-s5lailkp	178	13	:	:	:
cord-268140-s5lailkp	178	14	clinical	clinical	JJ
cord-268140-s5lailkp	178	15	response	response	NN
cord-268140-s5lailkp	178	16	to	to	IN
cord-268140-s5lailkp	178	17	viral	viral	JJ
cord-268140-s5lailkp	178	18	infection	infection	NN
cord-268140-s5lailkp	178	19	Coronavirus	Coronavirus	NNP
cord-268140-s5lailkp	178	20	Disease	Disease	NNP
cord-268140-s5lailkp	178	21	2019	2019	CD
cord-268140-s5lailkp	178	22	(	(	-LRB-
cord-268140-s5lailkp	178	23	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	178	24	)	)	-RRB-
cord-268140-s5lailkp	178	25	Treatment	Treatment	NNP
cord-268140-s5lailkp	178	26	&	&	CC
cord-268140-s5lailkp	178	27	Management	Management	NNP
cord-268140-s5lailkp	178	28	.	.	.
cord-268140-s5lailkp	179	1	Updated	update	VBN
cord-268140-s5lailkp	179	2	.	.	.
cord-268140-s5lailkp	180	1	2020	2020	CD
cord-268140-s5lailkp	181	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-268140-s5lailkp	181	2	or	or	CC
cord-268140-s5lailkp	181	3	chloroquine	chloroquine	NN
cord-268140-s5lailkp	181	4	with	with	IN
cord-268140-s5lailkp	181	5	or	or	CC
cord-268140-s5lailkp	181	6	without	without	IN
cord-268140-s5lailkp	181	7	a	a	DT
cord-268140-s5lailkp	181	8	macrolide	macrolide	NN
cord-268140-s5lailkp	181	9	for	for	IN
cord-268140-s5lailkp	181	10	treatment	treatment	NN
cord-268140-s5lailkp	181	11	of	of	IN
cord-268140-s5lailkp	181	12	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	181	13	:	:	:
cord-268140-s5lailkp	181	14	a	a	DT
cord-268140-s5lailkp	181	15	multinational	multinational	JJ
cord-268140-s5lailkp	181	16	registry	registry	NN
cord-268140-s5lailkp	181	17	analysis	analysis	NN
cord-268140-s5lailkp	181	18	Remdesivir	Remdesivir	NNP
cord-268140-s5lailkp	181	19	for	for	IN
cord-268140-s5lailkp	181	20	the	the	DT
cord-268140-s5lailkp	181	21	treatment	treatment	NN
cord-268140-s5lailkp	181	22	of	of	IN
cord-268140-s5lailkp	181	23	COVID-19-a	COVID-19-a	NNP
cord-268140-s5lailkp	181	24	preliminary	preliminary	JJ
cord-268140-s5lailkp	181	25	report	report	NN
cord-268140-s5lailkp	182	1	WHO	who	WP
cord-268140-s5lailkp	182	2	Director	Director	NNP
cord-268140-s5lailkp	182	3	-	-	HYPH
cord-268140-s5lailkp	182	4	General	General	NNP
cord-268140-s5lailkp	182	5	'	'	POS
cord-268140-s5lailkp	182	6	opening	opening	NN
cord-268140-s5lailkp	182	7	remarks	remark	NNS
cord-268140-s5lailkp	182	8	at	at	IN
cord-268140-s5lailkp	182	9	the	the	DT
cord-268140-s5lailkp	182	10	media	medium	NNS
cord-268140-s5lailkp	182	11	briefing	briefing	NN
cord-268140-s5lailkp	182	12	on	on	IN
cord-268140-s5lailkp	182	13	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	182	14	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	182	15	)	)	-RRB-
cord-268140-s5lailkp	182	16	treatment	treatment	NN
cord-268140-s5lailkp	182	17	guidelines	guideline	NNS
cord-268140-s5lailkp	182	18	Infectious	Infectious	NNP
cord-268140-s5lailkp	182	19	Diseases	Diseases	NNPS
cord-268140-s5lailkp	182	20	Society	Society	NNP
cord-268140-s5lailkp	182	21	of	of	IN
cord-268140-s5lailkp	182	22	America	America	NNP
cord-268140-s5lailkp	182	23	guidelines	guideline	NNS
cord-268140-s5lailkp	182	24	on	on	IN
cord-268140-s5lailkp	182	25	the	the	DT
cord-268140-s5lailkp	182	26	treatment	treatment	NN
cord-268140-s5lailkp	182	27	and	and	CC
cord-268140-s5lailkp	182	28	management	management	NN
cord-268140-s5lailkp	182	29	of	of	IN
cord-268140-s5lailkp	182	30	patients	patient	NNS
cord-268140-s5lailkp	182	31	with	with	IN
cord-268140-s5lailkp	182	32	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	182	33	Clinical	clinical	JJ
cord-268140-s5lailkp	182	34	management	management	NN
cord-268140-s5lailkp	182	35	of	of	IN
cord-268140-s5lailkp	182	36	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	182	37	INTERIM	INTERIM	NNP
cord-268140-s5lailkp	182	38	GUIDANCE	GUIDANCE	NNP
cord-268140-s5lailkp	182	39	ACE2	ACE2	NNP
cord-268140-s5lailkp	182	40	receptor	receptor	NN
cord-268140-s5lailkp	182	41	expression	expression	NN
cord-268140-s5lailkp	182	42	and	and	CC
cord-268140-s5lailkp	182	43	severe	severe	JJ
cord-268140-s5lailkp	182	44	acute	acute	JJ
cord-268140-s5lailkp	182	45	respiratory	respiratory	JJ
cord-268140-s5lailkp	182	46	syndrome	syndrome	NN
cord-268140-s5lailkp	182	47	coronavirus	coronavirus	NN
cord-268140-s5lailkp	182	48	infection	infection	NN
cord-268140-s5lailkp	182	49	depend	depend	VBP
cord-268140-s5lailkp	182	50	on	on	IN
cord-268140-s5lailkp	182	51	differentiation	differentiation	NN
cord-268140-s5lailkp	182	52	of	of	IN
cord-268140-s5lailkp	182	53	human	human	JJ
cord-268140-s5lailkp	182	54	airway	airway	NN
cord-268140-s5lailkp	182	55	epithelia	epithelium	NNS
cord-268140-s5lailkp	182	56	High	high	JJ
cord-268140-s5lailkp	182	57	expression	expression	NN
cord-268140-s5lailkp	182	58	of	of	IN
cord-268140-s5lailkp	182	59	ACE2	ACE2	NNP
cord-268140-s5lailkp	182	60	receptor	receptor	NN
cord-268140-s5lailkp	182	61	of	of	IN
cord-268140-s5lailkp	182	62	2019-nCoV	2019-ncov	CD
cord-268140-s5lailkp	182	63	on	on	IN
cord-268140-s5lailkp	182	64	the	the	DT
cord-268140-s5lailkp	182	65	epithelial	epithelial	JJ
cord-268140-s5lailkp	182	66	cells	cell	NNS
cord-268140-s5lailkp	182	67	of	of	IN
cord-268140-s5lailkp	182	68	oral	oral	JJ
cord-268140-s5lailkp	182	69	mucosa	mucosa	NN
cord-268140-s5lailkp	182	70	Tissue	tissue	NN
cord-268140-s5lailkp	182	71	distribution	distribution	NN
cord-268140-s5lailkp	182	72	of	of	IN
cord-268140-s5lailkp	182	73	ACE2	ACE2	NNP
cord-268140-s5lailkp	182	74	protein	protein	NN
cord-268140-s5lailkp	182	75	,	,	,
cord-268140-s5lailkp	182	76	the	the	DT
cord-268140-s5lailkp	182	77	functional	functional	JJ
cord-268140-s5lailkp	182	78	receptor	receptor	NN
cord-268140-s5lailkp	182	79	for	for	IN
cord-268140-s5lailkp	182	80	SARS	SARS	NNP
cord-268140-s5lailkp	182	81	coronavirus	coronavirus	NN
cord-268140-s5lailkp	182	82	.	.	.
cord-268140-s5lailkp	183	1	A	a	DT
cord-268140-s5lailkp	183	2	first	first	JJ
cord-268140-s5lailkp	183	3	step	step	NN
cord-268140-s5lailkp	183	4	in	in	IN
cord-268140-s5lailkp	183	5	understanding	understand	VBG
cord-268140-s5lailkp	183	6	SARS	SARS	NNP
cord-268140-s5lailkp	183	7	pathogenesis	pathogenesis	NN
cord-268140-s5lailkp	183	8	Angiotensin	Angiotensin	NNP
cord-268140-s5lailkp	183	9	-	-	HYPH
cord-268140-s5lailkp	183	10	converting	convert	VBG
cord-268140-s5lailkp	183	11	enzyme	enzyme	NN
cord-268140-s5lailkp	183	12	2	2	CD
cord-268140-s5lailkp	183	13	protects	protect	VBZ
cord-268140-s5lailkp	183	14	from	from	IN
cord-268140-s5lailkp	183	15	severe	severe	JJ
cord-268140-s5lailkp	183	16	acute	acute	JJ
cord-268140-s5lailkp	183	17	lung	lung	NN
cord-268140-s5lailkp	183	18	failure	failure	NN
cord-268140-s5lailkp	184	1	The	the	DT
cord-268140-s5lailkp	184	2	discovery	discovery	NN
cord-268140-s5lailkp	184	3	of	of	IN
cord-268140-s5lailkp	184	4	angiotensinconverting	angiotensinconverte	VBG
cord-268140-s5lailkp	184	5	enzyme	enzyme	NN
cord-268140-s5lailkp	184	6	2	2	CD
cord-268140-s5lailkp	184	7	and	and	CC
cord-268140-s5lailkp	184	8	its	-PRON-	PRP$
cord-268140-s5lailkp	184	9	role	role	NN
cord-268140-s5lailkp	184	10	in	in	IN
cord-268140-s5lailkp	184	11	acute	acute	JJ
cord-268140-s5lailkp	184	12	lung	lung	NN
cord-268140-s5lailkp	184	13	injury	injury	NN
cord-268140-s5lailkp	184	14	in	in	IN
cord-268140-s5lailkp	184	15	mice	mouse	NNS
cord-268140-s5lailkp	185	1	A	a	DT
cord-268140-s5lailkp	185	2	crucial	crucial	JJ
cord-268140-s5lailkp	185	3	role	role	NN
cord-268140-s5lailkp	185	4	of	of	IN
cord-268140-s5lailkp	185	5	angiotensin	angiotensin	NN
cord-268140-s5lailkp	185	6	converting	convert	VBG
cord-268140-s5lailkp	185	7	enzyme	enzyme	NN
cord-268140-s5lailkp	185	8	2	2	CD
cord-268140-s5lailkp	185	9	(	(	-LRB-
cord-268140-s5lailkp	185	10	ACE2	ACE2	NNP
cord-268140-s5lailkp	185	11	)	)	-RRB-
cord-268140-s5lailkp	185	12	in	in	IN
cord-268140-s5lailkp	185	13	SARS	SARS	NNP
cord-268140-s5lailkp	185	14	coronavirus	coronavirus	NN
cord-268140-s5lailkp	185	15	-	-	HYPH
cord-268140-s5lailkp	185	16	induced	induce	VBN
cord-268140-s5lailkp	185	17	lung	lung	NN
cord-268140-s5lailkp	185	18	injury	injury	NN
cord-268140-s5lailkp	185	19	Angiotensin	Angiotensin	NNP
cord-268140-s5lailkp	185	20	-	-	HYPH
cord-268140-s5lailkp	185	21	converting	convert	VBG
cord-268140-s5lailkp	185	22	enzyme	enzyme	NN
cord-268140-s5lailkp	185	23	2	2	CD
cord-268140-s5lailkp	185	24	in	in	IN
cord-268140-s5lailkp	185	25	lung	lung	NN
cord-268140-s5lailkp	185	26	diseases	disease	NNS
cord-268140-s5lailkp	185	27	Histopathologic	Histopathologic	NNP
cord-268140-s5lailkp	185	28	changes	change	NNS
cord-268140-s5lailkp	185	29	and	and	CC
cord-268140-s5lailkp	185	30	SARS	SARS	NNP
cord-268140-s5lailkp	185	31	-	-	HYPH
cord-268140-s5lailkp	185	32	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	185	33	immunostaining	immunostaining	NN
cord-268140-s5lailkp	185	34	in	in	IN
cord-268140-s5lailkp	185	35	the	the	DT
cord-268140-s5lailkp	185	36	lung	lung	NN
cord-268140-s5lailkp	185	37	of	of	IN
cord-268140-s5lailkp	185	38	a	a	DT
cord-268140-s5lailkp	185	39	patient	patient	NN
cord-268140-s5lailkp	185	40	with	with	IN
cord-268140-s5lailkp	185	41	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	185	42	Severe	severe	JJ
cord-268140-s5lailkp	185	43	acute	acute	JJ
cord-268140-s5lailkp	185	44	respiratory	respiratory	JJ
cord-268140-s5lailkp	185	45	syndrome	syndrome	NN
cord-268140-s5lailkp	185	46	coronavirus	coronavirus	NN
cord-268140-s5lailkp	185	47	viroporin	viroporin	NNP
cord-268140-s5lailkp	185	48	3a	3a	NNP
cord-268140-s5lailkp	185	49	activates	activate	VBZ
cord-268140-s5lailkp	185	50	the	the	DT
cord-268140-s5lailkp	185	51	NLRP3	NLRP3	NNP
cord-268140-s5lailkp	185	52	inflammasome	inflammasome	NNP
cord-268140-s5lailkp	185	53	.	.	.
cord-268140-s5lailkp	186	1	Front	Front	NNP
cord-268140-s5lailkp	186	2	Microbiol	Microbiol	NNP
cord-268140-s5lailkp	186	3	Cell	Cell	NNP
cord-268140-s5lailkp	186	4	pyroptosis	pyroptosis	NN
cord-268140-s5lailkp	186	5	,	,	,
cord-268140-s5lailkp	186	6	a	a	DT
cord-268140-s5lailkp	186	7	potential	potential	JJ
cord-268140-s5lailkp	186	8	pathogenic	pathogenic	JJ
cord-268140-s5lailkp	186	9	mechanism	mechanism	NN
cord-268140-s5lailkp	186	10	of	of	IN
cord-268140-s5lailkp	186	11	2019-nCoV	2019-ncov	CD
cord-268140-s5lailkp	186	12	infection	infection	NN
cord-268140-s5lailkp	186	13	Clinical	clinical	JJ
cord-268140-s5lailkp	186	14	features	feature	NNS
cord-268140-s5lailkp	186	15	of	of	IN
cord-268140-s5lailkp	186	16	patients	patient	NNS
cord-268140-s5lailkp	186	17	infected	infect	VBN
cord-268140-s5lailkp	186	18	with	with	IN
cord-268140-s5lailkp	186	19	2019	2019	CD
cord-268140-s5lailkp	186	20	novel	novel	JJ
cord-268140-s5lailkp	186	21	coronavirus	coronavirus	NN
cord-268140-s5lailkp	186	22	in	in	IN
cord-268140-s5lailkp	186	23	Wuhan	Wuhan	NNP
cord-268140-s5lailkp	186	24	Pathological	Pathological	NNP
cord-268140-s5lailkp	186	25	findings	finding	NNS
cord-268140-s5lailkp	186	26	of	of	IN
cord-268140-s5lailkp	186	27	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	186	28	associated	associate	VBN
cord-268140-s5lailkp	186	29	with	with	IN
cord-268140-s5lailkp	186	30	acute	acute	JJ
cord-268140-s5lailkp	186	31	respiratory	respiratory	JJ
cord-268140-s5lailkp	186	32	distress	distress	NN
cord-268140-s5lailkp	186	33	syndrome	syndrome	NN
cord-268140-s5lailkp	186	34	Pulmonary	pulmonary	JJ
cord-268140-s5lailkp	186	35	pathology	pathology	NN
cord-268140-s5lailkp	186	36	of	of	IN
cord-268140-s5lailkp	186	37	early	early	JJ
cord-268140-s5lailkp	186	38	phase	phase	NN
cord-268140-s5lailkp	186	39	2019	2019	CD
cord-268140-s5lailkp	186	40	novel	novel	NN
cord-268140-s5lailkp	186	41	coronavirus	coronavirus	NN
cord-268140-s5lailkp	186	42	(	(	-LRB-
cord-268140-s5lailkp	186	43	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	186	44	)	)	-RRB-
cord-268140-s5lailkp	186	45	pneumonia	pneumonia	NN
cord-268140-s5lailkp	186	46	in	in	IN
cord-268140-s5lailkp	186	47	two	two	CD
cord-268140-s5lailkp	186	48	patients	patient	NNS
cord-268140-s5lailkp	186	49	with	with	IN
cord-268140-s5lailkp	186	50	lung	lung	NN
cord-268140-s5lailkp	186	51	cancer	cancer	NN
cord-268140-s5lailkp	186	52	IL-6	IL-6	NNP
cord-268140-s5lailkp	186	53	as	as	IN
cord-268140-s5lailkp	186	54	a	a	DT
cord-268140-s5lailkp	186	55	keystone	keystone	JJ
cord-268140-s5lailkp	186	56	cytokine	cytokine	NN
cord-268140-s5lailkp	186	57	in	in	IN
cord-268140-s5lailkp	186	58	health	health	NN
cord-268140-s5lailkp	186	59	and	and	CC
cord-268140-s5lailkp	186	60	disease	disease	NN
cord-268140-s5lailkp	187	1	Can	Can	MD
cord-268140-s5lailkp	187	2	we	-PRON-	PRP
cord-268140-s5lailkp	187	3	use	use	VB
cord-268140-s5lailkp	187	4	interleukin-6	interleukin-6	NNP
cord-268140-s5lailkp	187	5	(	(	-LRB-
cord-268140-s5lailkp	187	6	IL-6	IL-6	NNP
cord-268140-s5lailkp	187	7	)	)	-RRB-
cord-268140-s5lailkp	187	8	blockade	blockade	NN
cord-268140-s5lailkp	187	9	for	for	IN
cord-268140-s5lailkp	187	10	coronavirus	coronavirus	NN
cord-268140-s5lailkp	187	11	disease	disease	NN
cord-268140-s5lailkp	187	12	2019	2019	CD
cord-268140-s5lailkp	187	13	(	(	-LRB-
cord-268140-s5lailkp	187	14	COVID-19)-induced	covid-19)-induce	VBN
cord-268140-s5lailkp	187	15	cytokine	cytokine	NN
cord-268140-s5lailkp	187	16	release	release	NN
cord-268140-s5lailkp	187	17	syndrome	syndrome	NN
cord-268140-s5lailkp	187	18	(	(	-LRB-
cord-268140-s5lailkp	187	19	CRS	CRS	NNP
cord-268140-s5lailkp	187	20	)	)	-RRB-
cord-268140-s5lailkp	187	21	?	?	.
cord-268140-s5lailkp	188	1	Clinical	clinical	JJ
cord-268140-s5lailkp	188	2	course	course	NN
cord-268140-s5lailkp	188	3	and	and	CC
cord-268140-s5lailkp	188	4	risk	risk	NN
cord-268140-s5lailkp	188	5	factors	factor	NNS
cord-268140-s5lailkp	188	6	for	for	IN
cord-268140-s5lailkp	188	7	mortality	mortality	NN
cord-268140-s5lailkp	188	8	of	of	IN
cord-268140-s5lailkp	188	9	adult	adult	NN
cord-268140-s5lailkp	188	10	inpatients	inpatient	NNS
cord-268140-s5lailkp	188	11	with	with	IN
cord-268140-s5lailkp	188	12	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	188	13	in	in	IN
cord-268140-s5lailkp	188	14	Wuhan	Wuhan	NNP
cord-268140-s5lailkp	188	15	,	,	,
cord-268140-s5lailkp	188	16	China	China	NNP
cord-268140-s5lailkp	188	17	:	:	:
cord-268140-s5lailkp	188	18	a	a	DT
cord-268140-s5lailkp	188	19	retrospective	retrospective	JJ
cord-268140-s5lailkp	188	20	cohort	cohort	NN
cord-268140-s5lailkp	188	21	study	study	NN
cord-268140-s5lailkp	188	22	Interleukin-6	Interleukin-6	NNP
cord-268140-s5lailkp	188	23	in	in	IN
cord-268140-s5lailkp	188	24	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	188	25	:	:	:
cord-268140-s5lailkp	188	26	a	a	DT
cord-268140-s5lailkp	188	27	systematic	systematic	JJ
cord-268140-s5lailkp	188	28	review	review	NN
cord-268140-s5lailkp	188	29	and	and	CC
cord-268140-s5lailkp	188	30	meta	meta	NNP
cord-268140-s5lailkp	188	31	-	-	HYPH
cord-268140-s5lailkp	188	32	analysis	analysis	NN
cord-268140-s5lailkp	188	33	.	.	.
cord-268140-s5lailkp	189	1	medRxiv	medRxiv	NNS
cord-268140-s5lailkp	189	2	A	a	DT
cord-268140-s5lailkp	189	3	pathological	pathological	JJ
cord-268140-s5lailkp	189	4	report	report	NN
cord-268140-s5lailkp	189	5	of	of	IN
cord-268140-s5lailkp	189	6	three	three	CD
cord-268140-s5lailkp	189	7	COVID-19	covid-19	CD
cord-268140-s5lailkp	189	8	cases	case	NNS
cord-268140-s5lailkp	189	9	by	by	IN
cord-268140-s5lailkp	189	10	minimally	minimally	RB
cord-268140-s5lailkp	189	11	invasive	invasive	JJ
cord-268140-s5lailkp	189	12	autopsies	autopsy	NNS
cord-268140-s5lailkp	189	13	COVID-19	covid-19	VBP
cord-268140-s5lailkp	189	14	:	:	:
cord-268140-s5lailkp	189	15	consider	consider	VB
cord-268140-s5lailkp	189	16	cytokine	cytokine	JJ
cord-268140-s5lailkp	189	17	storm	storm	NN
cord-268140-s5lailkp	189	18	syndromes	syndrome	NNS
cord-268140-s5lailkp	189	19	and	and	CC
cord-268140-s5lailkp	189	20	immunosuppression	immunosuppression	NN
cord-268140-s5lailkp	189	21	Inhibition	inhibition	NN
cord-268140-s5lailkp	189	22	of	of	IN
cord-268140-s5lailkp	189	23	NF	NF	NNP
cord-268140-s5lailkp	189	24	-	-	HYPH
cord-268140-s5lailkp	189	25	kappaB	kappaB	NNP
cord-268140-s5lailkp	189	26	-	-	HYPH
cord-268140-s5lailkp	189	27	mediated	mediate	VBN
cord-268140-s5lailkp	189	28	inflammation	inflammation	NN
cord-268140-s5lailkp	189	29	in	in	IN
cord-268140-s5lailkp	189	30	severe	severe	JJ
cord-268140-s5lailkp	189	31	acute	acute	JJ
cord-268140-s5lailkp	189	32	respiratory	respiratory	JJ
cord-268140-s5lailkp	189	33	syndrome	syndrome	NN
cord-268140-s5lailkp	189	34	coronavirus	coronavirus	NN
cord-268140-s5lailkp	189	35	-	-	HYPH
cord-268140-s5lailkp	189	36	infected	infect	VBN
cord-268140-s5lailkp	189	37	mice	mice	NN
cord-268140-s5lailkp	189	38	increases	increase	VBZ
cord-268140-s5lailkp	189	39	survival	survival	NN
cord-268140-s5lailkp	189	40	SARS	SARS	NNP
cord-268140-s5lailkp	189	41	:	:	:
cord-268140-s5lailkp	190	1	systematic	systematic	JJ
cord-268140-s5lailkp	190	2	review	review	NN
cord-268140-s5lailkp	190	3	of	of	IN
cord-268140-s5lailkp	190	4	treatment	treatment	NN
cord-268140-s5lailkp	190	5	effects	effect	NNS
cord-268140-s5lailkp	190	6	Clinical	clinical	JJ
cord-268140-s5lailkp	190	7	evidence	evidence	NN
cord-268140-s5lailkp	190	8	does	do	VBZ
cord-268140-s5lailkp	190	9	not	not	RB
cord-268140-s5lailkp	190	10	support	support	VB
cord-268140-s5lailkp	190	11	corticosteroid	corticosteroid	NN
cord-268140-s5lailkp	190	12	treatment	treatment	NN
cord-268140-s5lailkp	190	13	for	for	IN
cord-268140-s5lailkp	190	14	2019-nCoV	2019-ncov	CD
cord-268140-s5lailkp	190	15	lung	lung	NN
cord-268140-s5lailkp	190	16	injury	injury	NN
cord-268140-s5lailkp	191	1	Detectable	detectable	JJ
cord-268140-s5lailkp	191	2	serum	serum	NN
cord-268140-s5lailkp	191	3	SARS	SARS	NNP
cord-268140-s5lailkp	191	4	-	-	HYPH
cord-268140-s5lailkp	191	5	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	191	6	viral	viral	JJ
cord-268140-s5lailkp	191	7	load	load	NN
cord-268140-s5lailkp	191	8	(	(	-LRB-
cord-268140-s5lailkp	191	9	RNAaemia	RNAaemia	NNP
cord-268140-s5lailkp	191	10	)	)	-RRB-
cord-268140-s5lailkp	191	11	is	be	VBZ
cord-268140-s5lailkp	191	12	closely	closely	RB
cord-268140-s5lailkp	191	13	associated	associate	VBN
cord-268140-s5lailkp	191	14	with	with	IN
cord-268140-s5lailkp	191	15	drastically	drastically	RB
cord-268140-s5lailkp	191	16	elevated	elevate	VBN
cord-268140-s5lailkp	191	17	interleukin	interleukin	NN
cord-268140-s5lailkp	191	18	6	6	CD
cord-268140-s5lailkp	191	19	(	(	-LRB-
cord-268140-s5lailkp	191	20	IL-6	IL-6	NNP
cord-268140-s5lailkp	191	21	)	)	-RRB-
cord-268140-s5lailkp	191	22	level	level	NN
cord-268140-s5lailkp	191	23	in	in	IN
cord-268140-s5lailkp	191	24	critically	critically	RB
cord-268140-s5lailkp	191	25	ill	ill	JJ
cord-268140-s5lailkp	191	26	COVID-19	covid-19	CD
cord-268140-s5lailkp	191	27	patients	patient	NNS
cord-268140-s5lailkp	191	28	.	.	.
cord-268140-s5lailkp	192	1	medRxiv	medRxiv	NNS
cord-268140-s5lailkp	192	2	Cytotoxic	Cytotoxic	NNP
cord-268140-s5lailkp	192	3	therapy	therapy	NN
cord-268140-s5lailkp	192	4	for	for	IN
cord-268140-s5lailkp	192	5	severe	severe	JJ
cord-268140-s5lailkp	192	6	avian	avian	JJ
cord-268140-s5lailkp	192	7	influenza	influenza	NN
cord-268140-s5lailkp	192	8	A	a	NN
cord-268140-s5lailkp	192	9	(	(	-LRB-
cord-268140-s5lailkp	192	10	H5N1	H5N1	NNP
cord-268140-s5lailkp	192	11	)	)	-RRB-
cord-268140-s5lailkp	192	12	infection	infection	NN
cord-268140-s5lailkp	192	13	International	International	NNP
cord-268140-s5lailkp	192	14	Pulmonologist	Pulmonologist	NNP
cord-268140-s5lailkp	192	15	's	's	POS
cord-268140-s5lailkp	192	16	Consensus	Consensus	NNP
cord-268140-s5lailkp	192	17	On	on	IN
cord-268140-s5lailkp	192	18	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	192	19	National	National	NNP
cord-268140-s5lailkp	192	20	Health	Health	NNP
cord-268140-s5lailkp	192	21	Commission	Commission	NNP
cord-268140-s5lailkp	192	22	and	and	CC
cord-268140-s5lailkp	192	23	State	State	NNP
cord-268140-s5lailkp	192	24	Administration	Administration	NNP
cord-268140-s5lailkp	192	25	of	of	IN
cord-268140-s5lailkp	192	26	Traditional	Traditional	NNP
cord-268140-s5lailkp	192	27	Chinese	Chinese	NNP
cord-268140-s5lailkp	192	28	Medicine	Medicine	NNP
cord-268140-s5lailkp	192	29	.	.	.
cord-268140-s5lailkp	193	1	Diagnosis	diagnosis	NN
cord-268140-s5lailkp	193	2	and	and	CC
cord-268140-s5lailkp	193	3	treatment	treatment	NN
cord-268140-s5lailkp	193	4	protocol	protocol	NN
cord-268140-s5lailkp	193	5	for	for	IN
cord-268140-s5lailkp	194	1	novel	novel	JJ
cord-268140-s5lailkp	194	2	coronavirus	coronavirus	NN
cord-268140-s5lailkp	194	3	pneumonia	pneumonia	NN
cord-268140-s5lailkp	194	4	Tocilizumab	Tocilizumab	NNP
cord-268140-s5lailkp	194	5	:	:	:
cord-268140-s5lailkp	195	1	Drug	drug	NN
cord-268140-s5lailkp	195	2	information	information	NN
cord-268140-s5lailkp	196	1	Sarilumab	Sarilumab	NNP
cord-268140-s5lailkp	196	2	:	:	:
cord-268140-s5lailkp	197	1	Drug	drug	NN
cord-268140-s5lailkp	197	2	information	information	NN
cord-268140-s5lailkp	197	3	Siltuximab	Siltuximab	NNP
cord-268140-s5lailkp	197	4	:	:	:
cord-268140-s5lailkp	198	1	Drug	drug	NN
cord-268140-s5lailkp	198	2	information	information	NN
cord-268140-s5lailkp	199	1	Tocilizumab	tocilizumab	JJ
cord-268140-s5lailkp	199	2	treatment	treatment	NN
cord-268140-s5lailkp	199	3	in	in	IN
cord-268140-s5lailkp	199	4	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	199	5	:	:	:
cord-268140-s5lailkp	199	6	a	a	DT
cord-268140-s5lailkp	199	7	single	single	JJ
cord-268140-s5lailkp	199	8	center	center	NN
cord-268140-s5lailkp	199	9	experience	experience	NN
cord-268140-s5lailkp	199	10	Available	available	JJ
cord-268140-s5lailkp	199	11	at	at	IN
cord-268140-s5lailkp	199	12	:	:	:
cord-268140-s5lailkp	199	13	https	https	NNP
cord-268140-s5lailkp	199	14	:	:	:
cord-268140-s5lailkp	200	1	//clini	//clini	.
cord-268140-s5lailkp	201	1	caltr	caltr	NNP
cord-268140-s5lailkp	201	2	ials	ials	NNPS
cord-268140-s5lailkp	201	3	.	.	.
cord-268140-s5lailkp	202	1	gov	gov	NNP
cord-268140-s5lailkp	202	2	/	/	SYM
cord-268140-s5lailkp	202	3	ct2	ct2	NNP
cord-268140-s5lailkp	202	4	/	/	SYM
cord-268140-s5lailkp	202	5	resul	resul	NNP
cord-268140-s5lailkp	202	6	ts?cond	ts?cond	NNP
cord-268140-s5lailkp	203	1	=	=	NFP
cord-268140-s5lailkp	204	1	Covid	Covid	NNP
cord-268140-s5lailkp	204	2	-19&term	-19&term	POS
cord-268140-s5lailkp	204	3	=	=	SYM
cord-268140-s5lailkp	204	4	tocil	tocil	NNP
cord-268140-s5lailkp	204	5	izuma	izuma	NNP
cord-268140-s5lailkp	205	1	b&cntry	b&cntry	NN
cord-268140-s5lailkp	205	2	=	=	SYM
cord-268140-s5lailkp	205	3	&	&	CC
cord-268140-s5lailkp	205	4	state	state	NN
cord-268140-s5lailkp	206	1	=	=	NFP
cord-268140-s5lailkp	206	2	&	&	CC
cord-268140-s5lailkp	206	3	city=&dist=	city=&dist=	NNP
cord-268140-s5lailkp	206	4	Available	available	JJ
cord-268140-s5lailkp	206	5	at	at	IN
cord-268140-s5lailkp	206	6	:	:	:
cord-268140-s5lailkp	206	7	https	https	NNP
cord-268140-s5lailkp	206	8	:	:	:
cord-268140-s5lailkp	206	9	//clini	//clini	.
cord-268140-s5lailkp	207	1	caltr	caltr	NNP
cord-268140-s5lailkp	207	2	ials	ials	NNPS
cord-268140-s5lailkp	207	3	.	.	.
cord-268140-s5lailkp	208	1	gov	gov	NNP
cord-268140-s5lailkp	208	2	/	/	SYM
cord-268140-s5lailkp	208	3	ct2	ct2	NNP
cord-268140-s5lailkp	208	4	/	/	SYM
cord-268140-s5lailkp	208	5	resul	resul	NNS
cord-268140-s5lailkp	208	6	ts?cond=	ts?cond=	NNP
cord-268140-s5lailkp	209	1	saril	saril	NNP
cord-268140-s5lailkp	209	2	umab+COVID	umab+COVID	NNP
cord-268140-s5lailkp	209	3	+19&term=&cntry	+19&term=&cntry	NNP
cord-268140-s5lailkp	209	4	=	=	SYM
cord-268140-s5lailkp	209	5	&	&	CC
cord-268140-s5lailkp	209	6	state	state	NNP
cord-268140-s5lailkp	209	7	=	=	SYM
cord-268140-s5lailkp	209	8	&	&	CC
cord-268140-s5lailkp	209	9	city=&dist=	city=&dist=	NNP
cord-268140-s5lailkp	210	1	Available	available	JJ
cord-268140-s5lailkp	210	2	at	at	IN
cord-268140-s5lailkp	210	3	:	:	:
cord-268140-s5lailkp	210	4	https	https	NNP
cord-268140-s5lailkp	210	5	:	:	:
cord-268140-s5lailkp	210	6	//clini	//clini	.
cord-268140-s5lailkp	211	1	caltr	caltr	NNP
cord-268140-s5lailkp	211	2	ials	ials	NNPS
cord-268140-s5lailkp	211	3	.	.	.
cord-268140-s5lailkp	212	1	gov	gov	NNP
cord-268140-s5lailkp	212	2	/	/	SYM
cord-268140-s5lailkp	212	3	ct2	ct2	NNP
cord-268140-s5lailkp	212	4	/	/	SYM
cord-268140-s5lailkp	212	5	resul	resul	NNP
cord-268140-s5lailkp	212	6	ts?cond	ts?cond	NNP
cord-268140-s5lailkp	213	1	=	=	SYM
cord-268140-s5lailkp	213	2	siltu	siltu	NNP
cord-268140-s5lailkp	213	3	ximab	ximab	NNP
cord-268140-s5lailkp	213	4	+	+	SYM
cord-268140-s5lailkp	213	5	covid	covid	NNP
cord-268140-s5lailkp	213	6	+19&term=&cntry	+19&term=&cntry	NNP
cord-268140-s5lailkp	213	7	=	=	SYM
cord-268140-s5lailkp	213	8	&	&	CC
cord-268140-s5lailkp	213	9	state	state	NNP
cord-268140-s5lailkp	213	10	=	=	SYM
cord-268140-s5lailkp	213	11	&	&	CC
cord-268140-s5lailkp	213	12	city=&dist=	city=&dist=	NNP
cord-268140-s5lailkp	214	1	Chinese	Chinese	NNP
cord-268140-s5lailkp	214	2	Clinical	Clinical	NNP
cord-268140-s5lailkp	214	3	Trial	Trial	NNP
cord-268140-s5lailkp	214	4	Registry	Registry	NNP
cord-268140-s5lailkp	214	5	.	.	.
cord-268140-s5lailkp	215	1	A	a	DT
cord-268140-s5lailkp	215	2	multicenter	multicenter	NN
cord-268140-s5lailkp	215	3	,	,	,
cord-268140-s5lailkp	215	4	randomized	randomized	JJ
cord-268140-s5lailkp	215	5	controlled	control	VBN
cord-268140-s5lailkp	215	6	trial	trial	NN
cord-268140-s5lailkp	215	7	for	for	IN
cord-268140-s5lailkp	215	8	the	the	DT
cord-268140-s5lailkp	215	9	efficacy	efficacy	NN
cord-268140-s5lailkp	215	10	and	and	CC
cord-268140-s5lailkp	215	11	safety	safety	NN
cord-268140-s5lailkp	215	12	of	of	IN
cord-268140-s5lailkp	215	13	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	215	14	in	in	IN
cord-268140-s5lailkp	215	15	the	the	DT
cord-268140-s5lailkp	215	16	treatment	treatment	NN
cord-268140-s5lailkp	215	17	of	of	IN
cord-268140-s5lailkp	215	18	new	new	JJ
cord-268140-s5lailkp	215	19	coronavirus	coronavirus	NN
cord-268140-s5lailkp	215	20	pneumonia	pneumonia	NN
cord-268140-s5lailkp	215	21	(	(	-LRB-
cord-268140-s5lailkp	215	22	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	215	23	)	)	-RRB-
cord-268140-s5lailkp	215	24	Favipiravir	Favipiravir	NNP
cord-268140-s5lailkp	215	25	combined	combine	VBN
cord-268140-s5lailkp	215	26	with	with	IN
cord-268140-s5lailkp	215	27	tocilizumab	tocilizumab	NN
cord-268140-s5lailkp	215	28	in	in	IN
cord-268140-s5lailkp	215	29	the	the	DT
cord-268140-s5lailkp	215	30	treatment	treatment	NN
cord-268140-s5lailkp	215	31	of	of	IN
cord-268140-s5lailkp	215	32	corona	corona	NNP
cord-268140-s5lailkp	215	33	virus	virus	NN
cord-268140-s5lailkp	215	34	disease	disease	NN
cord-268140-s5lailkp	215	35	A	a	DT
cord-268140-s5lailkp	215	36	study	study	NN
cord-268140-s5lailkp	215	37	to	to	TO
cord-268140-s5lailkp	215	38	evaluate	evaluate	VB
cord-268140-s5lailkp	215	39	the	the	DT
cord-268140-s5lailkp	215	40	safety	safety	NN
cord-268140-s5lailkp	215	41	and	and	CC
cord-268140-s5lailkp	215	42	efficacy	efficacy	NN
cord-268140-s5lailkp	215	43	of	of	IN
cord-268140-s5lailkp	215	44	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	215	45	in	in	IN
cord-268140-s5lailkp	215	46	patients	patient	NNS
cord-268140-s5lailkp	215	47	with	with	IN
cord-268140-s5lailkp	215	48	severe	severe	JJ
cord-268140-s5lailkp	215	49	COVID-19	covid-19	JJ
cord-268140-s5lailkp	215	50	pneumonia	pneumonia	NN
cord-268140-s5lailkp	215	51	(	(	-LRB-
cord-268140-s5lailkp	215	52	COVACTA	COVACTA	NNP
cord-268140-s5lailkp	215	53	)	)	-RRB-
cord-268140-s5lailkp	216	1	Tocilizumab	Tocilizumab	NNP
cord-268140-s5lailkp	216	2	in	in	IN
cord-268140-s5lailkp	216	3	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	216	4	Pneumonia	Pneumonia	NNP
cord-268140-s5lailkp	216	5	(	(	-LRB-
cord-268140-s5lailkp	216	6	TOCIVID-19	TOCIVID-19	NNP
cord-268140-s5lailkp	216	7	)	)	-RRB-
cord-268140-s5lailkp	216	8	(	(	-LRB-
cord-268140-s5lailkp	216	9	TOCIVID-19	TOCIVID-19	NNP
cord-268140-s5lailkp	216	10	)	)	-RRB-
cord-268140-s5lailkp	216	11	.	.	.
cord-268140-s5lailkp	217	1	Available	available	JJ
cord-268140-s5lailkp	217	2	at	at	IN
cord-268140-s5lailkp	217	3	COVID-19	covid-19	CD
cord-268140-s5lailkp	217	4	)	)	-RRB-
cord-268140-s5lailkp	218	1	Severe	severe	JJ
cord-268140-s5lailkp	218	2	Pneumonitis	Pneumonitis	NNP
cord-268140-s5lailkp	218	3	Anti	Anti	NNP
cord-268140-s5lailkp	218	4	-	-	JJ
cord-268140-s5lailkp	218	5	il6	il6	JJ
cord-268140-s5lailkp	218	6	treatment	treatment	NN
cord-268140-s5lailkp	218	7	of	of	IN
cord-268140-s5lailkp	218	8	serious	serious	JJ
cord-268140-s5lailkp	218	9	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	218	10	disease	disease	NN
cord-268140-s5lailkp	218	11	with	with	IN
cord-268140-s5lailkp	218	12	threatening	threaten	VBG
cord-268140-s5lailkp	218	13	respiratory	respiratory	JJ
cord-268140-s5lailkp	218	14	failure	failure	NN
cord-268140-s5lailkp	218	15	(	(	-LRB-
cord-268140-s5lailkp	218	16	TOCIVID	tocivid	NN
cord-268140-s5lailkp	218	17	)	)	-RRB-
cord-268140-s5lailkp	219	1	Available	available	JJ
cord-268140-s5lailkp	219	2	at	at	IN
cord-268140-s5lailkp	219	3	:	:	:
cord-268140-s5lailkp	219	4	https	https	NNP
cord-268140-s5lailkp	219	5	:	:	:
cord-268140-s5lailkp	220	1	//pipel	//pipel	NN
cord-268140-s5lailkp	221	1	inere	inere	NNP
cord-268140-s5lailkp	221	2	view.com/index	view.com/index	NNP
cord-268140-s5lailkp	221	3	.php/20200	.php/20200	.
cord-268140-s5lailkp	221	4	42874	42874	CD
cord-268140-s5lailkp	221	5	458	458	CD
cord-268140-s5lailkp	222	1	/Antib	/Antib	NNP
cord-268140-s5lailkp	222	2	odies	odies	NNP
cord-268140-s5lailkp	222	3	/Tocil	/Tocil	.
cord-268140-s5lailkp	223	1	izuma	izuma	NNP
cord-268140-s5lailkp	223	2	b	b	NNP
cord-268140-s5lailkp	223	3	-	-	HYPH
cord-268140-s5lailkp	223	4	impro	impro	NNP
cord-268140-s5lailkp	223	5	ves	ves	NNP
cord-268140-s5lailkp	223	6	-	-	HYPH
cord-268140-s5lailkp	223	7	signi	signi	NNP
cord-268140-s5lailkp	223	8	fican	fican	NNP
cord-268140-s5lailkp	224	1	tly	tly	RB
cord-268140-s5lailkp	224	2	-	-	HYPH
cord-268140-s5lailkp	224	3	clini	clini	NNP
cord-268140-s5lailkp	224	4	cal	cal	JJ
cord-268140-s5lailkp	224	5	-	-	HYPH
cord-268140-s5lailkp	224	6	outco	outco	FW
cord-268140-s5lailkp	224	7	mes	mes	JJ
cord-268140-s5lailkp	224	8	-	-	JJ
cord-268140-s5lailkp	224	9	ofpatie	ofpatie	JJ
cord-268140-s5lailkp	224	10	nts	nts	NNPS
cord-268140-s5lailkp	224	11	-	-	HYPH
cord-268140-s5lailkp	224	12	with	with	IN
cord-268140-s5lailkp	224	13	-	-	HYPH
cord-268140-s5lailkp	224	14	moder	moder	NN
cord-268140-s5lailkp	224	15	ate	ate	VB
cord-268140-s5lailkp	224	16	-	-	HYPH
cord-268140-s5lailkp	224	17	or	or	CC
cord-268140-s5lailkp	224	18	-	-	HYPH
cord-268140-s5lailkp	224	19	sever	sever	NN
cord-268140-s5lailkp	224	20	e	e	NN
cord-268140-s5lailkp	224	21	-	-	JJ
cord-268140-s5lailkp	224	22	COVID	covid	JJ
cord-268140-s5lailkp	224	23	-19-pneum	-19-pneum	NNP
cord-268140-s5lailkp	224	24	onia	onia	NNP
cord-268140-s5lailkp	224	25	Press	Press	NNP
cord-268140-s5lailkp	224	26	Release	Release	NNP
cord-268140-s5lailkp	224	27	.	.	.
cord-268140-s5lailkp	225	1	First	first	RB
cord-268140-s5lailkp	225	2	randomized	randomized	JJ
cord-268140-s5lailkp	225	3	study	study	NN
cord-268140-s5lailkp	225	4	favorable	favorable	JJ
cord-268140-s5lailkp	225	5	to	to	IN
cord-268140-s5lailkp	225	6	tocilizumab	tocilizumab	NNP
cord-268140-s5lailkp	225	7	in	in	IN
cord-268140-s5lailkp	225	8	Covid-19	Covid-19	NNP
cord-268140-s5lailkp	225	9	Evaluation	Evaluation	NNP
cord-268140-s5lailkp	225	10	of	of	IN
cord-268140-s5lailkp	225	11	the	the	DT
cord-268140-s5lailkp	225	12	efficacy	efficacy	NN
cord-268140-s5lailkp	225	13	and	and	CC
cord-268140-s5lailkp	225	14	safety	safety	NN
cord-268140-s5lailkp	225	15	of	of	IN
cord-268140-s5lailkp	225	16	sarilumab	sarilumab	NNP
cord-268140-s5lailkp	225	17	in	in	IN
cord-268140-s5lailkp	225	18	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	225	19	patients	patient	NNS
cord-268140-s5lailkp	225	20	with	with	IN
cord-268140-s5lailkp	225	21	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	225	22	Sanofi	Sanofi	NNP
cord-268140-s5lailkp	225	23	arthritis	arthritis	NN
cord-268140-s5lailkp	225	24	drug	drug	NN
cord-268140-s5lailkp	225	25	may	may	MD
cord-268140-s5lailkp	225	26	only	only	RB
cord-268140-s5lailkp	225	27	help	help	VB
cord-268140-s5lailkp	225	28	critical	critical	JJ
cord-268140-s5lailkp	225	29	coronavirus	coronavirus	NN
cord-268140-s5lailkp	225	30	patients	patient	NNS
cord-268140-s5lailkp	225	31	:	:	:
cord-268140-s5lailkp	225	32	study	study	VB
cord-268140-s5lailkp	225	33	IL-6	IL-6	NNP
cord-268140-s5lailkp	225	34	inhibitors	inhibitor	NNS
cord-268140-s5lailkp	225	35	in	in	IN
cord-268140-s5lailkp	225	36	serious	serious	JJ
cord-268140-s5lailkp	225	37	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	225	38	Cohort	Cohort	NNP
cord-268140-s5lailkp	225	39	multiple	multiple	NN
cord-268140-s5lailkp	225	40	randomized	randomize	VBD
cord-268140-s5lailkp	225	41	controlled	control	VBN
cord-268140-s5lailkp	225	42	trials	trial	NNS
cord-268140-s5lailkp	225	43	open	open	JJ
cord-268140-s5lailkp	225	44	-	-	HYPH
cord-268140-s5lailkp	225	45	label	label	NN
cord-268140-s5lailkp	225	46	of	of	IN
cord-268140-s5lailkp	225	47	immune	immune	JJ
cord-268140-s5lailkp	225	48	modulatory	modulatory	JJ
cord-268140-s5lailkp	225	49	drugs	drug	NNS
cord-268140-s5lailkp	225	50	and	and	CC
cord-268140-s5lailkp	225	51	other	other	JJ
cord-268140-s5lailkp	225	52	treatments	treatment	NNS
cord-268140-s5lailkp	225	53	in	in	IN
cord-268140-s5lailkp	225	54	COVID-19	covid-19	JJ
cord-268140-s5lailkp	225	55	patients	patient	NNS
cord-268140-s5lailkp	225	56	-	-	HYPH
cord-268140-s5lailkp	225	57	sarilumab	sarilumab	JJ
cord-268140-s5lailkp	225	58	trial	trial	NN
cord-268140-s5lailkp	225	59	-	-	:
cord-268140-s5lailkp	225	60	CORIMUNO-19-SARI	CORIMUNO-19-SARI	NNP
cord-268140-s5lailkp	225	61	(	(	-LRB-
cord-268140-s5lailkp	225	62	CORI	CORI	NNP
cord-268140-s5lailkp	225	63	-	-	HYPH
cord-268140-s5lailkp	225	64	MUNO	MUNO	NNP
cord-268140-s5lailkp	225	65	-	-	HYPH
cord-268140-s5lailkp	225	66	SARI	SARI	NNP
cord-268140-s5lailkp	225	67	)	)	-RRB-
cord-268140-s5lailkp	226	1	Mast	mast	NN
cord-268140-s5lailkp	226	2	cells	cell	NNS
cord-268140-s5lailkp	226	3	contribute	contribute	VBP
cord-268140-s5lailkp	226	4	to	to	IN
cord-268140-s5lailkp	226	5	coronavirus	coronavirus	NN
cord-268140-s5lailkp	226	6	-	-	HYPH
cord-268140-s5lailkp	226	7	induced	induce	VBN
cord-268140-s5lailkp	226	8	inflammation	inflammation	NN
cord-268140-s5lailkp	226	9	:	:	:
cord-268140-s5lailkp	226	10	new	new	JJ
cord-268140-s5lailkp	226	11	anti	anti	JJ
cord-268140-s5lailkp	226	12	-	-	JJ
cord-268140-s5lailkp	226	13	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	226	14	strategy	strategy	NN
cord-268140-s5lailkp	226	15	Induction	Induction	NNP
cord-268140-s5lailkp	226	16	of	of	IN
cord-268140-s5lailkp	226	17	pro	pro	JJ
cord-268140-s5lailkp	226	18	-	-	JJ
cord-268140-s5lailkp	226	19	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	226	20	cytokines	cytokine	NNS
cord-268140-s5lailkp	226	21	(	(	-LRB-
cord-268140-s5lailkp	226	22	IL-1	IL-1	NNP
cord-268140-s5lailkp	226	23	and	and	CC
cord-268140-s5lailkp	226	24	IL-6	IL-6	NNP
cord-268140-s5lailkp	226	25	)	)	-RRB-
cord-268140-s5lailkp	226	26	and	and	CC
cord-268140-s5lailkp	226	27	lung	lung	NN
cord-268140-s5lailkp	226	28	inflammation	inflammation	NN
cord-268140-s5lailkp	226	29	by	by	IN
cord-268140-s5lailkp	226	30	Coronavirus-19	Coronavirus-19	NNP
cord-268140-s5lailkp	226	31	(	(	-LRB-
cord-268140-s5lailkp	226	32	COVI-19	COVI-19	NNP
cord-268140-s5lailkp	226	33	or	or	CC
cord-268140-s5lailkp	226	34	SARS	SARS	NNP
cord-268140-s5lailkp	226	35	-	-	HYPH
cord-268140-s5lailkp	226	36	CoV-2	CoV-2	NNP
cord-268140-s5lailkp	226	37	)	)	-RRB-
cord-268140-s5lailkp	226	38	:	:	:
cord-268140-s5lailkp	226	39	anti	anti	JJ
cord-268140-s5lailkp	226	40	-	-	JJ
cord-268140-s5lailkp	226	41	inflammatory	inflammatory	JJ
cord-268140-s5lailkp	226	42	strategies	strategy	NNS
cord-268140-s5lailkp	226	43	Outcomes	Outcomes	NNPS
cord-268140-s5lailkp	226	44	of	of	IN
cord-268140-s5lailkp	226	45	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	226	46	usage	usage	NN
cord-268140-s5lailkp	226	47	in	in	IN
cord-268140-s5lailkp	226	48	United	United	NNP
cord-268140-s5lailkp	226	49	States	States	NNP
cord-268140-s5lailkp	226	50	veterans	veteran	NNS
cord-268140-s5lailkp	226	51	hospitalized	hospitalize	VBN
cord-268140-s5lailkp	226	52	with	with	IN
cord-268140-s5lailkp	226	53	Covid-19	covid-19	NN
cord-268140-s5lailkp	226	54	.	.	.
cord-268140-s5lailkp	227	1	medRxiv	medRxiv	NNP
cord-268140-s5lailkp	227	2	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-268140-s5lailkp	227	3	in	in	IN
cord-268140-s5lailkp	227	4	patients	patient	NNS
cord-268140-s5lailkp	227	5	with	with	IN
cord-268140-s5lailkp	227	6	COVID-19	COVID-19	NNP
cord-268140-s5lailkp	227	7	:	:	:
cord-268140-s5lailkp	227	8	an	an	DT
cord-268140-s5lailkp	227	9	open	open	JJ
cord-268140-s5lailkp	227	10	-	-	HYPH
cord-268140-s5lailkp	227	11	label	label	NN
cord-268140-s5lailkp	227	12	,	,	,
cord-268140-s5lailkp	227	13	randomized	randomize	VBD
cord-268140-s5lailkp	227	14	No	no	DT
cord-268140-s5lailkp	227	15	evidence	evidence	NN
cord-268140-s5lailkp	227	16	of	of	IN
cord-268140-s5lailkp	227	17	rapid	rapid	JJ
cord-268140-s5lailkp	227	18	antiviral	antiviral	JJ
cord-268140-s5lailkp	227	19	clearance	clearance	NN
cord-268140-s5lailkp	227	20	or	or	CC
cord-268140-s5lailkp	227	21	clinical	clinical	JJ
cord-268140-s5lailkp	227	22	benefit	benefit	NN
cord-268140-s5lailkp	227	23	with	with	IN
cord-268140-s5lailkp	227	24	the	the	DT
cord-268140-s5lailkp	227	25	combination	combination	NN
cord-268140-s5lailkp	227	26	of	of	IN
cord-268140-s5lailkp	227	27	hydroxychloroquine	hydroxychloroquine	NN
cord-268140-s5lailkp	227	28	and	and	CC
cord-268140-s5lailkp	227	29	azithromycin	azithromycin	NNP
cord-268140-s5lailkp	227	30	in	in	IN
cord-268140-s5lailkp	227	31	patients	patient	NNS
cord-268140-s5lailkp	227	32	with	with	IN
cord-268140-s5lailkp	227	33	severe	severe	JJ
cord-268140-s5lailkp	227	34	COVID-19	covid-19	CD
cord-268140-s5lailkp	227	35	infection	infection	NN
cord-268140-s5lailkp	227	36	Respiratory	respiratory	JJ
cord-268140-s5lailkp	227	37	support	support	NN
cord-268140-s5lailkp	227	38	in	in	IN
cord-268140-s5lailkp	227	39	novel	novel	JJ
cord-268140-s5lailkp	227	40	coronavirus	coronavirus	NN
cord-268140-s5lailkp	227	41	disease	disease	NN
cord-268140-s5lailkp	227	42	(	(	-LRB-
cord-268140-s5lailkp	227	43	covid-19	covid-19	NNP
cord-268140-s5lailkp	227	44	)	)	-RRB-
cord-268140-s5lailkp	227	45	patients	patient	NNS
cord-268140-s5lailkp	227	46	,	,	,
cord-268140-s5lailkp	227	47	with	with	IN
cord-268140-s5lailkp	227	48	a	a	DT
cord-268140-s5lailkp	227	49	focus	focus	NN
cord-268140-s5lailkp	227	50	on	on	IN
cord-268140-s5lailkp	227	51	resource	resource	NN
cord-268140-s5lailkp	227	52	-	-	HYPH
cord-268140-s5lailkp	227	53	limited	limit	VBN
cord-268140-s5lailkp	227	54	settings	setting	NNS
cord-268140-s5lailkp	227	55	Funding	Funding	NNP
cord-268140-s5lailkp	227	56	None	None	NNP
cord-268140-s5lailkp	227	57	.	.	.
cord-268140-s5lailkp	228	1	Conflict	conflict	NN
cord-268140-s5lailkp	228	2	of	of	IN
cord-268140-s5lailkp	228	3	interest	interest	NN
cord-268140-s5lailkp	228	4	None	none	NN
cord-268140-s5lailkp	228	5	.	.	.